Specific conjugates for antibody drug conjugates

The use of zinc amino complexes for selective disulfide bond reduction in antibodies enables homogeneous ADCs with improved pharmacokinetics and reduced toxicity by ensuring high payload conjugation to the Fab region, overcoming the inefficiencies of current ADC preparation methods.

JP2024542073APending Publication Date: 2024-11-13HANGZHOU DAC BIOTECH CO LTD
View PDF 32 Cites 0 Cited by

Patent Information

Application Number
JP2024526538
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-08
Filing Date
2022-11-02
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current methods for antibody-drug conjugate (ADC) preparation face challenges such as dose-limiting toxicity, batch-to-batch inconsistency, and inefficient site-specific conjugation, leading to heterogeneous distribution of payloads, which affects the stability and efficacy of ADCs.

Method used

A method involving the use of a transition metal cation-amino complex, specifically zinc amino complexes, to selectively reduce disulfide bonds between antibody chains, allowing for stoichiometric conjugation of payloads to specific sites, particularly between the heavy and light chains, followed by controlled oxidation and quenching steps to achieve homogeneous ADCs.

Benefits of technology

The method results in ADCs with improved pharmacokinetic properties, reduced in vivo toxicity, and enhanced therapeutic efficacy by ensuring more than 80% payload conjugation to the Fab region, addressing the limitations of conventional methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542073000988
    Figure 2024542073000988
  • Figure 2024542073000989
    Figure 2024542073000989
  • Figure 2024542073000990
    Figure 2024542073000990
Patent Text Reader

Abstract

The present disclosure provides a method for producing homogeneous antibody or antibody-like protein conjugates by coupling at the cysteine ​​site between the heavy and light chains in an IgG antibody or antibody-like protein. Herein, specific methods are provided for providing conjugates with more than 75%, and in most cases more than 80%, of payload coupled at the cysteine ​​site between the heavy and light chains in an IgG antibody or antibody-like protein by generating specific thiols of the antibody or antibody-like protein agent coupled to the specific cysteine ​​site between the heavy and light chains of the IgG antibody or antibody-like protein and then reacting with a drug / conjugate complex, or by generating specific thiols of the antibody or antigen-like protein agent and coupling the synthesized conjugate-drug assembly with the thiols simultaneously in a one-pod reaction. Also provided are methods for using the homogeneous conjugates in the targeted prevention or treatment of cancer, infectious diseases, and immune disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Priority Information This application claims the benefit of PCT / CN2021 / 128453 (WO / 2022 / 078524), filed November 3, 2021, which is incorporated by reference in its entirety. This application also claims the benefit of PCT / CN2022 / 123901, filed October 8, 2022, which is incorporated by reference in its entirety. Thus, this application claims the benefit of both PCT / CN2021 / 128453 and PCT / CN2022 / 123901.

[0002] The present invention relates to a method for preparing homogeneous antibody or antibody-like protein molecule / agent conjugates via the linkage of sulfur groups at specific cysteine ​​sites in the antibody. The present invention also relates to a method for preparing the conjugates in a specific manner, including generating specific thiol groups on the antibody or antibody-like protein agent, followed by reaction with a drug / conjugate complex, or generating specific thiol groups on the antibody or antibody-like protein agent, and synthesizing the conjugate-drug assembly and conjugating with the protein in one pot simultaneously. It also relates to a method for using the homogeneous conjugates in the targeted prevention or treatment of cancer, infectious diseases, and immune disorders. [Background technology]

[0003] Currently, the pace of ADC development is accelerating, with the number of clinical trials increasing more than three-fold in the past five years, and seven of the 12 commercially available ADCs have been approved by the US FDA in the past two years, highlighting the enthusiasm for this transformative cancer treatment. Conjugation of payloads to antibodies by conjugates is a key aspect that determines the quality, safety, efficacy, and overall success of ADCs (Non-Patent Documents 1 and 2). A report published by the US FDA stated that for most ADCs currently in clinical development, dose-limiting toxicity (DLT) appears to be independent of the target antigen, but is driven by the payload / conjugate complex (Non-Patent Document 3). It is known that the conjugate and conjugation site of ADC also play an important role in the stability of ADCs during preparation and storage, as well as the strength or weakness of toxicity in the blood circulation in vivo (Non-Patent Document 4).

[0004] Therefore, one of the current research and development directions for ADC chemistry and design is the extension of conjugation chemistry to address the issues of the conjugate-payload compartment and dose-limiting toxicity (DLT) of ADCs against target diseases (Non-Patent Documents 5 and 6). Currently, the main research and development is to establish the development of novel and reliable site-specific ADC conjugation methods that are likely to have longer circulating half-life of ADCs, higher therapeutic efficacy, reduced off-target toxicity, and narrow range of in vivo pharmacokinetic (PK) properties, as well as improved batch-to-batch consistency of the manufacturing process, in order to extend the therapeutic window (TW) of ADCs (Non-Patent Documents 6-13).

[0005] In recent years, several methods have been developed to prepare ADCs site-selectively (Non-Patent Document 14). These methods include the introduction of unpaired cysteines into antibodies, such as engineered reactive cysteine ​​residues, called THIOMAB technology by Genentech (Non-Patent Documents 15 and 16, Patent Documents 1 to 5), the use of Streptoverticillium These include genetic introduction of glutamine tags using mobaraense transglutaminase (mTG) (Non-Patent Documents 12 and 17, Patent Document 6) or microbial transglutaminase (MTGase) (Non-Patent Document 18, Patent Documents 7 and 8), introduction of thiol fucose (Non-Patent Document 19), introduction of unnatural amino acids by mutagenesis (Non-Patent Documents 20-23, Patent Documents 9-19), introduction of selenocysteine ​​into antibodies (Non-Patent Document 24, Patent Document 20), conversion of cysteine ​​located in the CXPXR consensus sequence to formylglycine (FGly) by formylglycine generating enzyme (FGE) (Non-Patent Document 25, Patent Documents 21-25), introduction of sialic acid by glycoengineering using galactosyl- and sialyltransferases (Non-Patent Document 26 and Patent Document 26), introduction of cyclopropene of lysine followed by Diels-Alder cycloaddition reaction with tetrazine derivatives in conjugation to give 1,4-dihydropyridazine (Non-Patent Document 27). However, the above methods require reoptimization of antibody engineering processes and cell culture conditions, and usually suffer from problems such as reduced protein expression, low conjugate yield, limited conjugation sites, etc. Therefore, several simple homogeneous conjugation methods by recombining the reduced interchain disulfide bonds of natural antibodies, such as the use of bromo or dibromo maleimides (Non-Patent Document 28) or dibromopyridazinediones (Non-Patent Documents 29 and 30), called next-generation maleimides (NGMs), the application of bis-alkylation reagents via a three-carbon atom bridge (Non-Patent Document 31, Patent Documents 27 and 28) or arylenedipropiolonitrile (ADPN) molecule (Non-Patent Document 32), have actually been investigated.Recently, Coumans et al. used 2-(diphenylphosphine)-benzenesulfonic acid (diPPBS) as a reducing agent to reduce only the designed cysteines without destroying the interchain disulfide bonds in the antibody for the preparation of ADCs (Non-Patent Document 33). Wuxi biologics Co., developed a Zn-Zn complex to selectively control the reduction of cysteines in the antibody and then react with a payload containing a maleimide linker to improve the uniformity of ADC production. 2+ Ions (ZnCl in the buffer solution) 2 ) was applied (Patent Document 29). However, most antibodies are stored in phosphate-based buffers such as PBS buffer, and the solubility constant of zinc phosphate at neutral or basic pH is 9.1 × 10 -33 Therefore, zinc cations rapidly precipitate in phosphate buffer to form zinc phosphate (Martin, R. Bruce. "Solubility and Solubility Products (for Non-Patent Documents 34 and 35)" Non-Patent Documents 36, 37 and 38). Therefore, ZnCl 2 When used for the reduction of antibodies, the amount of phosphate anion and the pH of the buffer must be precisely controlled to avoid the formation of zinc phosphate precipitates. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] U.S. Patent No. 8,309,300 [Patent Document 2] U.S. Patent No. 7,855,275 [Patent Document 3] U.S. Patent No. 7,521,541 [Patent Document 4] U.S. Patent No. 7,723,485 [Patent Document 5] International Publication No. 2008 / 141044 [Patent Document 6] U.S. Patent No. 8,871,908 [Patent Document 7] US Patent Application Publication No. 2013 / 0189287 [Patent Document 8] U.S. Patent No. 7,893,019 [Patent Document 9] U.S. Patent No. 8,778,631 [Patent Document 10] US Patent Application Publication No. 2010 / 0184135 [Patent Document 11] International Publication No. 2010 / 081110 [Patent Document 12] International Publication No. 2006 / 069246 [Patent Document 13] International Publication No. 2007 / 059312 [Patent Document 14] U.S. Patent No. 7,332,571 [Patent Document 15] U.S. Patent No. 7,696,312 [Patent Document 16] U.S. Patent No. 7,638,299 [Patent Document 17] International Publication No. 2007 / 130453 [Patent Document 18] U.S. Patent No. 7,632,492 [Patent Document 19] U.S. Patent No. 7,829,659 [Patent Document 20] U.S. Patent No. 8,916,159 [Patent Document 21] U.S. Patent No. 7,985,783 [Patent Document 22] U.S. Patent No. 8,097,701 [Patent Document 23] U.S. Patent No. 8,349,910 [Patent Document 24] US Patent Application Publication No. 2014 / 0141025 [Patent Document 25] US Patent Application Publication No. 2010 / 0210543 [Patent Document 26] U.S. Patent Application Publication No. 2014 / 0294867 [Patent Document 27] International Publication No. 2013 / 190272 [Patent Document 28] International Publication No. 2014 / 064424 [Patent Document 29] International Application PCT / CN2020 / 075162 [Non-Patent Document]

[0007] [Non-Patent Document 1] M. Acchione, H. Kwon, et al, 2012, mAbs 4:3, 362 - 372 [Non-Patent Document 2] M. J. Birrer, K. N. Moore, et al, 2019, J. National Cancer Inst., 111(6), 538 - 549 [Non-Patent Document 3] H. Saber and J. K. Leighton, Regulatory Toxicology and PHarmacology 71 (2015) 444 - 452 [Non-Patent Document 4] J. R. McCombs and S. C. Owen, 2015, AAPS Journal 17, 339 - 351 [Non-Patent Document 5] Lambert, J. M. 2016, Ther. Deliv. 7, 279 - 82 [Non-Patent Document 6] Zhao, R. Y. et al, 2011, J. Med. Chem. 54, 3606 - 23 [Non-Patent Document 7] Hussain, A. F., et al, PHarmaceuticals (Basel), 2021, 14(4), 343 [Non-Patent Document 8] Sadiki, A., et al, Antib Ther. 2020, 3(4), 271-284

Non-licensed literature 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

Non-licensed Document 14

Non-licensed Document 15

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

Non-licensed Document 19

Non-licensed Document 20

Non-Patent Document 21

Non-Patent Document 22

Non-Patent Document 23

Non-Patent Document 24

Non-Patent Document 25

Non-Patent Document 26

Non-Patent Document 27

Non-Patent Document 28

Non-Patent Document 29

Non-Patent Document 30

Non-Patent Document 31

[0008] We have disclosed several conjugation methods to re-bridge pairs of thiol groups from reduced interchain disulfides of native antibodies, such as using bromomaleimide and dibromomaleimide linkers (WO 2014 / 009774), 2,3-disubstituted succinic acid / 2-monosubstituted / 2,3-disubstituted fumaric acid or maleic acid linkers (WO 2015 / 155753, WO 2016 / 596228), acetylenedicarboxyl linkers (WO 2015 / 151080, WO 2016 / 596228), hydrazine linkers (WO 2015 / 151081), and acryloylpropioyl linkers (WO 2018 / 086139). In this application, we have expanded the scope of our earlier patent application in the preparation of more homogeneous conjugates through the controlled selective reduction of disulfide bonds between antibodies and subsequent or simultaneous conjugation under the coordination of zinc amino complexes / chelate complexes. 2 In comparison with ZnCl, ZnCl is more effective in coordinating the reduction of disulfide bonds in antibodies. 2 First, zinc amino complexes have the advantage over ZnCl. 2 Second, zinc amino complexes are more stable in aqueous solutions; for example, the stability constant of the zinc ammonia complex ion is 2.9×10 9(https: / / chempedia.info / info / stability / ), which slows down precipitation in neutral pH phosphate buffer. More importantly, the zinc amino complex can be used to reduce the disulfide bond between the light and heavy chains of an IgG antibody in stoichiometric proportions without damaging the disulfide bond between the heavy chains (hinge part) of the antibody, and more specifically achieve bis-alkylation of two adjacent thiols of the conjugate, especially the bis-conjugate. In short, the conjugation strategy of the present invention has robust manufacturability that can obtain homogeneous ADCs in high yields without the need for antibody engineering modifications, and can resolve important shortcomings of current ADC preparation methods. This conjugation strategy can also be directly applied to other antibody-like proteins. The resulting homogeneous ADCs show improved pharmacokinetic properties, better efficacy, and reduced in vivo toxicity compared to conventional hetero ADCs. [Means for solving the problem]

[0009] The present invention provides a conjugation method that improves the homogeneity of antibody conjugates or antibody-like protein conjugates, particularly antibody-drug conjugates (ADCs), in which 75% or more of the payload (pharmaceutical) is specifically bound to the disulfide bond site between the heavy and light chains of an antibody.

[0010] This homogeneous conjugation method involves three key steps: (a) providing an effective amount of a transition metal cation-amino chelate / complex (Zn(NR 1 R 2 R 3 ) m1 2+incubating an antibody-like protein, in particular an IgG antibody, in a buffer system (e.g., PBS, Mes, Bis-Tris, Bis-Tris propane, Pipes, Aces, Mopso, Bes, Mops, Hepes, Tes, Pipps, Dipso, Tapso, Heppso, Tris-up, Tris-HCl, Tricine, Hepps, Gly-Gly, Bicine, Taps, Hepee, Acetate, Histidine, Citrate, MES, or Borate) in the presence of a phosphate buffer solution (PBS) and a reducing agent (e.g., Tris(2-carboxyethyl)); (b) adding an effective amount of a conjugate or payload / conjugate complex / assembly having a thiol-reactive group (e.g., a drug containing a maleimide terminus) to react with the thiol group generated in step (a); and (c) adding an effective amount of an oxidizing agent (e.g., dehydroascorbic acid) to reoxidize unreacted thiol groups, or adding a quenching agent (e.g., N-ethylmaleimide (NEM) or N-ethylmaleimide-3-sulfonate) to quench unreacted thiols in the protein, and then purifying the resulting conjugate; (d) Step (c) can optionally be replaced by adding an effective amount of cystine to quench excess conjugates or conjugate / payload complexes containing thiol-reactive groups (e.g., maleimides) and simultaneously or sequentially adding an azide compound (e.g., 4-(azidomethyl)benzoic acid) or a disulfide compound (e.g., cystine) to quench unreacted reducing agent (e.g., TCEP or tris(hydroxypropyl)phosphine). The addition of cystine to quench unreacted reducing agent (e.g., TCEP) can form a cysteine ​​that can simultaneously quench excess conjugates or conjugate / payload complexes containing thiol-reactive groups (e.g., maleimides).

[0011] Formula Zn(NR 1 R 2 R 3 ) m1 2+ R in 1 , R 2 and R 3are each independently, C 1 -C 8 Alkyl, C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 -C 8 m1 is selected from aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl. m1 is 1, 2, 3, 4, 5, 6, 7, or 8. Preferably, m1 is 1, 2, 3, or 4.

[0012] In addition, (NR 1 R 2 R 3 ) m1 can form dimers, trimers, tetramers, pentamers, or hexamers, and these polymers are N,R 1 , R 2 and / or R 3 They can be covalently linked to form a heterocycle, a carbocycle, a heterobicycle, or a carbobicycle.

[0013] The transition metal cation-amino complex M(NR 1 R 2 R 3 ) m1 m2+ The concentration of is 0.5 to 20 equivalents per mole of protein and is selected from ethanol, methanol, propanol, propanediol, DMA, DMSO, THF, or CH 3 The reaction solution may be added together with a water-miscible organic solvent selected from CN.

[0014] The reducing agent is an organic phosphine, preferably selected from tris(2-carboxyethyl)phosphine (TECP) or tris(hydroxypropyl)phosphine, and is used in a concentration of 0.02 mM to 1.0 mM in the reaction solution or in an amount of 1.0 to 20 equivalents per mole of protein. The oxidizing agent added in step (c) is DHAA, Fe 3+ , I 2 , Cu 2+ , Mn 3+ , MnO2 , or Fe 3+ / I - The oxidizing agent is used in the reaction solution at a concentration of 0.02 mM to 1.0 mM, or at 1 to 100 equivalents per mole of protein. The optimum pH for the conjugation reaction is usually about 5.0 to 8.0, preferably about 5.5 to 7.5. The optimum temperature for the binding reaction is usually about -5 to about 40°C, preferably about 0 to 37°C, more preferably about 2 to 8°C. The optimum time for the conjugation reaction is usually about 15 minutes to about 48 hours, preferably about 30 minutes to overnight (10 to 16 hours). The optimum reaction conditions (pH, temperature, buffer, reactant concentration, etc.) depend in particular on the antibody-like protein, payload / conjugate-linker complex, reducing agent and / or Zn(NR 1 R 2 R 3 ) m1 2+ Depends on.

[0015] The antibody or antibody-like protein in the conjugation method can be any kind of antibody or protein as long as it has two or more disulfide bonds in the protein for differentiation of reduction, and the payload / linker conjugate can be any kind or format as long as it has a thiol-reactive group.

[0016] In short, in the ADCs prepared by the method of the present application, more than 80% of the payload is conjugated to the Fab region of the antibody, as opposed to about 40% of the payload in the conventional method and about 70% of the payload in the Fab region of the antibody using the method of WO2020 / 164561. The advantages of the present application with improved conjugation methods for ADC homogeneity will become more apparent from the following detailed description of several embodiments, experiments, and figures. [Brief description of the drawings]

[0017] [Figure 1] The general synthesis of the components of the bis-linker is shown. [Diagram 2]The synthesis of camptothecin analogs and their conjugates, including bis-conjugated linkers, is presented. [Diagram 3] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 4] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Diagram 5] The general synthesis of the components of the bis-linker is shown. [Figure 6] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 7] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 8] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 9] The general synthesis of the components of the bis-linker is shown. [Figure 10] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 11] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 12] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 13] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 14] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 15] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 16] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 17] 1 shows the synthesis of components of a tubulysin B analogue. [Figure 18] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 19] 1 shows the synthesis of tubulysin B analogs containing bisconjugated linkers. [Figure 20] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 21]1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 22] The synthesis of camptothecin analogs and their conjugates, including bis-conjugated linkers, is presented. [Figure 23] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Figure 24] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers. [Diagram 25] 1 shows the synthesis of camptothecin analogs containing bisconjugated linkers and amanitin analog moieties. [Figure 26] 1 shows the synthesis of amanitin analogs containing bisconjugated linkers. [Figure 27] 1 shows the synthesis of amanitin analogs containing bisconjugated linkers. [Figure 28] 1 shows the synthesis of amanitin analogs containing bisconjugated linkers. [Figure 29] 1 shows the synthesis of amanitin analogs containing bisconjugated linkers. [Diagram 30] 1 shows the synthesis of a tubulysin B analogue conjugate containing a linker. [Diagram 31] 1 shows the synthesis of a tubulysin B analogue conjugate containing a linker. [Diagram 32] 1 shows the synthesis of a tubulysin B analogue conjugate containing a linker. [Diagram 33] 1 shows the synthesis of tubulysin B analogue conjugates containing bis-linkers. [Diagram 34] 1 shows the synthesis of tubulysin B analogue conjugates containing bis-linkers. [Diagram 35] 1 shows the synthesis of tubulysin B analogue conjugates containing bis-linkers. [Diagram 36] 1 shows the synthesis of tubulysin B analogue conjugates containing bis-linkers. [Figure 37] 1 shows the synthesis of tubulysin B analogue conjugates containing bis-linkers. [Figure 38] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Figure 39]1 shows the synthesis of tubulysin B analogue conjugates containing bis-linkers. [Diagram 40] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Diagram 41] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Diagram 42] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Diagram 43] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Diagram 44] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Diagram 45] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Figure 46] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Figure 47] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Figure 48] 1 shows the synthesis of amanitin conjugates containing linkers. [Figure 49] 1 shows the synthesis of a PBD dimer containing a bis-linker. [Figure 50] 1 shows the synthesis of conjugates of camptothecin analogs containing bis-linkers. [Figure 51] 1 shows the synthesis of camptothecin analogs containing bis-linkers. [Figure 52] 1 shows the synthesis of conjugates of camptothecin analogs containing bis-linkers. [Figure 53] 1 shows the synthesis of conjugates of camptothecin analogs containing bis-linkers. [Figure 54] 1 shows the synthesis of conjugates of camptothecin analogs containing bis-linkers. [Figure 55] 1 shows the synthesis of conjugates of camptothecin analogs containing bis-linkers. [Figure 56] 1 shows the synthesis of conjugates of camptothecin analogs containing linkers. [Figure 57] 1 shows the synthesis of conjugates of camptothecin analogs containing bis-linkers. [Figure 58] Mid-level characterization of BCMA-Tublysin B analog ADC (C-390) after N-deglycosylation and reduction. (a) rpHPLC chromatograms of ADC fragments obtained after deglycosylation and DTT reduction: light chains (LC) with 0 or 1 drug molecule attached (L0 and L1), (b) heavy chains with 0, 1, 2, or 3 drug molecules attached (H0, H1, H2, and H3). Results showed that the drug was predominantly (>85%) conjugated at the Fab region. [Figure 59] Percentage of drug-loaded peptides in BCMA ADC (C-390). (a): LC peptide with 0 or 1 drug molecule attached [GEC] (D0 and D1). (b): HC peptide with 0 or 1 drug molecule attached at the arm region [SCDK] (D0 and D1). (c): HC peptide with 0, 1, or 2 drug molecules attached at the hinge region [THTCPPCPAPELLGGPSVFLFPPKPK] (D0, D1, and D2). [Figure 60] Mid-level characterization of Trop2-C608 ADC after reduction: light chains (LC) with 0 or 1 drug molecule attached (L0 and L1), and heavy chains with 0, 1, 2, or 3 drug molecules attached (H0, H1, H2, and H3). Results showed that the drug was predominantly (>85%) conjugated at the Fab region. [Figure 61] Mid-level characterization of cross-linked cysteine ​​conjugates (conjugates of Muc-1-C606) after reduction: light chain (LC), heavy chain (HC), and LC containing a cysteine-bridged HC and one drug molecule (LC+HC+LP). Results showed that the drug was predominantly (>85%) conjugated at the Fab region. [Figure 62] Mid-level characterization of cross-linked cysteine ​​conjugates (conjugates of Muc-1-C72) after reduction: light chain (LC), heavy chain (HC), and LC containing a cysteine-bridged HC and one drug molecule (LC+HC+LP). Results showed that the drug was predominantly (>85%) conjugated at the Fab region. [Figure 63]Medium-level characterization of the reduced cross-linked cysteine conjugate (conjugate of Muc-1-C45). Light chain (LC), heavy chain (HC), and LC containing cysteine-cross-linked HC and one drug molecule (LC+HC+LP). [Figure 64] Medium-level characterization of the reduced cross-linked cysteine conjugate (conjugate of Muc-1-C140). Light chain (LC), heavy chain (HC), and LC containing cysteine-cross-linked HC and one drug molecule (LC+HC+LP). [Figure 65] Changes in tumor volume of BCMA (hu5D2) ADC (C-68a, C-115, C-192, C-202, C-221, C-290, C-306, C-385, C-390, C-399, C-402, C-417) by a series of single doses (3 mg / kg) using a human multiple myeloma NCI-H929 cell xenograft mouse model, compared with belantamab-mcMMAF and PBS buffer (control). This figure shows that all 13 conjugates have antitumor activity, and the order of antitumor activity is C-385 < C-306 < C-290 < C-68a < C-115 < belantamab-mcMMAF < C-192 < C-202 < C-399 < C-390 < C-417 < C-402 < C-221. [Figure 66] Changes in tumor volume of hu5D2-ADC by a series of single doses (5 mg / kg) using a human multiple myeloma JJN-3 cell xenograft mouse model, compared with belantamab-mcMMAF and PBS buffer (control). This figure shows that all 9 conjugates have antitumor activity, and the order of antitumor activity is paclitaxel < C-385 < belantamab-mcMMAF < C-195 < C-137 < C-181b < C-126 < C-83 < C-277 < C-258. [Figure 67]Changes in tumor volume of hu5D2-ADC following a series of single doses (2 mg / kg) using a human multiple myeloma NCI-H929 cell xenograft mouse model, compared with belantamab-mcMMAF and PBS buffer (control). This figure shows that all seven conjugates have antitumor activity, and the order of antitumor activity is belantamab-mcMMAF < C-406 < C-396 < C-399 < C-400 < C-221b < C-402. [Figure 68] Comparison of the antitumor effects of conjugates C-550, C-570-T (conventional conjugate with DAR = 4.0), C-543, C-595, C-570-H (by the homogeneous conjugation of the present invention), C-581, C-582, C-560, C-562, and C-561 with B7H3 antibody, and paclitaxel (15 mg / kg, 3×QW (injected weekly for 3 weeks)) at a dose of 6 mg / kg by intravenous single injection against Calu-6 cells. This figure shows that all ten conjugates have antitumor activity higher than that of paclitaxel, and conjugate C-570 prepared by the method of the present invention shows superior in vivo activity compared to the conjugate prepared by the conventional method. [Figure 69] Comparison of the antitumor effects of conjugates C-553, C-484, C-490, C-450, C-432-T (conventional conjugate with DAR = 4.0), C-501, C-519, C-432-H (by the homogeneous conjugation of the present invention), C-417, and C-560 with Muc1 antibody, and paclitaxel (15 mg / kg, 3×QW (injected weekly for 3 weeks)) at a dose of 6 mg / kg by intravenous single injection against Calu-6 cells. This figure shows that all ten conjugates have antitumor activity higher than that of paclitaxel, and conjugate C-432 prepared by the method of the present invention shows superior in vivo activity compared to the conjugate prepared by the conventional method.

Mode for Carrying Out the Invention

[0018] Definition

[0019] "Alkyl" refers to an aliphatic hydrocarbon group or a monovalent group derived from an alkane by removing one or two hydrogen atoms from a carbon atom. C in the chain1 ~C 8 It may be linear or branched having 1 to 8 carbon atoms. "Branched" refers to a linear alkyl group to which one or more low C alkyl groups, such as methyl, ethyl, or propyl groups, are bonded. Specific examples of the alkyl group include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4-dimethylpentyl, 2-methylheptyl, 3-methylheptyl, n-heptyl, isoheptyl, n-octyl, and isooctyl. 1 ~C 8 An alkyl group may be unsubstituted or substituted with one or more substituents, including but not limited to the following substituents: 1 -C 8 Alkyl, -O-(C 1 ~C 8 Alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH 2 , -C(O)NHR', -C(O)N(R') 2 , -NHC(O)R', -SR', -S(O) 2 R', -S(O)R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN, wherein each R' is independently C 1 ~C 8 It is selected from alkyl and aryl.

[0020] "Halogen" refers to fluorine, chlorine, bromine, or iodine atoms, with fluorine and chlorine atoms being preferred.

[0021] "Heteroalkyl" refers to a C alkyl group in which 1 to 4 carbon atoms are independently replaced by a heteroatom selected from the group consisting of O, S, and N. 2 ~C 8 It means alkyl.

[0022] "Carbocycle" refers to a monocyclic or bicyclic saturated or unsaturated ring having 3 to 8 carbon atoms or 7 to 13 carbon atoms. Monocyclic carbocycles have 3 to 6, more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms arranged as a [4,5], [5,5], [5,6], or [6,6] bicycle, or 9 to 10 ring atoms arranged as a [5,6] or [6,6] bicycle. Representative C 3 ~C 8 Carbocyclic rings (C 3 ~C 8 Carbocycles include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl.

[0023] C 3 ~C 8 Carbocycle (C 3 ~C 8 A carbocycle refers to a saturated or unsaturated non-aromatic hydrocarbon carbocyclic compound having 3, 4, 5, 6, 7, or 8 carbon atoms. 3 ~C 8 A carbocycle may be unsubstituted or substituted with one or more substituents, including, but not limited to, -C 1 ~C 8 Alkyl, -O-(C 1 ~C 8 Alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH 2 , -C(O)NHR', -C(O)N(R') 2, -NHC(O)R', -SR', -S(O)R', -S(O) 2 R', -OH, -halogen, -N 3 , -NH 2 , -NH(R'), -N(R') 2 and -CN, where each R' is independently C 1 ~C 8 It is selected from alkyl and aryl.

[0024] "Alkenyl" refers to an aliphatic hydrocarbon group having a carbon-carbon double bond, which may be straight or branched, having 2 to 8 carbon atoms in the chain. Alkenyl groups include, for example, ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, hexylenyl, heptenyl, and octenyl.

[0025] "Alkynyl" refers to an aliphatic hydrocarbon group having a carbon-carbon triple bond and may be straight or branched having 2 to 8 carbon atoms in the chain. Alkynyl groups include, for example, ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, 5-pentynyl, n-pentynyl, hexynyl, heptynyl, and octynyl.

[0026] "Alkylene" refers to a saturated, straight or branched chain or cyclic hydrocarbon group of 1 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Exemplary alkylene groups include methylene (-CH 2 -), 1,2-ethyl (-CH 2 CH 2 -), 1,3-propyl (-CH 2 CH 2 CH 2 -), 1,4-butyl (-CH 2 CH 2 CH 2 CH 2 -) and the like, but are not limited to these.

[0027] "Alkenylene" refers to an unsaturated, straight or branched chain or cyclic hydrocarbon group of 2 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene groups include, but are not limited to, 1,2-ethylene (-CH=CH-).

[0028] "Alkynylene" refers to an unsaturated, straight or branched chain or cyclic hydrocarbon group of 2 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene groups include, but are not limited to, acetylene, propargyl, and 4-pentynyl.

[0029] "Aryl" or Ar refers to an aromatic or heteroaromatic group consisting of one or several rings, containing 3 to 14 carbon atoms, preferably 6 to 10 carbon atoms. The term "heteroaromatic group" refers to an aromatic group in which one or several carbons, preferably 1, 2, 3 or 4 carbon atoms, on the aromatic group are replaced by O, N, Si, Se, P or S, preferably O, S and N. The term aryl or Ar also refers to an aromatic group in which one or several H atoms are independently replaced by -R', -halogen, -OR', -SR', -NR'R'', -N=NR', -N=R', -NR'R'', -NO 2 , -S(O)R', -S(O) 2 R', -S(O) 2 OR', -OS(O) 2 It also refers to being replaced by -OR', -PR'R'', -P(O)R'R'', -P(OR')(OR'', -P(O)(OR')(OR'', or -OP(O)(OR')(OR''), where R', R'' are independently H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, arylalkyl, carbonyl, or a pharmaceutical salt.

[0030] "Heterocycle" refers to a ring system in which one to four ring carbon atoms are independently replaced with a heteroatom from the group O, N, S, Se, B, Si, and P. Preferred heteroatoms are O, N, and S. Heterocycles are described in The Handbook of Chemistry and Physics, 78th Edition, CRC Press, Inc., 1997-1998, p. 225-226, the disclosure of which is incorporated herein by reference. Preferred non-aromatic heterocycles include, but are not limited to, epoxy, aziridinyl, thiiranyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydropyridyl, dihydropyridyl, tetrahydropyrimidinyl, dihydrothiopyranyl, azepanyl, as well as fused systems resulting from condensation with a phenyl group.

[0031] The term "heteroaryl" or aromatic heterocycle refers to a 3- to 14-membered, preferably 5- to 10-membered, aromatic hetero, monocyclic, bicyclic, or polycyclic ring. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, and fused systems resulting from condensation with a phenyl group.

[0032] The terms "alkyl", "cycloalkyl", "alkenyl", "alkynyl", "aryl", "heteroaryl", "heterocyclic", etc. also refer to the corresponding "alkylene", "cycloalkylene", "alkenylene", "alkynylene", "arylene", "heteroarylene", "heterocyclic", etc. formed by removing two hydrogen atoms. For the sake of convenience, this patent application does not completely distinguish between them.

[0033] "Arylalkyl" refers to an alkyl group consisting of a carbon atom, typically a terminal or sp 3 It refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethene-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl, and the like.

[0034] "Heteroarylalkyl" refers to a heteroaryl group consisting of a carbon atom, typically a terminal or sp 3 It refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced with a heteroaryl group. Typical heteroarylalkyl groups include, but are not limited to, 2-benzimidazolylmethyl, 2-furylethyl, and the like.

[0035] Examples of "hydroxy protecting groups" include, but are not limited to, methoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ether, benzyl ether, p-methoxybenzyl ether, trimethylsilyl ether, triethylsilyl ether, triisopropylsilyl ether, t-butyldimethylsilyl ether, triphenylmethylsilyl ether, acetate, substituted acetate, pivaloate, benzoate, methanesulfonate, and p-toluenesulfonate.

[0036] "Leaving group" refers to a functional group that can be replaced by another functional group. Such leaving groups are well known in the art and include, for example, but are not limited to, halides (e.g., chloride, bromide, and iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate. The leaving group is preferably selected from nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed with themselves or with other anhydrides (e.g., acetic anhydride, formic anhydride); or intermediates generated by condensation reagents for peptide coupling reactions or Mitsunobu reactions.

[0037] The following abbreviations may be used herein and have the definitions given below: Boc, tert-butoxycarbonyl; BroP, bromotrispyrrolidinophosphonium hexafluorophosphate; CDI, 1,1'-carbonyldiimidazole; DCC, dicyclohexylcarbodiimide; DCE, 1,2-dichloroethane; DCM, dichloromethane; DIAD, diisopropyl azodicarboxylate; DIBAL-H, diisobutylaluminum hydride; DIPEA, diisopropylethylamine; DEPC, diethylphosphoroanidinium; DMA, N,N-dimethylacetamide; DMAP, 4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMSO, dimethylsulfoxide; DTT, dithiothreitol. tol; EDC, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; ESI-MS, electrospray mass spectrometry; HATU, O-(7-azabenzotriazol-1-yl)-N,N,N'-N'-tetramethyluronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; HPLC, high pressure liquid chromatography; NHS, N-hydroxysuccinimide; MMP, 4-methylmorpholine; PAB, p-aminobenzyl; PBS, phosphate buffered saline (pH 7.0-7.5); PEG, polyethylene glycol; SEC, size exclusion chromatography; TCEP, tris(2-carboxyethyl)phosphine; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Val, valine.

[0038] The "amino acid(s)" may be natural and / or unnatural amino acids, preferably α-amino acids. Natural amino acids are those encoded by the genetic code: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, tryptophan, and valine. Unnatural amino acids are derived forms of protein-forming amino acids, including, for example, hydroxyproline, lanthionine, 2-aminoisobutyric acid, dehydroalanine, γ-aminobutyric acid (neurotransmitter), ornithine, citrulline, β-alanine (3-aminopropanoic acid), γ-carboxyglutamate, selenocysteine ​​(present in most eukaryotes, but not directly encoded by DNA), pyrrolysine (only found in some archaea and one bacterium), N-formylmethionine (often the first amino acid in proteins in bacteria, mitochondria, and chloroplasts), 5-hydroxytryptophan, L-dihydroxyphenylalanine, triiodothyronine, L-3,4-dihydroxyphenylalanine (DOPA), and O-phosphoserine. The term amino acid also includes amino acid analogs and mimetics. Analogs have the same general H group as the natural amino acids, except that the R group is not one found in the natural amino acids. 2 N(R)CHCO 2An amino acid mimetic is a compound having an H structure. Examples of analogues include homoserine, norleucine, methionine-sulfoxide, and methionine methylsulfonium. Preferably, an amino acid mimetic is a compound that has a structure different from the general chemical structure of an α-amino acid, but functions similarly thereto. The term "unnatural amino acid" is intended to represent the "D" stereochemical form, whereas natural amino acids are in the "L" form. When 1 to 8 amino acids are used in the present application, it is preferred that the amino acid sequence is a cleavage recognition sequence for a protease. Many cleavage recognition sequences are known in the art, see, e.g., Matayoshi et al. Science 247: 954 (1990); Dunn et al. Meth. Enzymol. 241: 254 (1994); Seidah et al. Meth. Enzymol. 244: 175 (1994); Thornberry, Meth. Enzymol. 244: 615 (1994); Weber et al. Meth. Enzymol. 244: 595 (1994); Smith et al. Meth. Enzymol. 244: 412 (1994); and Bouvier et al. Meth. Enzymol. 248: 614 (1995); the disclosures of which are incorporated herein by reference. In particular, the sequence is selected from the group consisting of Val-Cit, Ala-Val, Ala-Ala, Val-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys, Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser, and Glu.

[0039] "Pharmaceutically" or "pharmacologically acceptable" means that the corresponding compound or compound composition does not produce harmful, allergic or other adverse reactions when administered to animals or humans in a suitable manner.

[0040] "Pharmaceutically acceptable solvate" or "solvate" refers to an association of one or more solvent molecules with a disclosed compound. Examples of solvents that form pharmacologically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0041] Pharmaceutically acceptable auxiliary materials include all carriers, diluents, auxiliaries or excipients, such as preservatives, antioxidants, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, solvents, dispersion media, coating agents, antibacterial agents, antifungal agents, isotonic agents, absorption retardants, etc. In the pharmaceutical field, it is a common practice to add these auxiliary materials to active drug components. It can be said that it is reasonable to add auxiliary materials to drug components, except when the auxiliary materials are incompatible with the active drug components. In order to obtain good results, active auxiliary materials may be added to drug components.

[0042] In the present invention, the term "pharmaceutical salt" refers to the salt derivative of the compound of the present invention. Through appropriate modification, the compound of the present invention can be formed into a corresponding acid salt or alkali salt. The pharmaceutical salt includes commonly used non-toxic salts or quaternary ammonium salts, which can be prepared with the compound of the present invention and a corresponding non-toxic inorganic or organic acid. For example, inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, and nitric acid, and organic acids include acetic acid, propionic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, benzenesulfonic acid, glucuronic acid, glutamic acid, benzoic acid, salicylic acid, toluenesulfonic acid, oxalic acid, fumaric acid, and lactic acid, which can be used to form pharmaceutical acceptable salts. Other salts include ammonium salts such as trometamol, meglumine, and pyrrole ethanol, and metal salts such as sodium, potassium, calcium, zinc, and magnesium.

[0043] In the present invention, pharmaceutical salts can be prepared from parent compounds containing acidic or basic residues by conventional chemical methods. Generally, these salts can be obtained by reacting the free acid or free base forms of these compounds with a stoichiometric amount of an appropriate base or acid in water, an organic solvent, or a mixture of the two. Generally, ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred as non-aqueous reaction solvents. A list of suitable salts can be found in "Remington's Pharmaceutical Sciences", 17th Edition, Mack Publishing Company, Easton, PA, 1985, page 1418, the disclosure of which is incorporated by reference.

[0044] "Administering" or "Administration" refers to any manner in which a pharmaceutical or other agent is transferred, delivered, introduced, or conveyed to a subject. Such manners include oral administration, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, nasal, subcutaneous, or cavity administration. Also contemplated by the present invention is the use of a device or instrument in administering an agent. Such devices may utilize active or passive transport and may be slow or fast release delivery devices.

[0045] The abbreviations and chemical names of the biological buffers are as follows: ACES (N-(2-acetamido)-2-aminoethanesulfonic acid) is used for buffering at pH 6.1 to 7.5 (pKa = 6.88). ADA (N-(2-acetamido)iminodiacetic acid, N-(carbamoylmethyl)iminodiacetic acid) is useful for buffering at pH 6.0-7.2 (pKa=6.65). AMPD (2-amino-2-methyl-1,3-propanediol) is useful for buffering at pH 7.8 to 9.7. AMPSO (N-(1,1-dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid). BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid). Bicine (N,N-bis(2-hydroxyethyl)glycine), bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane) is used as a buffer at pH 5.8-7.2 (pKa=8.35). BisTris (Bis-(2-hydroxyethyl)amino-tris(hydroxymethyl)methane). BisTrisBisTrispropane (1,3-Bis[tris(hydroxymethyl)methylamino]propane). DIPSO (N,N-bis(2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid) is used for buffering at pH 7.0 to 8.2. Gly-Gly (diglycine, glycyl-glycine) is used for buffering at pH 7.5-8.9 (pKa=8.30). HEBPS (N-(2-hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) is a homologue of HEPES and EPPS with a higher pKa (pKa = 8.30) and is used for buffering at pH 7.6-9.0. HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 2-morpholinoethanesulfonic acid; 2-(4-morpholino)ethanesulfonic acid; 2-(N-morpholino)ethanesulfonic acid; morpholine-4-ethanesulfonic acid hydrate) is widely used for buffering at pH 6.8-8.2 and has a pKa of 7.45-7.65 at 20 °C. HEPPS or EPPS (3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonic acid hydrate, 4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid) hydrate) is used as a buffer at pH 7.3-8.7 (pKa=8.00 / piperazine ring). HEPPSO (4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid) hydrate). MES (2-(N-morpholino)ethanesulfonic acid, monohydrate) is used as a buffer at pH 5.2-7.1 (pKa: 6.16). MOBS (4-morpholinebutanesulfonic acid; 3-(N-morpholino)butanesulfonic acid hemi-sodium salt) is a homologue of MES and MOPS with a higher pKa / , and is used in buffer solutions with a pH range of 6.9 to 8.3 (pKa: 7.6). MOPS (4-morpholinepropanesulfonic acid sodium salt). MOPSO (β-hydroxy-4-morpholinepropanesulfonic acid, 3-morpholino-2-hydroxypropanesulfonic acid). PIPES (piperazine-1,4-bis(2-ethanesulfonic acid) is used to buffer at pH 6.1-7.5 (pKa=6.80). POPSO (Piperazine-1,4-bis(2-hydroxypropanesulfonic acid) dihydrate). TAPS ([(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]-1-propanesulfonic acid). TAPSO (2-hydroxy-3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid). TES (2-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]ethanesulfonic acid). Tricine (piperazine-N,N'-bis[2-hydroxypropanesulfonic acid]) is used to buffer at pH 7.4-8.8 (pKa: 8.16).

[0046] The term "antibody" is used herein in the broadest sense to encompass a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and fusion proteins comprising antibodies that exhibit the desired antigen-binding activity, and other modified configurations of immunoglobulin molecules that contain antigen recognition sites. Antibodies include antibodies of any class, such as IgG, IgA, or IgM (or subclasses thereof), and an antibody need not be of a particular class. Depending on the amino acid sequence of the constant region of the antibody's heavy chain, immunoglobulins can be assigned to various classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant regions corresponding to the various classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of the various classes of immunoglobulins are well known. "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab-SH, F(ab') 2Humanized antibodies include: diabodies, linear antibodies, single chain antibody molecules (e.g., scFv), and multispecific antibody fragments formed from antibody fragment(s). A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from a non-human HVR and amino acid residues from a human FR. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, with all or substantially all of the HVRs (e.g., CDRs) corresponding to those of a non-human antibody, and with all or substantially all of the HVRs (e.g., CDRs) corresponding to the variable domains of the non-human antibody. Substantially all of the FRs correspond to the FRs of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The heavy and light chain variable domains (VH and VL, respectively) of natural antibodies generally have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR) (see, e.g., Kindt et al., Kuby Immunology, 6 th ed., WH Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a specific antigen can be isolated using the VH or VL domain from an antibody that binds the antigen to screen libraries of complementary VH or VL domains, respectively. See, e.g., Portolano et al., J. Immunol.150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).

[0047] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical except for naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, acting specifically on a single antigenic site. The modifier "monoclonal" indicates that the antibody is obtained from a population of substantially homogeneous antibodies, and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be made by the hybridoma method first described by Kohler and Milstein, Nature 256:495, 1975, or by recombinant DNA methods such as those described in U.S. Pat. No. 4,816,567. Monoclonal antibodies can also be isolated from phage libraries generated using the techniques described in, for example, McCafferty et al., Nature 348:552-554, 1990.

[0048] As used herein, a "humanized" antibody refers to a form of a non-human (e.g., murine) antibody that is a chimeric immunoglobulin, immunoglobulin chain, or fragment thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen binding subsequence of the antibody) that contains minimal sequence derived from the non-human immunoglobulin. Preferably, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some cases, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. Generally, a humanized antibody comprises substantially all of at least one, typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are of the consensus sequence of a human immunoglobulin. The humanized antibody will optimally also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically of a human immunoglobulin. Antibodies with modified Fc regions are preferred, as described in WO 99 / 58572. Another form of humanized antibody has one or more CDRs (CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, or CDR H3) that are "derived from" one or more CDRs of the original antibody, also referred to as one or more CDRs.

[0049] As used herein, "human antibody" refers to an antibody having an amino acid sequence that corresponds to that of an antibody produced by a human and / or an antibody made using any of the techniques for making human antibodies disclosed herein or known to those of skill in the art. This definition of a human antibody includes antibodies that comprise at least one human heavy chain polypeptide or at least one human light chain polypeptide. One such example is an antibody that comprises a mouse light chain and a human heavy chain polypeptide. Human antibodies can be produced using a variety of techniques known in the art. In one embodiment, human antibodies are selected from phage libraries that express human antibodies (Vaughan et al., Nature Biotechnology, 14:309-314, 1996; Sheets et al., Proc. Natl. Acad. Sci (USA) 95:6157-6162, 1998; Hoogenboom and Winter, J. Mol. Biol., 227:381, 1991; Marks et al., J. Mol. Biol., 222:581, 1991). Human antibodies can also be produced by immunization of animals transgenic for human immunoglobulin loci in place of endogenous loci, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. This approach is described in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; and 5,633,425. Alternatively, human antibodies can be prepared by immortalizing human B lymphocytes that produce antibodies against the target antigen (such B lymphocytes can be recovered from an individual or from single cell cloning of cDNA or immunized in vitro). See, for example, Cole et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985; Boerner et al., J. Immunol., 147 (1):86-95, 1991; and U.S. Patent No. 5,750,373.

[0050] The term "chimeric antibody" is intended to refer to an antibody in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, e.g., the variable region sequences are derived from a murine antibody and the constant region sequences are derived from a human antibody.

[0051] The terms "polypeptide", "oligopeptide", "peptide", and "protein" are used interchangeably herein and refer to a chain of amino acids of any length, preferably relatively short (e.g., 10-100 amino acids). The chain may be linear or branched, may contain modified amino acids, and / or may be interrupted by non-amino acids. The term also includes amino acid chains that have been modified, either naturally or by intervention, for example, by formation of disulfide bonds, glycosylation, lipidation, acetylation, phosphorylation, or other manipulations or modifications, such as conjugation with a labeling component. Also included in this definition are polypeptides that contain, for example, analogs of one or more amino acids (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. It is understood that polypeptides can exist as single chains or linked chains.

[0052] A "monovalent antibody" contains one antigen binding site per molecule (e.g., IgG or Fab). In some cases, a monovalent antibody can have one or more antigen binding sites, but the binding sites are from different antigens.

[0053] A "monospecific antibody" contains two identical antigen-binding sites per molecule, such as two binding sites that bind to the same epitope on an antigen (e.g., IgG). Thus, they compete to bind one type of antigen molecule. Most naturally occurring antibodies are monospecific. In some cases, a monospecific antibody may be a monovalent antibody (e.g., Fab).

[0054] A "bivalent antibody" contains two antigen-binding sites per molecule (e.g., IgG). In some cases, the two binding sites may have the same antigen specificity. However, a bivalent antibody may be bispecific.

[0055] "Bispecific" or "dual-specific" refers to a hybrid antibody that has two different antigen-binding sites. The two antigen-binding sites of a bispecific antibody bind to two different epitopes located on the same or different protein targets.

[0056] A "bifunctional" antibody is one that has the same antigen-binding site (ie, the same amino acid sequence) in both arms, but each arm can recognize two different antigens.

[0057] A "heteromultimer," "heteromultimeric complex," or "heteromultimeric polypeptide" is a molecule that comprises at least a first polypeptide and a second polypeptide, where the second polypeptide differs in amino acid sequence from the first polypeptide at at least one amino acid residue. A heteromultimer may comprise a "heterodimer" formed by the first and second polypeptides, or may comprise a higher order tertiary structure that is formed when polypeptides are present in addition to the first and second polypeptides.

[0058] A "heterodimer," "heterodimeric protein," "heterodimeric complex," or "heterodimeric polypeptide" is a molecule comprising a first peptide and a second peptide, where the amino acid sequence of the second peptide differs from the amino acid sequence of the first peptide by at least one amino acid residue.

[0059] In this patent application, the terms "hinge region", "hinge sequence" and variants thereof include the meanings well known in the art, e.g., as set forth in Janeway et al., ImmunoBiology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999); Bloom et al., Protein Science (1997), 6:407-415; Humphreys et al., J. Immunol. Methods (1997), 209:193-202.

[0060] In this patent application, "immunoglobulin-like hinge region", "immunoglobulin-like hinge sequence" and variants thereof refer to the hinge region and hinge sequence of an immunoglobulin-like or antibody-like molecule (e.g., an immunoadhesin). In some embodiments, the immunoglobulin-like hinge region can come from or be derived from any of the IgG1, IgG2, IgG3, or IgG4 subtypes, or IgA, IgE, IgD, or IgM, including chimeric forms thereof, e.g., chimeric IgG1 / 2 hinge regions.

[0061] In this patent application, the term "immune effector cell" or "effector cell" refers to a cell within the natural cellular repertoire of the human immune system that can be activated to affect the viability of a target cell, including the ability of the cell to survive, proliferate, and / or interact with other cells.

[0062] The antibodies of the present invention can be prepared by techniques well known in the art, such as recombinant techniques, phage display techniques, synthetic techniques, or a combination of these techniques with other techniques known in the art (see, e.g., Jayasena, SD, Clin Chem., 45: 1628-50, 1999 and Fellouse, FA, et al., J. Mol. Biol., 373(4): 924-40, 2007).

[0063] In this patent application, the term "cytotoxic agent" refers to a substance that inhibits or prevents cellular function and / or causes cell death or destruction. Cytotoxic agents include radioisotopes (e.g., At211, I131, I125, Y90, In111, Re186, Re188, Sm153, Bi212, P32, Pb212, Zr89, F18, and radioisotopes of Lu, such as Lu177); chemotherapeutic agents or drugs (e.g., tubulysin, maytansine, auristatin, DNA minor groove binders (such as PBD dimers), ducarmysin, topoisomerase inhibitors, RNA polymerase inhibitors, DNA alkylating agents, melanoma inhibitors, erythropoietin ... growth inhibitors; enzymes and fragments thereof, such as nucleases; antibiotics; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin (including fragments and / or variants thereof); and various anti-tumor or anti-cancer agents disclosed throughout this application.

[0064] "Linker" refers to a chemical moiety that contains a covalent bond or chain of atoms that covalently attaches an antibody to a drug moiety. In various embodiments, the linker includes a divalent radical, such as alkyldiyl, aryldiyl, heteroaryldiyl, -(CR 2 ) n O(CR 2 ) n moieties such as -, repeating units of alkyloxy (e.g., polyethyleneoxy, PEG, polymethyleneoxy), and alkylamino (e.g., polyethyleneamino); diacid esters and amides include succinate, succinamide, diglycolate, malonate, and caproamide. In various embodiments, the linker can include one or more amino acid residues such as valine, phenylalanine, lysine, and homolysine.

[0065] In the present specification and claims, the terms "comprise", "comprising", "including" and "includes" are used to indicate the presence of features, integers, components, or steps, but do not exclude the presence or coexistence of one or more other features, integers, components, steps, or groups thereof. The novel conjugates disclosed herein use bridge linkers. Some suitable linkers and their synthetic examples are described herein in embodiments 1-468.

[0066] Conjugation Methods of the Invention

[0067] As disclosed above, a key element of the conjugation method of the present invention is the use of a transition metal cation-amino complex, Zn(NR 1 R 2 R 3 ) m1 2+ Preferably, specific interchain disulfide bonds in antibodies. Previous studies by LC-MS have shown that the interchain disulfide bonds of IgG antibodies are more susceptible to reduction than the intrachain disulfide bonds, and the disulfide bonds between the light and heavy chains are more susceptible to reduction than the disulfide bonds between the two heavy chains. Of the two inter-heavy chain disulfide bonds of IgG antibodies, the upper disulfide bond was more susceptible than the lower one. Furthermore, the disulfide bond of the CH2 domain was the most susceptible to reduction. The disulfide bonds of the VL, CL, VH, and CH1 domains have similar and intermediate susceptibility, while the disulfide bond of the CH3 domain was the least susceptible to reduction (Liu, H, et al Anal. Chem., 2010, 82, 5219-5226). In order to adjust the reduction of disulfide bonds in the IgG antibody of WO2020 / 164561, ZnCl is used at a low temperature of 2 to 8 °C. 2 The use of salts has made it possible to achieve the above distinct reductions. Here, the transition metal cation-amino complexes, M(NR 1 R 2 R3 ) m1 m2+ is very bulky and not only can tune disulfide reduction, but also sterically hinders reducing agents (such as TCEP) to access the disulfide bond between the two heavy chains of an IgG antibody, demonstrating better selective reduction and subsequent conjugation with drug / conjugate complexes.

[0068] The transition zinc cation-amino chelate / complex, Zn(NR 1 R 2 R 3 ) m1 2+ In the formula, R 1 , R 2 and R 3 are each independently, C 1 -C 8 Alkyl, C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 -C 8 m1 is selected from 1, 2, 3, 4, 5, 6, 7, or 8. Preferably, M is Zn 2+ wherein m1 is selected from 1, 2, 3, or 4, and m2 is 2, 3, or 4. More preferably, m1 is 2.

[0069] In addition, (NR 1 R 2 R 3 ) m1 can form dimers, trimers, tetramers, pentamers, or hexamers, and these polymers are N,R 1 , R 2 and / or R 3 Covalent bond between N and R 1 , R 2 and / or R 3 It can itself form a heterocycle, a carbocycle, a heterobicycle, or a carbobicycle.

[0070] Preferred M(NR 1 R2 R 3 ) m1 m2+ is exemplified as follows: Zn(NH 2 CH 3 ) 2 2+ , Zn(NH 2 CH 2 CH 3 ) 2 2+ , Zn(NH 2 CH 2 CH 2 CH 3 ) 2 2+ , Zn(NH 2 CH(CH 3 ) 2 ) 2 2+ , Zn(NH 2 C(CH 3 ) 3 ) 2 2+ , Zn(NH 2 CH 2 C(CH 3 ) 3 ) 2 2+ , Zn(NH(CH 3 ) 2 ) 2 2+ , Zn(NH(CH 2 CH 3 ) 2 ) 2 2+ , Zn(NH(CH(CH 3 ) 2 ) 2 ) 2 2+ , Zn(NH(C(CH 3 ) 3 ) 2 ) 2 2+ , Zn(NH(CH(CH 2 CH3) 2 ) 2 ) 2 2+ , Zn(NH(CH 2 C(CH 3 ) 3 ) 2 )2 2+ 、Zn(NH(CH 2 C(CH 2 CH 3 ) 3 ) 2 ) 2 2+ 、Zn(NH(CH 2 CH 2 C(CH 3 ) 3 ) 2 ) 2 2+ 、Zn(NH 2 CH 2 CH 2 OH) 2 2+ 、Zn(NH(CH 2 CH 2 OH) 2 ) 2 2+ 、Zn(N(CH 2 CH 2 OH) 3 ) 2 2+ 、Zn(NH 2 CH 2 COOH) 2 2+ 、Zn(NH 2 CH 2 CONH 2 ) 2 2+ 、Zn(NH 2 CH 2 COOCH 3 ) 2 2+ 、Zn(NH 2 CH 2 COOCH 2 CH 3 ) 2 2+ 、Zn(NH 2 CH 2 COOC(CH 3 ) 3 ) 2 2+ 、Zn(NH 2 CH 2 COOCH(CH 3 ) 2 ) 2 2+ 、Zn(NH2 CH 2 CH 2 COOH) 2 2+ 、Zn(NH(CH 2 COOH) 2 ) 2 2+ 、Zn(N(CH 2 CH 2 COOH) 3 ) 2 2+ 、Zn(NH 2 CH 3 ) 4 2+ 、Zn(NH 2 CH 2 CH 3 ) 4 2+ 、Zn(NH 2 CH 2 CH 2 CH 3 ) 4 2+ 、Zn(NH 2 CH(CH 3 ) 2 ) 4 2+ 、Zn(NH 2 C(CH 3 ) 3 ) 4 2+ 、Zn(NH 2 CH 2 C(CH 3 ) 3 ) 4 2+ 、Zn(NH(CH 3 ) 2 ) 4 2+ 、Zn(NH(CH 2 CH 3 ) 2 ) 4 2+ 、Zn(NH(CH(CH 3 ) 2 ) 2 ) 4 2+ 、Zn(NH(C(CH 3 ) 3 ) 2 ) 4 2+、Zn(NH(CH(CH 2 CH 3 ) 2 ) 2 ) 4 2+ 、Zn(NH(CH 2 C(CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH(CH 2 C(CH 2 CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH(CH 2 CH 2 C(CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH 2 CH 2 CH 2 OH) 4 2+ 、Zn(NH(CH 2 CH 2 OH) 2 ) 4 2+ 、Zn(N(CH 2 CH 2 OH) 3 ) 4 2+ 、Zn(NH 2 CH 2 COOH) 4 2+ 、Zn(NH 2 CH 2 CONH 2 ) 4 2+ 、Zn(NH 2 CH 2 COOCH 3 ) 4 2+ 、Zn(NH 2 CH 2 COOCH 2 CH 3 ) 4 2+ 、Zn(NH 2 CH 2 COOC(CH3 ) 3 ) 4 2+ , Zn(NH 2 CH 2 COOCH(CH 3 ) 2 ) 4 2+ , Zn(NH 2 CH 2 CH 2 COOH) 4 2+ , Zn(NH(CH 2 COOH) 2 ) 4 2+ , Zn(N(CH 2 CH 2 COOH) 3 ) 4 2+ , [ka] TIFF2024542073000002.tif211170

[0071] All of the complex cations are Cl - , Br - , I - , S.O. 4 2- , HSO 4 - , NO 3 - , P.O. 4 3- , H.P.O. 4 2- , H 2 PO 4 - , CO 3 2- , HCO 3 - , H.C.O.O. - , C.H. 3 COO - , F 3 CCOO - , Cl 3 CCOO - , F.C.H. 2 COO - , ClCH 2COO - , F 2 CHCOO - , Cl 2 CHCOO - , B.F. 4 - , S.O. 3 2- , HSO 3 - , C.H. 3 SO 3 - , C 6 H 5 CH 2 SO 3 - , C 6 H 5 SO 3 - , C 6 H 5 COO - , C 6 H 5 CH 2 COO - , C 6 F 5 O - , C 6 H 4 (OH)COO - , C 6 H 2 F 3 O - , C 6 H 4 (NO 2 )O - , and C 6 H 2 (NO 2 ) 3 O - The salts may be formed with anions selected from, but not limited to,

[0072] The amount of the transition metal cation-amino complex in the reaction solution is 0.5 to 20 equivalents of the antibody, and preferably 1.0 to 5.0 equivalents of the antibody. The transition metal cation-amino complex may be, but is not limited to, ethanol, methanol, propanol, propanediol, DMA, DMF, DMSO, THF, or CH 3The reaction solution may be added together with a water-miscible organic solvent selected from CN.

[0073] The reducing agent used in the reduction solution with transition metal cation-amino complexes is tris(hydroxypropyl)-phosphine (P(CH 2 CH 2 CH 2 OH) 3 ), P(CH 2 CH 3 ) 3 , P(CH 2 CH 2 CH 3 ) 3 , P(CH 2 CH 2 -CH 2 CH 3 ) 3 , P(CH(CH 3 ) 2 ) 3 , P(CH 2 CH=CH 2 ) 3 , P(CH 2 CH 2 CN) 3 , P(CH(CH 3 ) 2 ) 2 (CH 2 CH 2 NH 2 ), P(CH 2 CH 2 CONH 2 ) 3 , P(CH 2 CH 2 CONHCH 3 ) 3 , P(CH 2 CH 2 CH 2 NHCOCH 3 ) 3 , NaB(CN)H 3 , (C 6 H 11 ) 2 P(CH 2 ) 4 P(C 6 H 11 ) 2 , (C 6 H11 ) 2 P(CH 2 ) 3 P-(C 6 H 11 ) 2 , dicyclohexyl(ethyl)phosphine, bis[2-(di-tert-butylphosphine)ethyl]amine, tricyclohexylphosphine, 1,2-ethyldiylbis[dicyclohexyl]-phosphine, bis[2-(dicyclohexylphosphine)ethyl]amine, tris[2-(diphenylphosphine)ethyl]-phosphine ([(C 6 H 5 ) 2 PCH 2 CH 2 ] 3 P), triphenylphosphine, sulfonated triphenylphosphine (2-(diphenylphosphine)benzenesulfonic acid (diPPBS), 3-(diphenylphosphine))benzenesulfonic acid, 4-(diphenylphosphinyl)benzenesulfonic acid, 3,3',3''-phosphoryltribenzenesulfonic acid). Preferably, the reducing agent is selected from TECP or P(CH 2 CH 2 CH 2 OH) 3 The reducing agent is preferably selected from the group consisting of TECP, ...

[0074] Suitable buffers for selective reduction include, but are not limited to, PBS, Mes, Bis-Tris, Bis-Tris propane, Pipes, Aces, Mopso, Bes, Mops, Hepes, Tes, Pipps, Dipso, Tapso, Heppso, Tris-up, Tris-HCl, Tricine, Hepps, Gly-Gly, Bicine, Taps, Hepee, acetate, histidine, citrate, MES, borate, or any two, three or four thereof, and the pH of said buffer is 4.0-9.0, preferably 5.0-7.5, more preferably 5.5-7.5. The concentration of the buffer in the reaction is 0.02-1.0M, preferably 20-200mM, more preferably 20-100mM; as a co-solvent, up to 30% of a water-miscible organic solvent selected from DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropyl alcohol, dioxane, propylene glycol, or ethylene glycol can be added to the aqueous buffer solution.

[0075] The optimum temperature for the reduction reaction is usually controlled at about -5 to 40°C, and the reaction time is 15 minutes to 48 hours. However, it is well understood in the technical field of protein conjugation that the reaction time and temperature can be determined by a person skilled in the art based on the specific protein, especially the antibody to be conjugated. For example, a preferred reduction reaction can usually be controlled at about -5 to 40°C, preferably about 0 to 37°C, more preferably about 2 to 8°C, more precisely 4±1 degrees. The conjugation method is 15 minutes to 12 hours, more preferably at a temperature of about 2 to 8°C, and the process time is about 30 minutes to 15 hours (overnight).

[0076] During or after reduction, the drug / linker complex / assembly is added directly to the reduction reaction solution for conjugation. The drug / linker complex / assembly has formula (I) or (II), which is represented as follows: [ka]

[0077] Lv1 And Lv 2 are thiol reactive groups and are independently selected from: [ka] TIFF2024542073000005.tif238170TIFF2024542073000006.tif231170TIFF2024542073000007.tif244170TIFF20245420730 00008.tif254170TIFF2024542073000009.tif248170TIFF2024542073000010.tif248170TIFF2024542073000011.tif149170

[0078] In the formula, X 1 ' and X 2 ' are independently F, Cl, Br, I, OTf, OMs, OC 6 H 4 (NO 2 ), O.C. 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 HF 4 , or Lv 3 X 2 is O, NH, N(R 1 ), or C.H. 2 R 3 and R 5 are independently H, R 1 , aromatic, heteroaromatic, or aromatic group, and one or several H atoms are independently selected from -R 1 , -Halogen, -OR 1 , -SR 1 , -NR 1 R 2 , -NO 2 , -S(O)R 1 , -S(O) 2 R 1 , or -COOR 1 Replaced by; Lv 3 and Lv 3' is independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl, N-hydroxysuccinimide (NHS), phenoxyl, benzenethiol, dinitrophenoxyl, pentafluorophenoxyl, tetrafluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, triflate, imidazole, dichlorophenoxyl, tetrachlorophenoxyl, 1-hydroxybenzotriazole, tosylate, mesylate, 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed with themselves or other anhydrides, acetyl anhydride, formyl anhydride, or an intermediate molecule generated with a condensation reagent for a peptide coupling reaction or a Mitsunobu reaction.

[0079] E 1 Lv 1 And Lv 2 is a linking group that connects two thiol-reactive groups of E 1 , CH, CH 2 , NH, NHNH, N(R 3 ), N(R 3 )N(R 3’ ), N=N, NN, P, P(=O), S, Si, C 2 ~C 8 Alkyl, heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; a peptide comprising 1-4 units of an amino acid, preferably aspartic acid, glutamic acid, arginine, histidine, lysine, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, tyrosine, phenylalanine, glycine, proline, tryptophan, alanine; or any of the following structures:

[0080] [ka] TIFF2024542073000013.tif48170

[0081] X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 is O, NH, S, N(R 3 ), C.H. 2 are independently selected from; R 3 is C 1 ~C 6 It is an alkyl.

[0082] In formula (II) and formula (III), [ka] can be selected from: [ka] TIFF2024542073000016.tif251170TIFF2024542073000017.tif252170TIFF2024542073000018.tif226170TIFF20245420730 00019.tif232170TIFF2024542073000020.tif248170TIFF2024542073000021.tif247170TIFF2024542073000022.tif123170

[0083] In the formula, Lv 3 , Lv 3 ', X 1 ', and X 2 ' is as above; the bond in the middle of two atoms [ka] means that it can bond to either of the two atoms;

[0084] L 1 , L2 , L 1’ , and L 2’ are the same or different, and each independently represents O, NH, S, NHNH, N(R 3 ), N(R 3 )N(R 3 '), or the formula (OCH 2 CH 2 ) p OR 3 , (OCH 2 CH(CH 3 )) p OR 3 , NH(CH 2 CH 2 O) p OR 3 , NH(CH 2 CH(CH 3 )O)pR3 p OR 3 , N[(CH 2 CH 2 O) p R 3 ][(CH 2 CH 2 O) p’ R 3’ ], (OCH 2 CH 2 ) p COOR 3 , or C.H. 2 CH 2 (OCH 2 CH 2 ) p COOR 3 (wherein p and p' are independently an integer selected from 0 to about 1000), or a combination thereof; 1 -C 8 Alkyl;C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 -C 8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; 3 and R 3’ are independent of each other, H, C 1 -C8 Alkyl;C 2 -C 8 or an ester, ether, or amide having from 1 to 8 carbon atoms; or one to eight natural or unnatural amino acids as described in the definitions; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH(CH 3 )) p where p is an integer from 0 to about 1000, or a combination thereof;

[0085] L 1 , L 2 , L 1’ , and L 2’ may contain self-immolative or non-self-immolative moieties, peptidyl units, hydrazone bonds, disulfide, ester, oxime, amide, or thioether bonds, said self-immolative units including aromatic compounds electronically similar to para-aminobenzylcarbamoyl (PAB) groups, including 2-aminoimidazole-5-methanol derivatives, heterocyclic PAB analogs, β-glucuronides, and ortho- or para-aminobenzyl acetals;

[0086] Preferably, the self-immolative linker moiety has any of the following structures: [ka]

[0087] In the formula, ( * Atoms labeled with X are points of attachment to additional spacers, releasable linker units, cytotoxic agents, and / or cell binding molecules (CBAs); 1 , Y 1 , Z 2 , and Z 3 is independently NH, O or S; Z1 is independently H, NH, O, or S; v is 0 or 1; U 1 are independently H, OH, and C 1 -C 6 Alkyl, (OCH 2 CH 2 ) n , F, Cl, Br, I, OR 5 , S.R. 5 , N.R. 5 R 5’ , N=NR 5 , N=R 5 , N.R. 5 R 5’ , NO 2 , SOR 5 R 5’ , S.O. 2 R 5 , S.O. 3 R 5 , O.S.O. 3 R 5 , P.R. 5 R 5’ , POR 5 R 5’ , P.O. 2 R 5 R 5’ , OPO(OR 5 )(OR 5’ ), or OCH 2 PO(OR 5 )(OR 5’ ) in which R 5 and R 5’ is as above; preferably R 5 and R 5’ are independent of each other, H, C 1 -C 8 Alkyl;C 2 -C 8 Alkenyl, alkynyl, heteroalkyl; C 3 -C 8 aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or a medicinal cationic salt;

[0088] The non-self-immolative linker moiety has any of the following structures: [ka] TIFF2024542073000026.tif252170TIFF2024542073000027.tif66170

[0089] In the formula, ( * ) are atoms marked with an additional spacer R 1 , which is the point of attachment to the releasable linker unit, the cytotoxic agent, and / or the binding molecule; X 1 , Y 1 , U 1 , R 1 , R 5 , R 5’ is as defined above; r is 0 to 100; m and n are independently 0 to 6;

[0090] More preferably, L 1 Or L 2 may be comprised of one or more linker moieties that are 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe" or "af"), p-aminobenzyloxycarbonyl ("PAB"), 4-thiopentanoic acid ("SPP"), 4-(N-maleimidomethyl)cyclohexane-1 carboxylate ("MCC"), (4-acetyl)aminobenzoic acid ("SIAB"), 4-thiobutyric acid (SPDB), 4-thio-2-hydroxysulfonylbutyric acid (2-sulfo-SPDB), or a natural or unnatural peptide having from 1 to 8 natural or unnatural amino acid units.

[0091] More preferably, L 1 Or L 2may be a releasable conjugate. The term releasable conjugate refers to a conjugate that includes at least one bond that can be broken down under physiological conditions, such as pH labile, acid labile, base labile, oxidatively labile, metabolically labile, biochemically labile, or enzymatically labile. Physiological conditions that cause the breakdown of such bonds do not necessarily include biological or metabolic processes, but may instead include standard chemical reactions, such as hydrolysis or substitution reactions, for example disulfide bond exchange reactions with intracellular thiols such as glutathione, which is abundant in the millimolar range in endosomes, which have a lower pH than the cytosolic pH, and / or in malignant cells.

[0092] The releasable conjugate (L, L 1 , L 2 , L 1’ , or L 2’ ) examples include, but are not limited to: -(CR 5 R 6 ) m (Aa) r (CR 7 R 8 ) n (OCH 2 CH 2 ) t -, -(CR 5 R 6 ) m (CR 7 R 8 ) n (Aa) r (OCH 2 CH 2 ) t -, -(Aa) r -(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH 2 CH 2 ) t -, -(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH2 CH 2 ) r (Aa) t -、-(CR 5 R 6 ) m -(CR 7 =CR 8 )(CR 9 R 10 ) n (Aa) t (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (No. 11 CO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (Aa) t (No. 11 CO)(CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (CO)(Aa) t -(CR9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (No. 11 CO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m -(OCO)(Aa) t (CR 9 R 10 ) n -(AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m (CO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-(CR 5 R 6 ) m -phenyl-(CO)(Aa) t (CR 7 R 8 ) n -、-(CR 5 R 6 ) m -フリル-(CO)(Aa) t (CR 7 R 8 ) n -、-(CR5 R 6 ) m -Oxazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -(CR 5 R 6 ) m -Thiazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -(CR 5 R 6 ) t -Thienyl-(CO)(CR 7 R 8 ) n -, -(CR 5 R 6 ) t -Imidazolyl-(CO)(CR 7 R 8 ) n -, -(CR 5 R 6 ) t -Morpholino-(CO)(Aa) t (CR 7 R 8 ) n -, -(CR 5 R 6 ) t -Piperazino-(CO)(Aa) t (CR 7 R 8 ) n -, -(CR 5 R 6 ) t -N-Methylpiperazine-(CO)(Aa) t (CR 7 R 8 ) n -, -(CR 5 R 6 ) m -(Aa) t Phenyl-, -(CR 5 R 6 ) m -(Aa) t Frill-,-(CR 5 R 6 ) m -Oxazolyl (Aa)t -, -(CR 5 R 6 ) m -Thiazolyl (Aa) t -, -(CR 5 R 6 ) m -Thienyl (Aa) t -, -(CR 5 R 6 ) m -Imidazolyl (Aa) t -, -(CR 5 R 6 ) m -Morpholino-(Aa) t -, -(CR 5 R 6 ) m -Piperazino-(Aa) t -, -(CR 5 R 6 ) m -N-Methylpiperazino-(Aa) t -, -K(CR 5 R 6 ) m (Aa) r (CR 7 R 8 ) n (OCH 2 CH 2 ) t -, -K(CR 5 R 6 ) m (CR 7 R 8 ) n (Aa) r (OCH 2 CH 2 ) t -, -K(Aa) r (CR 5 R 6 ) m (CR 7 R 8 ) n (OCH 2 CH 2 ) t -, -K(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH2 CH 2 ) r (Aa) t -、-K(CR 5 R 6 ) m (CR 7 =R 8 )(CR 9 R 10 ) n (Aa) t (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (No. 11 CO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (Aa) t (No. 11 CO)(CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (CO)(Aa) t (CR9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (No. 11 CO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m (CO)(Aa) t (CR 9 R 10 ) n (AND 2 CH 2 ) r -、-K(CR 5 R 6 ) m -phenyl-(CO)(Aa) t (CR 7 R 8 ) n -、-K(CR 5 R 6 ) m -フリル-(CO)(Aa) t (CR 7 R 8 ) n -、-K(CR5 R 6 ) m -Oxazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -Thiazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Thienyl-(CO)(CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Imidazolyl-(CO)(CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Morpholino-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Piperazino-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -N-Methylpiperazine-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -(Aa) t Phenyl-, -K(CR 5 R 6 ) m -(Aa) t Frill-,-K(CR 5 R 6 ) m -Oxazolyl (Aa)t -, -K(CR 5 R 6 ) m -Thiazolyl (Aa) t -, -K(CR 5 R 6 ) m -Thienyl (Aa) t -, -K(CR 5 R 6 ) m -Imidazolyl (Aa) t -, -K(CR 5 R 6 ) m -Morpholino-(Aa) t -, -K(CR 5 R 6 ) m -Piperazino-(Aa) t G-, -K(CR 5 R 6 ) m -N-Methylpiperazino-(Aa) t .

[0093] In the formula, m, Aa, m, n, R 3 , R 4 , and R 5 is defined as above; t and r are independently 0 to 100; R 6 , R 7 , and R 8 are independently: H; halide; C 1 ~C 8 Selected from alkyl, aryl, alkenyl, alkynyl, ether, ester, amine, or amide, and one or more of halide, CN, NR 1 R 2 , C.F. 3 , OR 1 , aryl, heterocycle, S(O)R 1 , S.O. 2 R 1 , -CO 2 H, -SO 3 H, -OR 1 , -CO 2 R 1 , -CONR 1 , -PO 2 R 1 R 12 , -PO3 H or P(O)R 1 R 2 R 3’ K is optionally substituted with NR 1 , -SS-, -C(=O)-, -C(=O)NH-, -C(=O)O-, -C=NH-O-, -C=N-NH-, -C(=O)NH-NH-, O, S, Se, B, or C 3 ~C 6 It is a heteroaromatic ring.

[0094] The connector L 1 , L 2 , L 1’ , and L 2’ The structure may be the following structures or combinations thereof: [ka] TIFF2024542073000029.tif252170TIFF2024542073000030.tif242170TIFF2024542073000031.tif252170TIFF2024542073 000032.tif244170TIFF2024542073000033.tif233170TIFF2024542073000034.tif248170TIFF2024542073000035.tif48170

[0095] In the formula, X 2 , X 3 , X 4 , X 5 , or X 6 are independently NH, NHNH;N(R 12 );N(R 12 )N(R 12’ );O;S;C 1 ~C 6 Alkyl;C 2 ~C 6 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 ~C 8Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl;CH 2 OR 12 , C.H. 2 S.R. 12 , C.H. 2 NHR 12 or 1 to 8 amino acids; 12 and R 12’ are independent, H;C 1 ~C 8 Alkyl;C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH(CH 3 )) p where p is an integer from 0 to about 100; or a combination thereof.

[0096] Furthermore, L 1 , L 2 , X 1 , X 2 , X 3 , X 1’ , X 2’ , and X 3’ may not be present independently.

[0097] In other embodiments, a conjugate of formula (VI), (VII), (VIII), or (IX): In formula (VI), [ka] In formula (VII), [ka] In formula (VIII), [ka] In formula (IX), [ka] is preferably selected from the following structures: [ka] TIFF2024542073000041.tif241170TIFF2024542073000042.tif246170TIFF2024542073000043.tif63170

[0098] During the ceremony, [ka] is a drug or linker L 1 Or L 2 "#" is the site of attachment to an antibody S (thiol), O (phenol), NH (amino), CHO (aldehyde), C(=O) (ketone), C(O)(NH) (amide), C(O)(OH) (carboxylate); Aa is an L- or D-natural or unnatural amino acid.

[0099] R 1 , R 1’ , R 2 , and R 2’ are independent of each other, H, C 1 -C 8 Alkyl, OH, CH 2 OH, CH 2 CH 2 OH, NH 2 , S.H., S.C.H. 3, C.H. 2 COOH, CH 2 CH 2 COOH, CH 2 CH 2 CH 2 CH 2 NH 2 , C 6 H 5 , C.H. 2 C 6 H 5 , C.H. 2 C 6 H 4 OH, CH(OH)CH 3 , C.H. 2 C(O)NH 2 , C.H. 2 CH 2 C(O)NH 2 , C.H. 2 CH 2 CH 2 NHC(=NH)NH 2 is selected from.

[0100] r,r 1 , r 1’ , r 2 , and r 2’ each independently represents 0 to 12; when r is not 0, (Aa)r represents an amino acid or peptide unit of the same or different sequence.

[0101] m 1 and m 1’ are independently 1-18;m 2 and m 2’ are independently 1-100; m 3 and m 3’ are independently 1-8; m 4 and m 4’ are independently 0-8;m 5 and m 5’ are independently 1-8;

[0102] Y 7 and Y 7’ NH, OCH 2 NH, NHC(=O), NHNH, C(=O)NH, N(R 1 ), SO 2, P(O)(OH), NHS(O) 2 , NHS(O) 2 NH, NHS(O) 2 NHC(O), NHS(O) 2 NHC(O)O, NHS(O) 2 NHC(O)NH, NHP(O)(OH), NHP(O)(OH)NH, OP(O)(OH)O, NHP(O)(OH)O, OP(O)(OH)NH, S, O, OP(O)(OH)OP(O)(OH)NH, NHP(O)(OH)OP(O)(OH)NH, NHP(O)(OH)OP(O)(OH)O, OCH 2 CH 2 O, OCH 2 CH 2 NH, N(CH 2 CH 2 ) 2 N, N.H.C. 6 H 4 N.H., C.H. 2 It is.

[0103] Y 8 and Y 8’ is NHC(=O), NHS(O 2 ), NH(SO), NHS(O 2 )NH, NHP(O)(OH)NH, or C(O)NH.

[0104] Y 9 and Y 9’ is H, (O=)CR 1 , (O=)CNHR 1 , R 1 COOH, R 1 (COCH 2 NH)m 2 H, R 1 (Aa) r or R 1 (COCH 2 NCH 3 ) m2 H, where R 1 is defined above.

[0105] The cytotoxic agent is selected from, but not limited to:

[0106] 1) Chemotherapy: a) alkylating agents selected from the group consisting of: nitrogen mustards: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, nobembitine, phenesterine, prednimustine, thiotepa, trofosfamide, uracil mustard; CC-1065 and synthetic analogs of adozelesin, carzelesin and bizelesin; duocarmycin and its synthetic analogs KW-2189 and CBI-TMI; benzodiazepine dimers or pyrrolobenzodiazepine (PBD) dimers, tomaymycin dimers, indolinobenzodiazepine dimers. nitrosourea compounds including carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine; alkylsulfonates including busulfan, treosulfan, improsulfan, and piposulfan; triazenes or dacarbazines; platinum-containing compounds including carboplatin, cisplatin, and oxaliplatin; aziridines, benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelanamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramine, and trimethylolomelamine; b) plant alkaloids selected from the group consisting of: vinca alkaloids including vincristine, vinblastine, vindesine, vinorelbine, navelbine; taxoids including paclitaxel and docetaxel and analogs thereof; maytansinoids including DM1, DM2, DM3, DM4, DM5, DM6, DM7, maytansine, ansamitocins and analogs thereof; cryptophycins including the cryptophycin 1 and cryptophycin 8 groups; epothilones, eleutherobin, discodermolide, bryostatins, dolostatins, auristatins, tubulysins, cephalostatins; pancratistatin; sarcodictiin; spongistatin; c) DNA topoisomerase inhibitors selected from: epipodophyllins, including 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acid (retinols), teniposide, topotecan, 9-nitrocamptothecin, or RFS 2000; and mitomycins, and their analogs; d) Antimetabolites: {[Antifolates: (DHFR inhibitors: including methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid), or other folate analogs); IMP dehydrogenase inhibitors (including mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase inhibitors (including hydroxyurea, deferoxamine)]; [Pyrimidine analogs: uracil uridine analogs (including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-fluorouracil, floxuridine, raltitrexed); cytosine analogs: (including cytarabine, cytosine arabinoside, fludarabine); purine analogs: (including azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine); folic acid supplements such as folinic acid; e) Hormonal Therapy: Receptor Antagonists: [Antiestrogens: (including megestrol, raloxifene, tamoxifen); LHRH Agonists: (including goserelin, leuprolide acetate); Antiandrogens: (including bicalutamide, flutamide, calsterone, dromostanolone propionate, epithiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane, and other similar androgen inhibitors. retinoids / deltoids: [vitamin D3 analogs: (including CB1093, EB1089, KH1060, cholecalciferol, ergocalciferol); photodynamic therapy agents: (including verteporfin, phthalocyanines, photosensitizer Pc4, demethoxyhypocrelin A); cytokines: (including interferon alpha, interferon gamma, tumor necrosis factor (TNF), TNF domain-containing human proteins)]}; f) Kinase inhibitors: selected from the group consisting of BIBW2992 (anti-EGFR / Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab, panitumumab, ispinesib; g) a poly(ADP-ribose) polymerase (PARP) inhibitor selected from the group consisting of olaparib, niraparib, iniparib, talazoparib, veliparib, CEP9722 (Cephalon), E7016 (Eisai), BGB-290 (Beigene), or 3-aminobenzamide; h) enediyne antibiotics (selected from the calicheamicins, calicheamicin gamma 1, delta 1, alpha 1, or beta 1; dynemicins including dynemicin A and deoxydynemicin; esperamicin, kedarcidin, C-1027, maduropeptin, or neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunomycin, Antibiotics selected from rubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin, epirubicin, eribulin, esorubicin, idarubicin, marcelomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potofilomycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; i) Polyketides (acetogenins), bullatacin and bullatacinone; gemcitabine, epoxomicins and carfilzomib, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, zygeva, probenge, elvoi, isoprenylation inhibitors and lovastatin, dopaminergic neurotoxins and 1-methyl-4-phenyl Pyridine ion, cell cycle inhibitors (including staurosporine), actinomycins (including actinomycin D and dactinomycin), amanitins, bleomycins (including bleomycin A2, bleomycin B2, and peplomycin), anthracyclines (including daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, and zorubicin), mitoxantrone, MDR inhibitors or verapamil, Ca 2+ATP inhibitors or thapsigargin, histone deacetylase inhibitors (including vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat (MGCD0103), belinostat, PCI-24781, entinostat, SB939, resminostat, gibinostat, AR-42, CUDC-101, sulforaphane, trichostatin A); thapsigargin, celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A, antiadrenal drugs (selected from the group consisting of aminoglutethimide, mitotane, trilostanca); aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; arabinoside, bestravsil; bisanto len;edatrexate;defofamine;demecolcine;diaziquone;elfornitine (DFMO), elfomitine;elliptinium acetate;ethocluside, gallium nitrate, gacytosine, hydroxyurea;ibandronate, lentinan;lonidamine;mitoguazone;mopidamol;nitracrine;pentostatin;phenamet;pirarubicin;podophyllic acid;2-ethylhydrazide;procarbazine;PSK (registered trademark);razoxane;rhizoxin;sizofiran;spirogermanium;tenuazonic acid;triaziquone;2,2',2''-trichlorotriethylamine;trichothecenes (including T2 toxin, verrucarin A, roridin A, and anguidine);urethane, siRNA, antisense drugs, nucleases;

[0107] 2) Anti-autoimmune disease drugs: cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticoids (including amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, triamcinolone acetonide, and beclomethasone dipropionate), DHEA, etanercept, hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenolate, prednisone, sirolimus, and tacrolimus;

[0108] 3) Anti-infectives, including but not limited to: a) Aminoglycosides: amikacin, astromycin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamycin; b) Amphenicols: azidamphenicol, chloramphenicol, florfenicol, thiamphenicol; c) Ansamycins: geldanamycin, herbimycin; d) Carbapenems: biapenem, doripenem, ertapenem, imipenem, cilastatin, meropenem, panipenem; e) Cephalosporins: carbacephems (loracarbef), cephacetrile, cefaclor, cephradine, cefadroxil, cephalonium, cephaloridine, cephalothin or cephalothin, cephalexin, cephaloglycin, cefamandole, cephapirin, cefatrizine, cefazaflur, cephazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, fetameth, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftiolene, ceftizoxime, ceftobiprol, ceftriaxone, cefuroxime, cefuzonam, cephamycins (including cefoxitin, cefotetan, cefmetazole), oxacephems (flomoxef, latamoxef); f) Glycopeptides: bleomycin, vancomycin (including oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g) Glycylcyclines: Tigecycline; h) β-lactamase inhibitors: penams (sulbactam, tazobactam), clavams (clavulanic acid); i) Lincosamides: clindamycin, lincomycin; j) Lipopeptides: daptomycin, A54145, calcium-dependent antibiotics (CDA); k) Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolides (telithromycin, cethromycin), midecamycin, miocamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; l) Monobactams: aztreonam, tigemonam; m) Oxazolidinones: Linezolid; n) Penicillins: amoxicillin, ampicillin, pivampicillin, hetacillin, bacampicillin, methampicillin, talampicillin, azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, methicillin, nafcillin, oxacillin, penamecillin, penicillin, phenethicillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o) Polypeptides: bacitracin, colistin, polymyxin B; p) Quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, canotrovafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin; q) Streptogramins: Pristinamycin, quinupristin / dalfopristin; r) Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s) Steroidal antibacterial agents: fusidic acid, etc.; t) Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (tigecycline, etc.); u) Other antibiotics: annonacin, arsphenamine, bactoprenol inhibitors (bacitracin), DADAL / AR inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin / dalfopristin, rifampicin (rifampin), tazobactam tinidazole, uvaricin;

[0109] 4) Antiviral drugs: a) Entry / fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO140, CD4 (ibalizumab); b) Integrase inhibitors: Raltegravir, Elvitegravir, Globoidonan A; c) Maturation inhibitors: Bevirimat, Vivecon; d) Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e) Nucleosides and Nucleotides: Abacavir, Acyclovir, Adefovir, Amdoxovir, Apricitabine, Brivudine, Cidofovir, Clevudine, Dexerbucitabine, Didanosine (DDI), Elvucitabine, Emtricitabine (FTC), Entecavir, Famciclovir, Fluorouracil (5-FU), 3'-Fluoro substituted 2',3'-deoxynucleoside analogues (e.g., 3'-Fluoro-2',3'-dideoxythymidine (FLT) and 3'-Fluoro-2',3'-deoxythymidine (FLT)). dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridine, lamivudine (3TC), L-nucleosides (e.g., β-L-thymidine and β-L-2'-deoxycytidine), penciclovir, rasvir, ribavirin, stampidine, stavudine set (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine, valacyclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f) Non-nucleosides: amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphorylformate), imiquimod, interferon alpha, loviride, rhodnosine, methisazone, nevirapine, NOV-205, peginterferon alpha, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g) Protease inhibitors: amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h) Other antiviral drugs: Abzyme, Arbidol, Calanolide A, Seragenin, Cyanovirin-N, Diarylpyrimidines, Epigallocatechin gallate (EGCG), Foscarnet, Griffithsin, Taribavirin (Viramidine), Hydroxyurea, KP-1461, Miltefosine, Pleconaril, Portmanteau inhibitors, Ribavirin, Seliciclib;

[0110] 5) Drugs used in the bridged conjugates of the present invention also include radioisotopes. Examples of radioisotopes (radionuclides) are: 3 H, 11 C. 14 C. 18 F, 32 P, 35 S, 64 Cu, 68 Ga, 86 Y, 99 Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 133 Xe, 177 Lu, 211 At, or 213 Bi. Radioisotope-labeled antibodies are useful for receptor targeting imaging experiments or can be used for targeted therapy, such as with the antibody-drug conjugates of the present invention (Wu et al (2005) Nature Biotechnology 23(9): 1137-46). Cell-binding molecules, such as antibodies, can be labeled with ligand reagents via the bridge linkers of this patent that bind, chelate, or complex to radioisotope metals using techniques described in Current Protocols in Immunology, Volume 1 and 2, Coligen et al, Ed. Wiley-Interscience, New York, Pubs. (1991). Chelating ligands that can complex with metal ions include DOTA, DOTP, DOTMA, DTPA, and TETA (Macrocyclics, Dallas, Tex. USA).

[0111] 6) Pharmaceutically acceptable salts, acids, or derivatives of any of the above drugs.

[0112] In another embodiment, the drug D can be a chromophore molecule for detecting, monitoring or studying the interaction of the cell-binding molecule with the target cell. A chromophore molecule capable of absorbing UV light, fluorescent light, IR light, near-IR light, visible light; xanthophores, erythrophores, iridophores, leucophores, melanophores, cereophores; a class or subclass of fluorescent molecules, which are fluorescent chemicals that re-emit light with light; a class or subclass of visual light-sensitive molecules; a class or subclass of light-emitting molecules; a class or subclass of luminescent molecules; and a class or subclass of luciferin compounds.

[0113] Chromophore molecules include, but are not limited to, the following non-protein organic fluorophores: xanthene derivatives (including fluorescein, rhodamine, Oregon Green, eosin, and Texas Red); cyanine derivatives (including cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, and merocyanine); squalene derivatives and ring-substituted squaraines (including Seta, SeTau, and Square dyes); naphthalene derivatives (including dansyl and prodan derivatives); coumarin derivatives; oxadiazole derivatives (including pyridyloxazole, nitrobenzoxadiazole, and benzoxadiazole); anthracene derivatives (including anthraquinones, including DRAQ5, DRAQ7, and CyTRAK Orange); pyrene derivatives (Cascade Blue); oxazine derivatives (including Nile Red, Nile Blue, Cresyl Violet, Oxazine 170); acridine derivatives (including proflavine, acridine orange, acridine yellow); arylmethine derivatives (including auramine, crystal violet, malachite green). It may be selected from tetrapyrrole derivatives (including porphines, phthalocyanines, bilirubins).

[0114] Alternatively, the chromophore molecule can be selected from analogs and derivatives of the following fluorophore compounds: CF dyes (Biotium), DRAQ and CyTRAK probes (BioStatus), BODIPY (Invitrogen), Alexa Fluor (Invitrogen), DyLight Fluor (Thermo Scientific, Pierce), Atto and Trancy (Sigma Aldrich), FluoProbes (Interchim), Abberior dyes (Abberior), DY and MegaStokes dyes (Dyomics), SulfoCy dyes (SETA BioMedicals), HiLyte Fluor (Biosearch Technologies), Seta, SeTau and Square dyes (SETA BioMedicals), Quasar and Cal Flour dyes (Biosearch Technologies), SureLight dyes (APC, RPEPerCP, Phycobilisomes) (Columbia Biosciences), APC, APCXL, RPE, BPE (Phyco-Biotech).

[0115] Examples of widely used fluorophore compounds that are reactive or conjugable with the conjugates of the invention are: allophycocyanin (APC), aminocoumarin, APC-Cy7 conjugates, BODIPY-FL, Cascade Blue, Cy2, Cy3, Cy3.5, Cy3B, Cy5, Cy5.5, Cy7, fluorescein, FluorX, hydroxycoumarin, Lissamine rhodamine B, Lucifer Yellow, methoxycoumarin, NBD, Pacific Blue, Pacific Orange, PE-Cy5 conjugate, PE-Cy7 conjugate, PerCP, R-Phycoerythrin (PE), Red613, Seta-555-azide, Seta-555-DBCO, Seta-555-NHS, Seta-580-NHS, Seta-680-NHS, Seta-780-NHS, Seta-APC-780, Seta-PerCP-680, Seta-R-PE-670, SeTau380-NHS, SeTau405-maleimide, SeTau405-NHS, SeTau425-NHS, SeTau647-NHS, Texas Red, TRITC, TruRed, and X-Rhodamine.

[0116] For the study of nucleic acids or proteins, fluorophore compounds that can be attached to the conjugates of the invention are selected from the following compounds or their derivatives: 7-AAD (7-aminoactinomycin D, CG selective), acridine orange, chromomycin A3, CyTRAK orange (red excitation dark), DAPI, DRAQ5, DRAQ7, ethidium bromide, Hoechst 33258, Hoechst 33342, LDS751, mithramycin, propidium iodide (PI), SYTOX blue, SYTOX green, S YTOX Orange, Thiazole Orange, TO-PRO: Cyanine Monomer, TOTO-1, TO-PRO-1, TOTO-3, TO-PRO-3, YOseta-1, YOYO-1; Fluorescent dyes including the following compounds or their derivatives: DCFH (2'7'-dichlorodihydro-fluorescein, oxidized form), DHR (dihydrorhodamine 123, oxidized form, photocatalytic oxidation), Fluo-3 (AM ester, pH>6), Fluo-4 (AM ester, pH7.2), Indo-1 (AM ester, low / high calcium (Ca 2+)), SNARF (pH6 / 9), Allophycocyanin (APC), AmCyan1 (tetramer, Clontech), AsRed2 (tetramer, Clontech), Azami Green (monomer), Azurite, B-Phycoerythrin (BPE), Cerulean, CyPet, DsRed monomer (Clontech), DsRed2 ("RFP"), EBFP, EBFP2, ECFP, EGFP (weak dimer), Emerald (weak dimer), EYFP (weak dimer), GFP (S65A mutant), GFP (S65C mutant), GFP (S65L mutant), GFP (S65T mutant), GFP (Y66F mutant), GFP (Y66H mutant), GFP (Y66W mutant), GFP uv , HcRed1, J-Red, Katyusha, Kusabira Orange (monomer, MBL), mCFP, mCherry, mCitrine, Midriishi Cyan (dimer, MBL), mKate (TagFP635, monomer), mKeima-Red (monomer), mKO, mOrange, mPlum, mRaspberry, mRFP1 (monomer), mStrawberry, mTFP1, mTurquoise2, P3 (phycobilisome complex), Peridinin Chlorophyll (PerCP), R-phycoerythrin (RPE), T-Sapphire, TagCFP (dimer), TagGFP (dimer), TagRFP (dimer), TagYFP (dimer), tdTomato (tandem dimer), Topaz, TurboFP602 (dimer), TurboFP635 (dimer), TurboGFP (dimer), TurboRFP (dimer), TurboYFP635 (dimer), Venus, native GFP, YPet, Zs Green 1 (tetramer), Zs Yellow 1 (tetramer), and their derivatives.

[0117] In another embodiment, drug D can be a polyalkylene glycol used to extend the half-life of a cell-binding antibody or antibody-like protein molecule when administered to a mammal. Polyalkylene glycols include, but are not limited to, polyalkylene glycols selected from poly(ethylene glycol) (PEG), poly(propylene glycol), and copolymers of ethylene oxide and propylene oxide; particularly preferred are PEGs, and more particularly preferred are monofunctionally activated hydroxyPEGs (e.g., hydroxyPEGs activated at one end, including hydroxyPEG-monocarboxylic acids, hydroxyPEG-monoaldehydes, hydroxyPEG-monoamines, hydroxyPEG-monohydrazides, hydroxyPEG-monocarbazides, hydroxyPEG-monoiodoacetamides, hydroxyPEG-monomaleimides, hydroxyPEG-orthopyridine disulfides, hydroxyPEG-monoximes, hydroxyPEG-monophenylcarbonates, hydroxyPEG-monophenylglyoxals, hydroxyPEG-monothiazolidine-2-thiones, hydroxyPEG-monothioesters, hydroxyPEG-monothiols, hydroxyPEG-monotriazines, and hydroxyPEG-monovinylsulfones).

[0118] In certain such embodiments, the polyalkylene glycol has a molecular weight of about 10 Daltons to about 200 kDa, preferably about 88 Da to about 40 kDa; two branches each having a molecular weight of about 88 Da to about 40 kDa; and more preferably, two branches each having a molecular weight of about 88 Da to about 20 kDa. In a particular embodiment, the polyalkylene glycol is poly(ethylene) glycol and has a molecular weight of about 10 kDa; about 20 kDa, or about 40 kDa. In certain embodiments, the PEG is PEG 10 kDa (linear or branched), PEG 20 kDa (linear or branched), or PEG 40 kDa (linear or branched). Many U.S. patents, such as U.S. Patent Nos. 5,428,128; 5,621,039; 5,622,986; 5,643,575; 5,728,560; 5,730,990; 5,738,846; 5,811,076; 5,824,701; 5,840,900; 5,880,131; 5,900,402; 5,902,588; 5,919,455; 5,951,974; 5,965,119; 5,965,566; 5,969,040; 5,981,709; 6,011,042; 6,042,822; Nos. 6,113,906; 6,127,355; 6,132,713; 6,177,087; and 6,180,095 disclose the preparation of linear or branched "non-antigenic" PEG polymers and their derivatives or conjugates.

[0119] In yet another embodiment, D is more preferably a potent cytotoxic agent, such as tubulysin and its analogs, maytansine and its analogs, taxanes and its analogs, CC-1065 and its analogs, daunorubicin or doxorubicin and its analogs, amatoxin and its analogs, benzodiazepine dimers (dimers of pyrrolobenzodiazepines (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinobenzodiazepines) and their analogs, calicheamicin, and enediyne antibiotic analogs, actinomycin and its analogs, azaserine and its analogs, bleomycin and its analogs, epirubicin and its analogs, tamoxifen and its analogs, idarubicin and its analogs, dolastatins and their analogs, auristatins (including monomethylauristatin (MMAE), MMAF, auristatin PYE, auristatin TP, auristatin 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)) and their analogs, combretastatins, duocarmycins and their analogs, and its analogues, camptothecin and its analogues, geldanamycin and its analogues, methotrexate and its analogues, thiotepa and its analogues, vindesine and its analogues, vincristine and its analogues, hemiasterin and its analogues, nazmamide and its analogues, spliceostatin, pladienolide, microginin and its analogues, radiosumin and its analogues, alterobactin and its analogues, microsclerodermin and its analogues, theonellamide and its analogues, The therapeutic agent is selected from esperamicin and its analogs, PNU-159682 and its analogs, protein kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, immunotoxins, specific cell receptor agonists, cell stimulatory or intracellular signaling molecules, one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA), as well as stereoisomers, equivalents, analogs, or derivatives of the above-mentioned drugs.

[0120] Tubulysin and its analogs are well known in the art and can be isolated from natural sources according to known methods or prepared synthetically according to known methods (e.g., Balasubramanian, R., et al. J. Med. Chem., 2009, 52, 238-40; Wipf, P., et al. Org. Lett., 2004, 6, 4057-60; Pando, O., et al. J. Am. Chem. Soc., 2011, 133, 7692-5; Reddy, JA, et al. Mol. Pharmaceutics, 2009, 6, 1518-25; Raghavan, B., et al. J. Med. Chem., 2008, 51, 1530-33; Patterson, AW, et al. J. Org. Chem., 2008, 73, 4362-9; Pando, O., et al. Org. Lett., 2009, 11 (24), 5567-9; Wipf, P., et al. Org. Lett., 2007, 9 (8), 1605-7; Friestad, GK, Org. Lett., 2004, 6, 3249-52; Peltier, HM et al., J. Am. Chem. Soc., 2006, 128, 16018-9; Chandrasekhar, S., et al. J. Org. Chem., 2009, 74, 9531-4; Liu, Y., et al. Mol. Pharmaceutics, 2012, 9, 168-75; Friestad, GK, et al Org. Lett., 2009, 11, 1095-8; Kubicek, K., et al., Angew Chem Int Ed Engl, 2010.49: 4809-12; Chai, Y., et al., Chem Biol, 2010, 17 : 296-309; Ullrich, A., et al.,Angew Chem Int Ed Engl, 2009, 48, 4422-5; Sani, M., et al., Angew Chem Int Ed Engl, 2007, 46, 3526-9. Domling, A., et al., Angew Chem Int Ed Engl, 2006, 45, 7235-9; Patent Applications: Zanda, M., et al., Canadian Patent Application CA 2710693 (2011); Chai, Y., et al., European Patent Application 2174947 (2010), WO 2010034724; Leamon, C., et al., WO2010033733, WO2009002993; Ellman, J., et al., PCT WO2009134279; WO 2009012958, US Applications 20110263650, 20110021568; Matschiner, G., et al., WO2009095447; Vlahov, I., et al., WO2009055562, WO2008112873; Low, P., et al., WO2009026177; Richter W., WO2008138561; Kjems, J., et al.,WO 2008125116; Davis, M., et al., WO2008076333; Diener, J., et al., U.S. Patent Application No. 20070041901, WO2006096754; Matschiner, G., et al., WO2006056464; Vaghefi, F., et al., WO2006033913; Doemling, A., German Patent Application DE102004030227, WO2004005327, WO2004005326, WO2004005269; Stanton, M., et al, US Patent No. 20040249130; Hoefle, G., et al, Ger. OffenDE10254439, DE10241152, DE10008089; Leung, D., et al. al, WO2002077036; Reichenbach, H., et al, Ger. Offen. DE19638870; Wolfgang, R., US20120129779; Chen, H. Preferred structures of tubulysin for conjugation with cell-binding molecules by the methods of the present patent application are described in patent application PCT / IB2012 / 053554.

[0121] A tubulysin analog having the following formula (IV): or a pharma- ceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystal structure; or an optical isomer, racemate, diastereomer, or enantiomer thereof: [ka]

[0122] [ka] is independent, L 1 and / or L 2 This is the binding site that binds to [ka] Two of them are L 1 and L 2 , R 1 and R 2 , or Z 2 and Z 3 Preferably it is a double bond site, when it binds to both:

[0123] R 1 , R 2 , R 3 , and R 4 are independent of each other, H, C 1 ~C 8 Alkyl;C 2 ~C 8 Heteroalkyl or heterocyclic ring; C 3 ~C 8 Ar is aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or R1 R 2 , R 1 R 3 , R 2 R 3 , R 3 R 4 , R 5 R 6 , R 11 R 12 , or R 13 R 14 forms a 3- to 7-membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; L 1 Or L 2 When independently or simultaneously bound to R 1 and R 2 may be absent independently; Y 1 is N or CH.

[0124] In the formula, R 5 , R 6 , R 8 , R 10 , and R 11 are independently H or C 1 ~C 4 It is alkyl or heteroalkyl.

[0125] In the formula, R 7 are independent, H, R 14 , -R 14 C(=O)X 1 R 15 ; or -R 14 X 1 R 15 X 1 are O, S, SS, NH, and CH 2 , or NR 14 It is.

[0126] In the formula, R 9 are H, OH, -O-, =O, -OR 14 , -OC(=O)R 14 , -OC(=O)NHR 14 -, -OC(=O)R 14 SSR 15 -, OP(=O)(OR 14 )-, -OC(=O)NR 14R 15 ,OP(=O)(OR 14 ), OR 14 OP(=O)(OR 15 ) is selected.

[0127] In the formula, R 11 are independent, H, R 14 , -R 14 C(=O)R 16 , -R 14 X 2 R 16 , -R 14 C(=O)X 2 Wherein, X 2 -O-, -S-, -NH-, -N(R 14 )-, -OR 14 -, -SR 14 -, -S(=O)-R 14 - or -NHR 14 It is.

[0128] In the formula, R 12 is R 15 , -OH, -SH, -NH 2 , N.H., N.H. 2 , -NH(R 15 ), -OR 15 , -R 15 COR 16 , -R 15 COOR 16 , -R 15 C(O)NH 2 , -R 15 C(O)NHR 17 , -SR 16 , R 15 S(=O)R 16 , -R 15 P(=O)(OR 17 ) 2 , -R 15 OP(=O)(OR 17 ) 2 , -CH 2 OP(=O)(OR 17 ) 2 , -R 15 SO 2 R 17 , -R 15 X 2 R16 , -R 15 C(=O)X 2 Wherein X 2 -O-, OH, SH, -S-, NH 2 , -NH-, -N(R 15 )-, -OR 15 -, -SR 15 -, -S(=O)-R 15 -, CH 2 , or -NHR 15 -It is.

[0129] R 13 and R 14 are independently H, O, S, NH, N(R 15 ), NHNH, -OH, -SH, -NH 2 , N.H., N.H. 2 , -NH(R 15 ), -OR 15 , CO, -COX 2 , -COX 2 R 16 , R 17 , F, Cl, Br, I, SR 16 , N.R. 16 R 17 , N=NR 16 , N=R 16 , NO 2 , SOR 16 R 17 , S.O. 2 R 16 , S.O. 3 R 16 , O.S.O. 3 R 16 , P.R. 16 R 17 , POR 16 R 17 , P.O. 2 R 16 R 17 , OP(O)(OR 17 ) 2 , O.C.H. 2 OP(O)(OR 17 ) 2 , O.C.(O)R 17 ,OC(O)OP(O)(OR 17 ) 2 , PO(OR 16 )(OR 17), OP(O)(OR 17 )OP(O)(OR 17 ) 2 , O.C.(O)N.H.R. 17 ;-O-(C 4 ~C 12 Glycoside), -N-(C 4 ~C 12 Glycoside);C 1 ~C 8 Alkyl, heteroalkyl;C 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl;C 3 ~C 8 Aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, or an ester, ether, or amide having 2 to 8 carbon atoms; or a peptide containing 1 to 8 amino acids (NH(Aa) 1~8 or CO(Aa) 1~8 (N-terminus or C-terminus (Aa) r , r=1 to 8 identical or different amino acid sequences), or the formula (OCH 2 CH 2 ) p or (OCH 2 CH(CH 3 )) p (wherein p is an integer from 0 to about 1000), or a combination of the above groups; X 2 are O, S, SS, NH, and CH. 2 , O.H., S.H., and N.H. 2 , C.H.R. 14 , or N.R. 14 It is.

[0130] R 15 , R 16 , and R 17 are independent of each other, H, C 1 ~C 8 Alkyl, heteroalkyl;C 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl;C 3 ~C 8Aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, alkylcarbonyl, or Na + , K + , Cs + , Li + , Ca 2+ , Mg + , Zn 2+ , N + (R 1 )(R 2 )(R 3 )(R 4 ) or HN + (C 2 H 5 OH) 3 It's salt.

[0131] Y 1 and Y 2 is independently N or CH; q is 0 or 1; when q=0, Y 3 does not exist, and Y 4 , Y 5 , Y 6 , and Y 7 are independently CH, N, NH, O, S, or N(R1), so that Y 2 , Y 4 , Y 5 , Y 6 , and Y 7 forms heteroaromatic rings of furan, pyrrole, thiophene, thiazole, oxazole, imidazole, pyrazole, triazole, tetrazole, thiadiazole; when q=1, Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 are independently CH or N, so Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 form the aromatic rings of benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine, and pentazine.

[0132] In particular, tubulysin analogs have the structure shown below: [ka] TIFF2024542073000049.tif238170TIFF2024542073000050.tif247170TIFF2024542073000051.tif253170 TIFF2024542073000052.tif253170TIFF2024542073000053.tif247170TIFF2024542073000054.tif252170 TIFF2024542073000055.tif251170TIFF2024542073000056.tif227170TIFF2024542073000057.tif222170 TIFF2024542073000058.tif251170TIFF2024542073000059.tif243170TIFF2024542073000060.tif125170

[0133] In the formula, R 20 is H;C 1 ~C 8 linear or branched alkyl or heteroalkyl; 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 or a carboxylate, ester, ether, or amide having 1 to 8 carbon atoms; or an amino acid having 1 to 8 carbon atoms; or a compound of the formula (OCH 2 CH 2 ) p or (OCH 2 CH(CH 3 )) pwhere p is an integer from 0 to about 1000; or R 20 is absent and the oxygen atom forms a ketone, or a combination of the above.

[0134] Z 2 and Z 3 are independently H, OH, and NH 2 , O, NH, COOH, COO, C(O), C(O), C(O)NH, C(O)NH 2 , R 18 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO(OR 18 ) 2 , NHPO(OR 18 ) 2 , OP(O)(OR 18 )OP(O)(OR 18 ) 2 , O.C.(O)R 18 , O.C.(O)N.H.R. 18 , O.S.O. 2 (OR 18 ), O-(C 4 ~C 12 -glycoside), C 1 ~C 8 linear or branched alkyl or heteroalkyl; 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ).

[0135] R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl, C 2 ~C8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ).

[0136] R 19 are H, OH, and NH. 2 , O.S.O. 2 (OR 18 ), XCH 2 OP(O)(OR 18 ) 2 , XPO(OR 18 ) 2 , XC(O)OP(O)(OR 18 ) 2 , XC(O)R 18 , XC(O)NHR 18 , C 1 ~C 8 Alkyl or carboxylate; C 2 ~C 8 Alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl;C 3 ~C 8 aryl or alkylcarbonyl; or a pharmaceutical salt.

[0137] X is O, S, NH, NHNH, or CH 2 It is.

[0138] R 7 is the same as defined above;

[0139] In the formula, the binding site in formulae (IV-01) to (IV-94) [ka] is the same as the binding site described in formula (IV).

[0140] Calicheamicin and related enediyne antibiotics are described in: Nicolaou, KC et al, Science 1992, 256, 1172-1178; Proc. Natl. Acad. Sci USA. 1993, 90, 5881-8), US Patent Nos. 4, 970, 198; 5, 053, 394; 5, 108, 912; 5, 264, 586; 5, 384, 412; 5, 606, 040; 5, 712, 374; 5, 714, 586; 5, 739, 116; 5, 770, 701; 5, 770, 710; 5, 773, 001; 877, 296; 6, 015, 562; 6, 124, 310; 8, 153, 768. Exemplary enediynes include, but are not limited to, calicheamicin, esperamicin, uncialamicin, dynemicin, and derivatives thereof. The structure of calicheamicin is preferably of the following formula: or an isotope of a chemical element, or a pharma- ceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystal structure, or an optical isomer, racemate, diastereomer, or enantiomer thereof.

[0141] [ka]

[0142] Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (heat shock protein 90) and is used as an antitumor drug. Exemplary geldanamycins include, but are not limited to, 17-AAG (17-N-allylamino-17-demethoxygeldanamycin) and 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin).

[0143] [ka]

[0144] Maytansine or its derivatives, maytansinoids, inhibit cell proliferation by inhibiting microtubule formation during mitosis through inhibition of tubulin polymerization. See Remillard et al., Science 189:1002-1005 (1975). Exemplary maytansine and maytansinoids include, but are not limited to, mertansine (DM1, DM4), maytansinol and its derivatives, and ansamitocins. Maytansinoids are disclosed in U.S. Pat. Nos. 4,256, 746, 4,361, 650, 4,307, 016, 4,294, 757, 4,294, 757, 4,371, 533, 4,424, 219, 4,331, 598, 4,450, 254, 4,364, 866, 4,313, 946, 4,315, 929, 4,362, 663, 4,322, 348, 4,371, 533, 4,424, 219, 5,208, 020, 5,416, 064, 5, 208, 020; 5, 416, 064; 6, 333.410; 6, 441, 163; 6, 716, 821, 7, 276, 497, 7, 301, 019, 7, 303, 749, 7, 368, 565, 7, 411, 063, 7, 851, 432, and 8, 163, 888. The structure of the maytansinoid is preferably represented by the following formula:

[0145] [ka]

[0146] Camptothecins (CPTs) and their derivatives are topoisomerase inhibitors that cause DNA damage that prevents DNA religation and thus triggers apoptosis and have been described in the following publications: Shang, XF et al, Med Res Rev. 2018, 38(3) 775-828; Botella, P. and Rivero-Buceta, EJ Control Release 2017, 247: 28-54; Martino, E. et al, Bioorg Med Chem Lett. 2017, 27(4):701-707; Lu, A., et al., Acta Pharmacol Sin 2007, 28(2): 307-314. Camptothecins include SN-38, topotecan, irinotecan (CPT-11), ciratecan (DB-67, AR-67), cositecan (BNP-1350), etirinotecan, exatecan, lurtotecan, gimatecan (ST1481), belotecan (CKD-602), rubitecan, and several others (Shang, XF et al, Med Res Rev. 2018, 38(3):775-828).So far, three CPT analogs, topotecan, irinotecan, and belotecan, have been approved and used in cancer chemotherapy (Palakurthi, S., Expert Opin Drug Deliv. 2015;12(12):1911-21; Shang, XF et al, Med Res Rev. 2018, 38(3):775-828), and both SN-38 and exatecan have been successfully used as payloads for ADC conjugates in clinical trials (Ocean, AJ et al, Cancer. 2017, 123(19): 3843-3854; Starodub, AN, et al, Clin Cancer Res. 2015, 21(17): 3870-8; Cardillo, TM, et al, Bioconjug Chem. 2015, 26(5): 919-31; Ogitani, Y . et al, Bioorg Med Chem Lett. 2016, 26(20): 5069-5072; Takekawa, N. et al, Int J Cancer. 2017 Oct 15;141(8):1682-1689. U.S. Patents 7, 591, 994; 7, 999, 083, 8, 080, 250, 8, 268, 317; U.S. Patent Applications 20130090458, 20140099258, 20150297748, 20160279259).

[0147] Camptothecin (CPT) has the structure shown in the following formula, or one or more isotopes of chemical elements, or a pharma- ceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer: [ka]

[0148] In the formula, R 1 , R 2 , and R 4 are independently H, F, Cl, Br, CN, and NO2 , C 1 ~C 8 Alkyl;OC 1 ~C 8 Alkyl;NH-C 1 ~C 8 Alkyl;C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C 3 ~C 8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; R 3 H, OH, NH 2 , C 1 ~C 8 Alkyl;OC 1 ~C 8 Alkyl;NH-C 1 ~C 8 Alkyl;C 2 ~C 8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; or R 1 R 2 , R 2 R 3 , and R 3 R 4 independently form a 5- to 7-membered carbocyclic, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system.

[0149] [ka] is an internal site to which L1 or L2 can bind.

[0150] The structure of camptothecin is preferably the following formula, or one or more isotopes of the chemical elements, or a pharma- ceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer: [ka] TIFF2024542073000068.tif225170TIFF2024542073000069.tif249170

[0151] During the ceremony, [ka] L 1 Or L 2 It is the binding site for;

[0152] P 1 are H, OH, and NH. 2 , COOH, C(O)NH 2 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO(OR 18 ) 2 , NHPO(OR 18 ) 2 , O.C.(O)R 18 , OP(O)(OR 18 )OP(O)(OR 18 ) 2 , O.C.(O)N.H.R. 18 , O C (O) N (C 2 H 4 ) 2 NCH 3 , O.S.O. 2 (OR 18 ), O-(C 4 -C 12 -glycosides), OC(O)N(C 2 H 4 ) 2 CH 2 N(C2 H 4 ) 2 CH 3 , O-(C 1 ~C 8 (linear or branched alkyl), C 1 ~C 8 linear or branched alkyl or heteroalkyl; 2 ~C 8 Straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 );R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl; C 2 ~C 8 Straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Linear or branched aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ).

[0153] Combretastatins are naturally occurring phenols with intratumoral vascular disrupting properties. Exemplary combretastatins and their derivatives include, but are not limited to, combretastatin A-4 (CA-4), CA4-βGal, CA-4PD, CA4-NPs, and ombrabulin: [ka]

[0154] Taxanes, including the cytotoxic natural product paclitaxel (taxol), the semisynthetic derivative docetaxel (taxotere), and their analogs suitable for conjugation are described in K C. Nicolaou et al., J. Am. Chem. Soc. 117, 2409-20, (1995); Ojima et al, J. Med. Chem. 39:3889-3896 (1996); 40:267-78 (1997); 45, 5620-3 (2002); Ojima et al., Proc. Natl. Acad. Sci., 96:4256-61 (1999); Kim et al., Bull. Korean Chem. Soc., 20, 1389-90 (1999); Miller, et al. J. Med. Chem., 47, 4802-5 (2004); US Patent Nos. 5, 475, 011 5, 728, 849, 5, 811, 452; 6, 340, 701; 6, 372, 738; 6, 391, 913, 6.436, 931; 6, 589, 979; 6, 596, 757; 6, 706, 708; 7, 008, 942; 7, 186, 851; 7, 217, 819; 7, 276, 499; 7, 598, 290; and 7, 667, 054. The structure of the taxane is preferably of the formula:

[0155] [ka]

[0156] During the ceremony, [ka] , L 1 Or L 2 Ar and Ar' are independently aryl or heteroaryl.

[0157] Anthracyclines are mammalian DNA topoisomerase II inhibitors that can stabilize enzyme-DNA complexes in which DNA strands are cleaved and are covalently linked to antibody-like proteins. These anticancer drugs have played an important role in the treatment of many forms of solid tumors and acute leukemias for the past several decades. However, anthracyclines cause cardiovascular morbidity and mortality (Sagi, JC, et al, Pharmacogenomics. 2016, 17(9), 1075-87; McGowan, JV, et al, Cardiovasc Drugs Ther. 2017, 31(1), 63-75). Therefore, to increase the specific activity of such molecules while reducing cardiotoxicity, researchers have actively used conjugation of anthracyclines with cell-binding antibodies or antibody-like protein molecules as a general approach to improve the therapeutic index of these drugs (Mollaev, M. et al, Int J Pharm. 2018 Dec 29. pii: S0378-5173(18) 30991-8; Rossin, R., et al, Bioconjug Chem. 2016, 27(7):1697-706; Dal Corso, A,. et al, J Control Release. 2017, 264:211-218). Exemplary anthracyclines include, but are not limited to, daunorubicin, doxorubicin (i.e., adriamycin), epirubicin, idarubicin, valrubicin, and mitoxantrone. The structure of the anthracycline used in the present application is preferably represented by the following formula:

[0158] [ka] TIFF2024542073000075.tif188170

[0159] Vinca alkaloids are a set of antimitotic and antimicrotubule alkaloid agents that act by inhibiting the ability of cancer cells to divide. Vinca alkaloids include vinblastine, vincristine, vindesine, leurosine, vinorelbine, catharanthine, vindoline, vincaminol, vineridine, minovincine, methoxyminovincine, minovincine, vincadifformine, desoxyvincaminol, vincamazine, vincamine, vinpocetine, and vinbrunin. The structure of the vinca alkaloids is preferably vinblastine, vincristine, which has the following formula:

[0160] [ka] TIFF2024542073000077.tif146170

[0161] Dolastatins and their peptide analogs and derivatives, the auristatins, are highly potent antimitotic agents that have been shown to have anticancer and antifungal activity (see, e.g., U.S. Patent No. 5,663,149 and Pettit et al., Antimicrob. Agents Chemother. 42:2961-2965, 1998). Exemplary dolastatins and auristatins include, but are not limited to, dolastatin 10, auristatin E (AE), auristatin EB (AEB), auristatin EFP (AEFP), MMAD (monomethylauristatin D or monomethyldolastatin 10), MMAF (monomethylauristatin F or N-methylvaline-valine-dolaisoloiin-dolaproine-phenylalanine), MMAE (monomethylauristatin E or N-methylvaline-valine-dolaisoloiin-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), auristatin F phenylenediamine (AFP), and other novel auristatins. Auristatins are described in Int. J. Oncol. 15: 367-72 (1999); Molecular Cancer Therapeutics, vol. 3, No. 8, pp. 921-32 (2004); U.S. Application Nos. 11134826, 20060074008, 2006022925.U.S. Patent Nos. 4414205, 4753894, 4764368, 4816444, 4879278, 4943628, 4978744, 5122368, 5165923, 5169774, 5286637, 5410024, 5521284, 5530097, 5554725, 5585089, 5599902, 5629197, 5635483, 5654399, 5663149, 5665860, 5708146, 5714586, 5741892, 5767236, 5767237, 5780588, 5821337, 5840699, 5965537, 6004934, 6033876, 6034065, 6048720, 6054297, 6054561, 6124431, 6143721, 6162930, 6214345, 6239104, 6323315, Listed in 6342219, 6342221, 6407213, 6569834, 6620911, 6639055, 6884869, 6913748, 7090843, 7091186, 7097840, 7098305, 7098308, 7498298, 7375078, 7462352, 7553816, 7659241, 7662387, 7745394, 7754681, 7829531, 7837980, 7837995, 7902338. The structure of the auristatin analog is preferably of the following formulas (Ih-01), (Ih-02), (Ih-03), (Ih-04), (Ih-05), (Ih-06), (Ih-07), (Ih-08), (Ih-09), (Ih-10), and (Ih-11), or one or more isotopes of chemical elements, or a pharma- ceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer:

[0162] [ka] TIFF2024542073000079.tif243170TIFF2024542073000080.tif31170

[0163] In the formula, R 1 , R2 , R 3 , R 4 , and R 5 are independent, H;C 1 ~C 8 or a peptide containing 1 to 8 amino acids of the formula (OCH 2 CH 2 ) p or (OCH 2 CH(CH 3 )) p (wherein p is an integer from 1 to about 5000); 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 may be taken together to form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group.

[0164] Y 1 and Y 2 is the connection site (independently binds to L1 and / or L2) [ka] and independently O, NH, NHNH, or NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 or the connection site [ka] When not combined with, OH, NH 2 , NHNH 2 , NHR 5 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )(C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 is.

[0165] R 12 is OH, NH 2 , NHR 1 , NHNH 2 , NHNHCOOH, O-R 1 -COOH, NH-R 1 -COOH, NH-(Aa) n COOH, O(CH 2 CH 2 O) p CH 2 CH 2 OH, O(CH 2 CH 2 O) p CH 2 CH 2 NH 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 , NR 1 R 1’ , NHOH, NHOR 1 , O(CH 2 CH 2 O) p CH 2 CH 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 , NH-Ar-COOH, NH-Ar-NH 2 , O(CH2 CH 2 O) p CH 2 CH 2 NHSO 3 H、NH(CH 2 CH 2 O) p CH 2 CH 2 NHSO 3 H、R 1 -NHSO 3 H、NH-R 1 -NHSO 3 H、O(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 NH(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 OR 1 、R 1 -NHPO 3 H 2 、R 1 -OPO 3 H 2 、O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 OR 1 -NHPO 3 H 2 、NH-R 1 -NHPO 3 H 2 NH(CH 2 CH 2 NH) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 S) p CH 2 CH 2 NH 2 NH(CH 2 CH2 NH) p CH 2 CH 2 OH, NH(CH 2 CH 2 S) p CH 2 CH 2 OH, NH-R 1 -NH 2 , or NH(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 where Aa is 1 to 8 identical or different amino acids; p is 1 to 5000.

[0166] R 1 , R 2 , R 3 , R 4 , R 5 , R 5’ , Z 1 , Z 2 , and n are as defined above.

[0167] Hemiasterlin and its analogs (such as HTI-286) bind to tubulin, disrupt normal microtubule dynamics, and depolymerize microtubules in stoichiometric amounts. The structure of maytansinoids is preferably of the formula: [ka]

[0168] In the formula, R 1 , R 2 , R 3 , R 4 , and R 5 are independent, H;C 1 ~C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a peptide of the formula (OCH 2 CH2 ) p Or (OCH 2 CH(CH 3 )) p (wherein p is an integer of 1 to about 5000); 2 R 3 can form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group.

[0169] Eribulin binds primarily to a small number of high affinity sites at the plus ends of pre-existing microtubules and has both cytotoxic and non-cytotoxic modes of action. Its cytotoxic effects are related to its antimitotic activity, inducing apoptosis of cancer cells after prolonged and irreversible mitotic inhibition (Kuznetsov, G. et al, Cancer Research. 2004, 64 (16): 5760-6.; Towle, M. J et al, Cancer Research, 2010, 71 (2): 496-505). Preclinical studies in human breast cancer models have shown that in addition to its cytotoxic, antimitotic-based mechanisms, eribulin also exerts complex effects on the biology of surviving cancer cells and residual tumors that appear to be independent of its antimitotic effects. Eribulin has been approved by the US FDA for the treatment of metastatic breast cancer that has received at least two chemotherapy regimens for advanced disease, including both anthracycline and taxane chemotherapy, and for the treatment of liposarcoma (a type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or has progressed (metastatic). Eribulin has been used as the payload in ADC conjugates (US20170252458). The structure of eribulin is preferably of the following formula Eb01:

[0170] [ka]

[0171] Nicotinamide phosphoribosyltransferase inhibitors (NAMPT) could be interesting ADC payloads due to their unique mechanism of potent activity (Sampath D, et al, Pharmacol Ther 2015; 151, 16-31). NAMPT regulates intracellular levels of nicotinamide adenine dinucleotide (NAD). NAD functions as an essential redox cofactor that supports energy and anabolic metabolism. NAD plays several important roles in metabolism; it acts as a coenzyme in redox reactions, as a donor of the ADP-ribose moiety in ADP-ribosylation reactions, as a precursor of the second messenger molecule cyclic ADP-ribose, as well as a substrate for bacterial DNA ligase and NAD + In addition to these metabolic functions, they also act as a group of enzymes called sirtuins that use NAD to remove acetyl groups from proteins. +It appears as an adenine nucleotide and is released from cells spontaneously or by regulated mechanisms (Smyth L. M, et al, J. Biol. Chem. 2004, 279 (47), 48893-903; Billington R. A, et al, Mol Med. 2006, 12, 324-7) and therefore may have important extracellular roles (Billington R. A, et al, Mol Med. 2006, 12, 324-7). In the presence of inhibitors of NAMPT, NAD levels fall below those required for metabolism, creating an energy crisis and leading to cell death. Thus far, clinical NAMPT inhibitor candidates FK-866, CHS-828, and GMX-1777 have progressed into clinical trials, but all encountered dose-limiting toxicity before achieving objective responses (Holen K., et al, Invest New Drugs 2008, 26, 45-51; Hovstadius, P., et al, Clin Cancer Res 2002, 8, 2843-50; Pishvaian, MJ, et al, J Clin Oncol 2009, 27, 3581). Thus, the use of ADCs for targeted delivery of NAMPT inhibitors may avoid systemic toxicity and achieve a broader therapeutic index. The structure of the NAMPT inhibitor is preferably of the following formula: NP01, NP02, NP03, NP04, NP05, NP06, NP07, NP08, and NP09, or one or more isotopes of chemical elements, or a pharma- ceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer:

[0172] [ka]

[0173] During the ceremony, [ka] is the same as above;X 5 is F, Cl, Br, I, OH, OR 1 , R 1 , OPO 3 H 2 , O.S.O. 3 H, N.H.R. 1 , O.C.O.R. 1 , N.H.C.O.R. 1 It is.

[0174] Benzodiazepine dimers and their analogs (e.g., pyrrolobenzodiazepine (PBD) or (tomaymycin) dimers, indolinobenzodiazepine (IGN) dimers, imidazobenzothiadiazepine dimers, or oxazolidinobenzodiazepine dimers) are antitumor agents that contain one or more imine functional groups that bind to double-stranded DNA, or their equivalents. PBD and IGN molecules are based on the natural product athramycin and interact with DNA in a sequence-selective manner, with a preference for purine-guanine-purine sequences. Benzodiazepine dimers that are preferred in the present invention are exemplified by the following U.S. Patents: 8,153,627; 8,034,808; 7,834,005; 7,741,319; 7,704,924; 7,691,848; 7,678,787; 7,612,062; 7,608,615; 7,557,099; 7,528,128; 7,528,126; 7,511,032; 7,429,658; 7,407,951; 7,326,700; 7,312,210; 7,265,105; 7,202,239; 7,189,710; 7,173,026; 7,109,193; 7,067,511; 7,064,120; 7,056,913; 7,049,311; 7,022,699; 7,015,215; 6,979,684; 6,951,853; 6,884,799; 6,800,622; 6, 747, 144; 6,660,856; 6, 608, 192; 6,562,806; 6, 977, 254; 6,951,853; 6,909,006; 6, 344, 451; 5,880,122; 4, 935, 362; 4,764,616; 4,761,412; 4,723,007; 4,723,003; 4,683,230; 4,663,453; 4,508,647; 4, 464, 467; 4,427,587; 4,000,304; U.S. Patent Application Publication Nos. 20100203007, 20100316656, 20030195196.Exemplary structures of antibody-benzodiazepine dimer conjugates are shown below as PB01, PB02, PB03, PB04, PB05, PB06, PB07, PB08, PB09, PB10, PB11, PB12, PB13, PB14, PB15, PB16, PB17, PB18, PB19, PB20, PB21, PB22, PB23, PB24, PB25, PB26, PB27, and PB28.

[0175] [ka] TIFF2024542073000088.tif252170TIFF2024542073000089.tif236170TIFF2024542073000090.tif246170TIFF2024542073000091.tif186170 or isotopes of one or more chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers.

[0176] In the formula, X 1 , X 2 , Y 1 , Y 2 , Z 1 , Z 2 , and n are defined as above. Preferably, X 1 , X 2 , Y 1 , and Y 2 are independently O, N, NH, NHNH, and NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 1 ), CH, C(O)NHNHC(O), and C(O)NR 1 It is.

[0177] R 1 , R 2 , R 3 , R 1’, R 2’ , and R 3’ are independently: H; F; Cl; = O; = S; OH; SH; C 1 -C 8 Linear or branched alkyl, aryl, alkenyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester (COOR 5 Or -OC(O)R 5 ), Ester (OR 5 ), amide (CONR 5 ), carbamates (OCONR 5 ), amines (NHR 5 , N.R. 5 R 5’ ), heterocycloalkyl, or acyloxylamine (-C(O)NHOH, -ONHC(O)R 5 or a peptide comprising 1 to 20 natural or unnatural amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH(CH 3 )) p where p is an integer from 1 to about 1000; 1 R 2 , R 2 R 3 , R 1 R 3 , R 1’ R 2’ , R 2’ R 3’ , or R 1’ R 3’ can independently form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group.

[0178] X 3 and Y 3 are independently N, NH, CH, or CR 1 or X 3 and Y 3 Any one of may be omitted.

[0179] R 1 and R2 is C 1 ~C 8 linear or branched alkyl, heteroalkyl; 3 ~C 8 aryl, heteroaryl, alkylcycloalkyl, acylosyl, alkylaryl, alkylaryloxyl, alkylarylamino, alkylarylthiol; or 1 to 6 identical or different amino acid / peptide sequences (Ar)r (r=1-6).

[0180] R 4 , R 5 , R 5’ , R 6 , R 12 , and R 12’ are independently H, OH, and NH 2 , NH(CH 3 ), NHNH 2 , COOH, SH, OZ 3 , S.Z. 3 , F, Cl, or C 1 -C 8 It is a straight or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxylamine.

[0181] Z 3 H,OP(O)(OM 1 )(OM 2 ), O.C.H. 2 OP(O)(OM 1 )(OM 2 ), O.S.O. 3 M 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 -Glycoside; M 1 and M 2 are independently H, Na, K, Ca, Mg, and NH 4 , N.R. 1 R 2 R 3 It is.

[0182] X 6is CH, N, P(O)NH, P(O)NR 1 , CHC(O)NH, C 3 ~C 8 Aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, or Aa (an amino acid, preferably selected from Lys, Phe, Asp, Glu, Ser, Thr, His, Cys, Tyr, Trp, Gln, Asn, Arg).

[0183] [ka] is either a single bond or a double bond;

[0184] [ka] has the same definition as above.

[0185] CC-1065 analogs and duocarmycin analogs are also preferably used in the conjugates of the present invention. Examples of CC-1065 analogs and duocarmycin analogs, as well as their synthesis, are described in Warpehoski, et al, J. Med. Chem. 31:590 603 (1988); D. Boger et al.,J. Org. Chem; 66; 6654-61, 2001; U.S. Patent Nos.: 4169888, 4391904, 4671958, 4816567, 4912227, 4923990, 4952394, 4975278, 4978757, 4994578, 5037993, 5070092, 5084468, 5101038, 5117006, 5137877, 5138059, 5147786, 5187186, 5223409, 5225539, 5288514 , 5324483, 5332740, 5332837, 5334528, 5403484, 5427908, 5475092, 5495009, 5530101, 5545806, 5547667, 5569825, 5571698, 5573922, 5580717, 5585089, 5585499, 5587161, 5595499, 5606017, 5622929, 562512 6, 5629430, 5633425, 5641780, 5660829, 5661016, 5686237, 5693762, 5703080, 5712374, 5714586, 5739116, 5739350, 5770429, 5773001, 5773435, 5786377, 5786486, 5789650, 5814318, 5846545, 5874299, 58772 96, 5877397, 5885793, 5939598, 5962216, 5969108, 5985908, 6060608, 6066742, 6075181, 6103236, 6114598, 6130237, 6132722, 6143901, 6150584, 6162963, 6172197, 6180370, 6194612, 6214345, 6262271, 6281 354, 6310209, 6329497, 6342480, 6486326, 6512101, 6521404, 6534660, 6544731, 6548530, 6555313, 6555693, 6566336, 6586618, 6593081, 6630579, 6756 397, 6759509, 6762179, 6884869, 6897034, 6946455, 7049316, 7087600, 7091186, 7115573, 7129261, 7214663, 7223837, 7304032, 7329507, 7,329,760, 7,Nos. 388,026, 7,655,660, 7,655,661, 7,906,545, and 8,012,978. Exemplary structures of antibody-CC-1065 analog conjugates via the linkers of this patent are shown below in CC01, CC02, CC03, CC04, CC05, CC06, and CC07.

[0186] [ka] TIFF2024542073000095.tif39170

[0187] During the ceremony, X 1 , X 2 , Y 1 , and Y 2 is the connection site [ka] and independently O, NH, NHNH, or NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 or the connection site [ka] If not bonded to OH, NH 2 , N.H.N.H. 2 , N.H.R. 1 , SH, C(O)OH, C(O)NH 2 , O-C(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2), C(O)NHNHC(O)OH, and C(O)NHR 1 It is.

[0188] Z 3 H,PO(OM 1 )(OM 2 ), SO 3 M 1 , C.H. 2 PO(OM 1 )(OM 2 ), C.H. 3 N(CH 2 CH 2 ) 2 NC(O)-, O(CH 2 CH 2 ) 2 NC(O)-, R 1 , or a glycoside; R 1 , R 2 , R 3 , M 1 , M 2 , and n are as defined above.

[0189] Amatoxins and their analogues are a subgroup that includes at least 10 toxic compounds that are found primarily in several genera of poisonous mushrooms, most notably Amanita phalloides, and several other mushrooms, and are preferred for use in the conjugates of this patent. These ten amatoxins, namely α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanulin, amanuric acid, amaninamide, and amanine, proamanitin, are rigid bicyclic peptides synthesized as precursors of proteins containing 35 amino acids, which are finally cleaved by eight amino acid prolyl oligopeptidases (Litten, W. 1975 Scientific American232 (3): 90-101; HE Hallen, et al 2007 Proc. Nat. Aca. Sci. USA 104, 19097-101; K. Baumann, et al, 1993 Biochemistry 32 (15): 4043-50; Karlson-Stiber C, Persson H. 2003, Toxicon 42 (4): 339-49; Horgen, PA et al. 1978 Arch. Microbio. 118 (3): 317-9). Amatoxins kill cells by inhibiting RNA polymerase II (Pol II) and blocking gene transcription and protein synthesis (Brodner, OG and Wieland, T. 1976 Biochemistry, 15(16): 3480-4; Fiume, L., Curr Probl Clin Biochem, 1977, 7: 23-8; Karlson-Stiber C, Persson H. 2003, Toxicon 42(4): 339-49; Chafin, DR , Guo, H. & Price, DH 1995 J. Biol. Chem. 270 (32): 19114-19; Wieland (1983) Int. J. Pept. Protein Res. 22(3): 257-76.). Amatoxins were collected from Amanita phalloides (Yocum, RR1978 Biochemistry 17(18): 3786-9; Zhang, P. et al, 2005, FEMS Microbiol. Lett.252(2), 223-8), or by fermentation with Basidiomycete (Muraoka, S. and Shinozawa T., 2000 J. Biosci. Bioeng. 89(1): 73-6), or by fermentation with A. Fissa (Guo, XW, et al, 2006 Wei Sheng Wu Xue Bao 46(3): 373-8), or by culturing A. cholera mushroom (WO / 1990 / 009799, JP11137291). However, the yields of these isolations and fermentations are rather low (less than 5 mg / l of culture). In the past 30 years, several methods for the preparation of amatoxins and their analogues have been reported (WE Savige, A. Fontana, Chem. Commun. 1976, 600-1; Zanotti, G., et al, Int J Pept Protein Res. 1981. 18(2): 162-8; Wieland, T., et al, Eur. J. Biochem. 1981, 117, 161-4; PA Bartlett, et al, Tetrahedron Lett. 1982, 23, 619-22; Zanotti, G., et al., Biochim Biophys Acta, 1986. 870(3): 454-62; Zanotti, G., et al., Int. J. Peptide Protein Res. 1987, 30, 323-9; Zanotti, G., et al. al., Int. J. Peptide Protein Res. 1987, 30, 450-9; Zanotti, G., et al., Int J Pept Protein Res, 1988. 32(1): 9-20; G. Zanotti, T. et al, Int. J. Peptide Protein Res. 1989, 34, 222-8; Zanotti, G., et al. al., Int J Pept Protein Res, 1990. 35(3): 263-70; Mullersman, JE and JF Preston, 3rd, Int J Pept Protein Res, 1991. 37(6): 544-51; Mullersman, JE, et al, Int J Pept Protein Res, 1991. 38(5): 409-16; Zanotti, G., et al, Int J Pept Protein Res, 1992. 40(6): 551-8; Schmitt, W. et al, J. Am. Chem. Soc. 1996, 118, 4380-7; Anderson, M. O., et al, J. Org. Chem., 2005, 70(12): 4578-84; JP May, et al, J. Org. Chem. 2005, 70, 8424-30; F. Brueckner, P. Cramer, Nat. Struct. Mol. Biol. 2008, 15, 811-8; JP May, DM Perrin, Chem. Eur. J. 2008, 14, 3404-9; JP May, et al, Chem. Eur. J. 2008, 14, 3410-17; Q. Wang, et al, Eur. J. Org. Chem. 2002, 834-9; May, J.P. and D.M. Perrin, Biopolymers, 2007. 88(5): 714-24; May, J.P., et al., Chemistry, 2008. 14(11): 3410-7; S. De Lamo Marin, et al, Eur. J. Org. Chem. 2010, 3985-9; Pousse, G., et al., Org Lett, 2010. 12(16): 3582-5; Luo, H., et al., Chem Biol, 2014. 21(12): 1610-7; Zhao, L., et al., Chembiochem, 2015.16(10): 1420-5), most of which are partial synthetic methods. Due to their extremely potent potency and unique cytotoxic mechanism, amatoxins have been used as conjugate payloads (Fiume, L., Lancet, 1969. 2 (7625): 853-4; Barbanti-Brodano, G. and L. Fiume, Nat New Biol, 1973. 243(130): 281-3; Bonetti, E., M. et al, Arch Toxicol, 1976. 35(1): p. 69-73; Davis, MT, Preston, JF Science 1981, 213, 1385-1388; Preston, JF, et al, Arch Biochem Biophys, 1981. 209(1): 63-71; H. Faulstich, et al, Biochemistry 1981, 20, 6498-504; Barak, LS, et al., Proc Natl Acad Sci USA, 1981. 78(5): 3034-8; Faulstich, H. and L. Fiume, Methods Enzymol, 1985. 112: 225-37; Zhelev, Z., A. et al, Toxicon, 1987. 25(9): 981-7; Khalacheva, K., et al, Eksp Med Morfol, 1990. 29(3): 26-30; U. Bermbach, H. Faulstich, Biochemistry 1990, 29, 6839-45; Mullersman, JE and JF Preston, Int. J. Peptide Protein Res. 1991, 37, 544-51; Mullersman, JE and JF Preston, Biochem Cell Biol, 1991. 69(7): 418-27; J. Anderl, H. Echner, H. Faulstich, Beilstein J. Org. Chem. 2012, 8, 2072-84; Moldenhauer, G., et al, J. Natl. Cancer Inst. 2012, 104, 622-34; A. Moshnikova, et al; Biochemistry 2013, 52, 1171-8; Zhao, L., et al., Chembiochem, 2015. 16(10): 1420-5; Zhou, B., et al., Biosens Bioelectron, 2015. 68: 189-96; WO2014 / 043403, US20150218220, EP 1661584). We have been studying the conjugation of amatoxins for some time. The structures of the amatoxins applicable to the present invention are preferably the following Am01, Am02, Am03 and Am04, or isotopic substitutions of one or more chemical elements, or pharma- ceutically acceptable salts, hydrates or hydrated salts, or polycrystalline structures of these compounds, or optical isomers, racemates, diastereomers or enantiomers:

[0190] [ka]

[0191] In the formula, X 1 and Y 1 are independently O, NH, NHNH, and NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 1 ), C.H. 2 , CHNH, CH 2 O, C(O)NHNHC(O), and C(O)NR 1 is;

[0192] R 7 , R 8 , and R 9 are independently H, OH, and OR 1 , N.H. 2 , N.H.R. 1 , C 1 ~C6 Alkyl, or lacking;

[0193] Y 2 , O, O 2 , N.R. 1 , NH, or absent;

[0194] R 10 is CH 2 , O, NH, NR 1 , NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR 1 ), (NR 1 )C(O)(NR 1 ), C(O)R 1 , or lacking;

[0195] R 11 OH, NH 2 , N.H.R. 1 , N.H.N.H. 2 , NHNHCOOH, OR 1 -COOH, NH-R 1 -COOH, NH-(Aa) r COOH, O(CH 2 CH 2 O) p CH 2 CH 2 OH, O(CH 2 CH 2 O) p CH 2 CH 2 NH 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 , N.R. 1 R 2 , O(CH 2 CH 2 O) p CH 2 CH 2 -COOH, NH(CH 2 CH 2 O) p CH 2 CH 2COOH, NH-Ar-COOH, NH-Ar-NH 2 , O(CH 2 CH 2 O) p CH 2 CH 2 -NHSO 3 H, NH(CH 2 CH 2 O) p CH 2 CH 2 NHSO 3 H, R 1 -NHSO 3 H, NH-R 1 -NHSO 3 H, O(CH 2 CH 2 O) p -CH 2 CH 2 NHPO 3 H 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 , OR 1 , R 1 -NHPO 3 H 2 , R 1 -OPO 3 H 2 , O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 , OR 1 -NHPO 3 H 2 , N.H.-R. 1 -NHPO 3 H 2 , or NH(CH 2 CH 2 O) p CH 2 -CH 2 NHPO 3 H 2 where, (Aa) r is 1 to 8 amino acids;

[0196] n and m 1 is independently 1 to 20; p is 1 to 5000;

[0197] R 1 , R 2 , Ar, and [ka] is the same as the definition above.

[0198] Spliceostatins and pladienolides are antitumor compounds that inhibit splicing and interact with the spliceosome SF3b. ​​Examples of spliceostatins include, but are not limited to, spliceostatin A, FR901464, and (2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-hydrazinyl-2-oxoethyl)-4-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl-1}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate, which has the core structure of Sp-01:

[0199] [ka]

[0200] Examples of pladienolides include, but are not limited to, pladienolide B, pladienolide D, and E7107.

[0201] The addition of phosphate groups (PO 4Protein kinase inhibitors that block the action of enzymes that add a 5'-amino acid to a protein can modulate protein function. They can be used to treat diseases by modulating cell function to overcome overactivity of protein kinases (including mutant or overexpressed kinases) in cancer or other disease factors. The structures of protein kinase inhibitors are preferably those having the following formulae PK01 to PK40: adavosertib, afatinib, axitinib, bafetinib, bosutinib, cobimetinib, crizotinib, cabozantinib, dasatinib, entrectinib, erdafitinib, erlotinib, erlotinib, fostamatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, nissert ... Lotinib, Pazopanib, Pegaptanib, Ponatinib, Revastinib, Regorafenib, Ruxolitinib, Sorafenib, Sunitinib, SU6656, Tofacitinib, Vandetanib, Vemurafenib, Entrectinib, Palbociclib, Ribociclib, Abemaciclib, Dacomitinib, Neratinib, Rociletinib (CO-1686), Osimertinib, AZD3759, Nazartinib (EGF816):

[0202] [ka] TIFF2024542073000102.tif251170TIFF2024542073000103.tif240170TIFF20245420730 00104.tif235170TIFF2024542073000105.tif253170TIFF2024542073000106.tif236170

[0203] In the formula, Z 5 and Z 5’ are independently O, NH, NHNH, and NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR1 is selected from.

[0204] MEK inhibitors inhibit the mitogen-activated protein kinases MEK1 and / or MEK2, which are often overactivated in some cancers. MEK inhibitors are used specifically to treat BRAF-mutated melanoma, KRAS / BRAF-mutated colorectal cancer, breast cancer, and non-small cell lung cancer (NSCLC). MEK inhibitors are selected from PD0325901, selumetinib (AZD6244), cobimetinib (XL518), refametinib, trametinib (GSK1120212), pimasertib, binimetinib (MEK162), AZD8330, RO4987655, RO5126766, WX-554, E6201, GDC-0623, PD-325901, and TAK-733. Preferred MEK inhibitors are selected from trametinib (GSK1120212), cobimetinib (XL518), binimetinib (MEK162), selumetinib, which have the following formula:

[0205] [ka]

[0206] In the formula, Z 5 are O, NH, NHNH, and NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 is selected from.

[0207] The protease inhibitor used as the payload of the conjugate is preferably selected from carfilzomib, clindamycin, retapamulin, and indibulin, which have the following structures:

[0208] [ka]

[0209] Immunotoxins are generally macromolecular drugs that are cytotoxic proteins derived from bacterial or plant proteins, such as diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA), erythrogenic toxin, diphtheria toxin, AB toxin, type III exotoxin, and the like. They may also be highly toxic bacterial pore-forming protoxins that require proteolytic treatment for activation. Examples of such protoxins include proerolysin and its genetically modified form, topsalicin. Topsalicin is a modified recombinant protein designed to be selectively activated by an enzyme present in the prostate, causing localized cell death and tissue destruction without damaging adjacent tissues and nerves. The immunotoxins of the present invention are preferably conjugated by the methods of the present invention to an amino acid having a free amino, thiol, or carboxyl group, more preferably the N-terminal amino acid.

[0210] Additionally, cell receptor agonists, cell stimulatory molecules, or intracellular signaling molecules can be conjugated as drug D by the methods of the present invention.

[0211] The cell-binding ligands and receptor agonists are selected from the following: folic acid derivatives; glutamic acid urea derivatives; somatostatin and its analogs (selected from the group consisting of octreotide (Sandostatin) and lanreotide (Somatilin); aromatic sulfonamides; pituitary adenylate cyclase activating peptide (PACAP) (PAC1); vasoactive intestinal peptide (VIP / PACAP) (VPAC1, VPAC2); melanocyte stimulating hormone (α-MSH); cholecystokinin (CCK) / gastrin receptor agonists, bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2neurotensin receptor ligands (NTR1, NTR2, NTR3), substance P (NK1 receptor) ligands; neuropeptide Y (Y1-Y6); homing peptides including RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), dimeric and multimeric cyclic RGD peptides (cRGDfV), TAASGVRSMH, and LTLRWVGLMS (chondroitin sulfate proteoglycan NG2 receptor ligand), and F3 peptide; cell membrane permeable peptides. peptide hormones, luteinizing hormone releasing hormone (LHRH) agonists and antagonists, and gonadotropin releasing hormone (GnRH) agonists, which act by targeting follicle stimulating hormone (FSH) and luteinizing hormone (LH) as well as testosterone production, including buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ), goserelin (Pyr-His-Trp-Ser-)Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH 2 ), histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH 2 ), Triptorelin (Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 ), nafarelin, deslorelin, abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH 2), Cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH 2 ), degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carbamoyl)-Leu-isopropylLys-Pro-D-Ala-NH 2 ), and ganirelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-(N9,N10-diethyl)-homoArg-Leu-(N9,N10-diethyl)-homoArg-Pro-D-Ala-NH 2 ); pattern recognition receptors (PRRs) selected from Toll-like receptor (TLR) ligands, C-type lectins, and Nodlike receptor (NLR) ligands; calcitonin receptor agonists; integrin receptors and their receptor subtypes (α V β 1 , α V β 3 , α V β 5 , α V β 6 , α 6 β 4 , α 7 β 1 , α L β 2 , α IIb β 3 agonists (selected from the group consisting of GRGDSPK, cyclo(RGDfV)(L1) and its derivatives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo(RG-N(Me)D-fV), cyclo(RGD-N(Me)fV), cyclo(RGDf-N(Me)V-) (silengitide)]; anticalins (derivatives of lipocalin); adnectins (tenth FN3 (fibronectin)); designed ankyrin repeat proteins (DARPins); avimers; EGF receptor or VEGF receptor agonists;

[0212] The cell binding molecule / ligand or cell receptor agonist is selected from the following: LB01 (folic acid), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (somatostatin), LB06 (somatostatin), LB07 (octreotide, somatostatin analog), LB08 (ramareotide, somatostatin analog), LB09 (vapreotide (sambar), somatostatin analog), LB10 (CAIX ligand), LB11 (CAIX ligand), LB12 (gastrin releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone releasing hormone (LH-RH) ligand and GnRH), LB14 (luteinizing hormone releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (α v β 3 for integrin receptors), LB19 (heterobivalent peptide ligand for VEGF receptors), LB20 (neuromedin B), LB21 (bombesin for G protein-coupled receptors), LB22 (TLR for Toll-like receptors), 2 ), LB23 (for androgen receptor), LB24 (α vCilengitide / cyclo(-RGDfV-) for integrin receptors, LB23 (Fludrocortisone), LB25 (Rifabutin analog), LB26 (Rifabutin analog), LB27 (Rifabutin analog), LB28 (Fludrocortisone), LB29 (Dexamethasone), LB30 (Fluticasone propionate), LB31 (Beclomethasone dipropionate), LB32 (Triamcinolone acetonide), LB33 (Prednisone), LB34 (Prednisolone), LB35 (Methylprednisolone), LB36 (Betamethasone), LB37 (Irinotecan analog), LB3 8 (crizotinib analog), LB39 (bortezomib analog), LB40 (carfilzomib analog), LB41 (carfilzomib analog), LB42 (leuprolide analog), LB43 (triptorelin analog), LB44 (clindamycin), LB45 (liraglutide analog), LB46 (semaglutide analog), LB47 (retapamulin analog), LB48 (indibulin analog), LB49 (vinblastine analog), LB50 (lixisenatide analog), LB51 (osimertinib analog), LB52 (nucleoside analog), LB53 (erlotinib analog), or LB54 (lapatinib analog);

[0213] [ka] TIFF2024542073000110.tif244170TIFF2024542073000111.tif226170TIFF202 4542073000112.tif234170TIFF2024542073000113.tif249170TIFF20245420730 00114.tif225170TIFF2024542073000115.tif239170TIFF2024542073000116.t if241170TIFF2024542073000117.tif244170TIFF2024542073000118.tif210170

[0214] In the formula, X 4 and Y1 are independently O, NH, NHNH, and NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 It is.

[0215] In another embodiment, one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA) are conjugated as drugs by the methods of the present invention: [ka]

[0216] During the ceremony, [ka] is the attachment site for the side chain linker of this patent. [ka] is a single-stranded or double-stranded DNA, RNA, mRNA, siRNA, miRNA, or piRNA; X 1 and Y is independently O, NH, NHNH, NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 )C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 It is.

[0217] In some embodiments, the oxidizing agent that can be added in step (c) of the method of the present invention (after the coupling reaction step) to reoxidize the unreacted sulfhydryl group is preferably selected from dehydroascorbic acid (DHAA), which reconstructs the disulfide bonds of the antibody or antibody-like protein and makes the antibody have a longer half-life. The concentration of the oxidizing agent in the reaction solution can be 0.01 mM to 1.0 mM.

[0218] Instead of adding DHAA in the method of the present invention, an excess of a disulfide compound such as cysteine ​​can also be added in step (c). Thus, the disulfide compound can be reduced by an excess of a reducing agent, e.g., TCEP in step (b), to form a thiol compound, which is simultaneously conjugated in excess with a linker or linker / payload conjugate containing a thiol reactive group (e.g., maleicide), and the resulting thiol-succinimide linker / payload conjugate is then removed by chromatography.

[0219] In some embodiments, a specific thiol is introduced into an antibody or antibody-like protein by the conjugation method of the present invention (in the conjugation method of the present invention, when the antibody or antibody-like protein is an IgG antibody, it is highly likely that only the disulfide bond between the heavy and light chains is reduced to generate a thiol), and then the thiol is independently reacted with formula (I), (II), (III), or (IV) simultaneously or sequentially in the conjugation reaction to form a conjugate of formula (VI), (VII), (VIII), or (IX) as shown below:

[0220] [ka]

[0221] In the formula, n is 1 to 20; n' is 1 to 10; preferably, n' is 1 to 8 and n' is 1 to 4; more preferably, n is 2 to 4 and n' is 1 to 2; D 1 , D 2 , L 1 , L 2, and E 1 is the same as defined above; S (sulfur) is generated by reducing a disulfide bond in an antibody or antibody-like protein (e.g., an antibody); mAb is an antibody or antibody-like protein; Lv 1’ And Lv 2’ are independent, and the thiols in the mAb are Lv 1 And Lv 2 It is a group obtained by reacting with Lv 1’ And Lv 2’ independently have the structure:

[0222] [ka]

[0223] In the formula, Ar, X 2’ and R 3 has the same definition as above;

[0224] In formulae (VII), (VII) and (IX), [ka] may be independently selected from: [ka] TIFF2024542073000126.tif231170TIFF2024542073000127.tif238170TIFF2024542073000128.tif251170TIFF2024542073000129.tif75170

[0225] In the formula, R 1 , R 2 , and X 2 has the same definition as above; mAb is an antibody or antibody-like protein, preferably, when the antibody-like protein is particularly an antibody, the conjugate specifically binds to a thiol between the heavy and light chains of the antibody.

[0226] In another embodiment, under the method of the present patent invention, first, a conjugate of formula (X), (XI), (XII), (XIII), or (X) as shown below can be independently reacted with a selectively reduced thiol in an antibody or antibody-like protein (e.g., typically the thiol between the heavy and light chains when the antibody or antibody-like protein is an IgG antibody), and then condensed with a cytotoxic agent or cytotoxic agent / conjugate complex to form a conjugate of formula (VI), (VII), (VIII), or (IX) as shown above:

[0227] [ka]

[0228] In the formula, L 1 , L 1’ , L 2 , L 2’ , E 1 , Lv 1 , and Lv 2 is the same as defined above for formulas (VI), (VII), (VIII), and (IX). 5 And Lv 6 are independently selected from: [ka] TIFF2024542073000132.tif32170

[0229] In the formula, X 1’ are F, Cl, Br, I, OTs (tosylate), OTf (triflate), OMs (mesylate), and OC 6 H 4 (NO 2 ), O.C. 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 HF 4 , or Lv 3X 2’ is O, NH, N(R 1 ), or CH 2 R 3 and R 5 are independent, H, R 1 , aromatic, heteroaromatic, or one or several H atoms are independently -R 1 , -Halogen, -OR 1 , -SR 1 , -NR 1 R 2 , -NO 2 , -S(O)R 1 , -S(O) 2 R 1 , or -COOR 1 is an aromatic group substituted by; Lv 3 And Lv 3’ are independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl; N-hydroxysuccinimide (NHS); phenoxyl; benzenethiol, dinitrophenoxyl; pentafluorophenoxyl; tetrafluorophenoxyl; difluorophenoxyl; monofluorophenoxyl; pentachlorophenoxyl; triflate; imidazole; dichlorophenoxyl; tetrachlorophenoxyl; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed with themselves or with other anhydrides selected from acetyl anhydride and formyl anhydride, or intermediate molecules generated with condensation reagents for peptide coupling reactions or Mitsunobu reactions; wherein the reaction is 1 Or Lv 2 As long as the reaction between the functional group Lv and the thiols in antibody-like proteins, especially antibodies, is at least 1-fold faster or slower than that between the functional group Lv and the thiols in antibody-like proteins, especially antibodies, 5 And / or Lv 6 can also react with thiols in cytotoxic agents.

[0230] In another embodiment, under the method of the present patent invention, a specific thiol is introduced into the antibody-like protein, typically a thiol is generated between the heavy and light chains when the antibody or antibody-like protein is an IgG antibody, and then in a conjugation method, the thiol is reacted simultaneously or sequentially with the conjugate of the above formula (X), (XI), (XII), or (XIII) to form the antibody / conjugate conjugate molecule of the following formula (XIV), (XV), (XVI), or (XVII), followed by the addition of a cytotoxic agent D. 1 Or D 2 to form a conjugate of formula (V), (VI), (VII), or (VIII): [ka]

[0231] In the formula, Lv 5 , Lv 6 , L 1 , L 2 , L 1’ , L 2’ , E 1 , Lv 1’ , Lv 2’ , mAb, n, and n' are defined as above.

[0232] In some embodiments, under the method of the present invention, the conjugate of formula (X), (XI), (XII) or (XIII) above can be first reacted with a cytotoxic agent to form a cytotoxic agent / conjugate molecule of formula (I), (II), (III) or (IV), and then reacted independently with a reduced thiol in an antibody or antibody-like protein to form a conjugate of formula (VI), (VII), (VIII) or (IX). The first-step condensation reaction with a cytotoxic agent of formula (X), (XI), (XII) or (XIII) can be carried out in a separate pot, and the resulting cytotoxic agent / conjugate conjugate of formula (I), (II), (III) or (IV) can be optionally purified by chromatography, extraction or precipitation before coupling with a reduced thiol in an antibody-like protein. The first step of specific reduction of disulfide bonds in the antibody-like protein and the conjugation reaction with formula (I), (II), (III) or (IV) are preferably carried out in the same pot without separation of intermediates.

[0233] Lv against cytotoxic agents 5 And / or Lv 6 and the reaction between Lv and thiols in antibody-like proteins. 1 And / or Lv 2To distinguish between the reactions between the above, reactions involving the linker of formula (X), (XI), (XII) or (XIII) can be carried out in the same or different reaction pods under different conditions. For example, a drug having an amino group can be condensed with a carboxyl group in the linker in the presence of a condensation reagent such as EDC, TBTU, BroP, etc. to obtain a modified cytotoxic drug / linker conjugate of formula (I), (II), (III) or (IV) having an amide bond. This condensation reaction can proceed in a physiological buffer by activating a carboxyl group at one end of a linker of formula (X), (XI), (XII) or (XIII), which can react with a pharmaceutical having an amino group to produce a cytotoxic agent / linker conjugate of formula (I), (II), (III) or (IV), with n-hydroxyimide (NHS), pentafluorophenyl, dinitrophenyl ester, or carboxylic acid chloride, or the like, and then simultaneously or sequentially conjugating with a thiol of an antibody-like protein by the methods of the invention to form a conjugate of formula (VI), (VII), (VIII) or (IX). In another embodiment, the amines have a thiol-reactive group (e.g., maleimide, vinylsulfonyl, haloacetyl, acryl, substituted propionyl) at one end and a group capable of reacting with a drug (e.g., hydroxysuccinimidyl (NHS), pentafluorophenyl, dinitrophenyl ester, amino, alkyloxyamino, or a group capable of click chemistry (e.g., azide, alkyne, dibenzocyclooctyne, BCN ((1R,8S,9s)-bicyclo[6.1.0]non-4-yne-9 The conjugate of formula (VIII), (IX), or (X), having both the aryl group and the thiol group (aryl-1-ylmethanol) (the aryl group) can be conjugated to a thiol of an antibody-like protein (preferably, an antibody) in a buffer solution at pH 4.5 to 7.5 and 2° C. to 40° C. (preferably 2° C. to 8° C.) with or without the addition of an organic solvent that can be mixed with 0 to 30% of water by the method of the present application, to independently obtain an antibody-like protein-conjugate conjugate of formula (XIV), (XV), (XVI), or (XVII).Then, drugs capable of reacting with the reactive groups in the antibody-like protein-conjugate conjugate of formula (XIV), (XV), (XVI), or (XVII) are added sequentially or simultaneously to the reaction solution to obtain the conjugate of formula (VI), (VII), (VIII), or (IX). Optionally, the antibody-like protein-conjugate conjugate of formula (XIV), (XV), (XVI), or (XVII) can be purified before condensation with the drug, and the condensation conditions in the second step can be modified, for example, by adjusting the pH to 6.5 to 8.5 and / or the temperature to 20 to 45°C.

[0234] In some embodiments, prior to conjugation with a drug during the conjugation methods of the invention, the antibody-like protein is conjugated with an amine to sulfhydryl (succinimidyl (NHS) ester / maleimide, NHS ester / pyridyldithiol, NHS ester / haloacetyl) conjugation, a diazirine (SDA) to sulfhydryl conjugation, an azide to sulfhydryl conjugation, an alkyne to sulfhydryl conjugation, a sulfhydryl to carbohydrate (maleimide / hydrazide, pyridyldithiol, thiocarbamate, etc.) conjugation. The nucleotides may be modified by conjugation with heterobifunctional bridge linkers of formula (XIV), (XV), (XVI), or (XVII), such as linkers of thiol / hydrazide, haloacetyl / hydrazide, hydroxyl to sulfhydryl (isocyanate / maleimide), sulfhydryl to DNA (maleimide / psoralen, pyridyldithiol / psoralen, haloacetyl / psoralen), and sulfhydryl to carboxyl (carbodiimide).

[0235] The reactive group of the drug / cytotoxic agent that reacts with the modified antibody-conjugate complex of formula (XIV), (XV), (XVI), or (XVII) to give the final conjugate can be by different methods accordingly. For example, conjugates linked via disulfide bonds can be achieved by a first step of conjugating a conjugate of formula (X), (XI), (XII) or (XIII) to an antibody-like protein at 2° C.-8° C. and pH 4.5-6.0 by reduction and conjugation of the antibody-like protein according to the present invention, followed by disulfide exchange between the drug containing a free thiol group and the disulfide bond (e.g., pyridyldithio moiety) in the conjugate bound to the modified antibody-like protein at pH 6.5-8.0 and 20° C.-40° C. Prior to the addition of the drug containing a free thiol for conjugation, excess reducing agent (such as TCEP or tri(3-hydroxypropyl)phosphine) is preferably removed from the reaction vessel. The synthesis of thioether linked conjugates is accomplished by first reacting a linker containing both thiol reactive ends, maleimide, haloacetyl, ethylsulfonyl, or substituted propionyl groups, with a thiol in an antibody reduced by the methods of this patent application at 2° C.-8° C. and pH 4.5-6.0 to produce an antibody-conjugate conjugate of formula (XIV), (XV), (XVI), or (XVII), followed by reaction with a thiol containing drug at pH 6.5-8.0 and 20° C.-40° C. to give a conjugate of formula (VI), (VII), (VIII), or (IX). If the same pH and / or temperature conditions are selected for the two-step reaction of the thioether linked conjugates, the linker containing the reactive dual end thiol is used for the conjugation at 4-fold or more equivalents. It should be noted that the preferred method of synthesis of disulfide or thiol-ether bond conjugates is by first chemical synthesis of a drug-conjugate conjugate having a disulfide or thiol-ether bond of formula (I), (II), (III) or (IV), followed by reaction with a thiol in a protein (antibody) according to the methods of the present invention. Synthesis of conjugates having acid-labile hydrazone bonds can be achieved by reacting a carbonyl group with a hydrazide moiety in the linker by methods known in the art (e.g., P. Hamann et al., Cancer Res. 53, 3336-34, 1993; B. Laguzza et al., J. Med. Chem., 32; 548-55, 1959; P. Trail et al., Cancer Res., 57; 100-5, 1997). The synthesis of conjugates bearing a triazole bond can be achieved by reacting the 1-yne group of the drug with an azide moiety in the linker via click chemistry (Huisgen cycloaddition) (Lutz, JF. et al, 2008, Adv. Drug Del Rev. 60, 958-70; Sletten, EM et al 2011, Acc Chem. Research 44, 666-76). The synthesis of conjugates linked via oximes is achieved by reaction of modified antibody-like proteins containing ketones or aldehydes with drugs containing oxyamine groups. Drugs bearing hydroxyl or thiol groups can be reacted with modified conjugates of formula (XIV), (XV), (XVI), or (XVII) bearing halogens, particularly alpha halides of carboxylic acids, in the presence of a weak base, e.g., at pH 8.0-9.5, to obtain modified drug / conjugate conjugates bearing ether or thiol ether bonds of formula (I), (II), (III), or (IV). Drugs containing hydroxyl groups can be condensed with conjugates of formula (XIV), (XV), (XVI), or (XVII) bearing carboxyl groups in the presence of a dehydrating agent, such as EDC or DCC, to form ester bonds, and the drug / conjugate conjugates can then be conjugated to antibody-like proteins under the methods of the present invention.Drugs containing an amino group can be condensed with NHS, imidazole, nitrophenoxyl carboxyl ester; N-hydroxysuccinimide (NHS); methylsulfonylphenoxyl; dinitrophenoxyl; pentafluorophenoxyl; tetrafluorophenoxyl; difluorophenoxyl; monofluorophenoxyl; pentachlorophenoxyl; triflate; imidazole; dichlorophenoxyl; tetrachlorophenoxyl; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate on the antibody-conjugate of formula (XIV), (XV), (XVI), or (XVII) to obtain an amide bond-mediated conjugate of formula (VII), (VII), (VII), or (IX). For conjugates of formula (X), (XI), (XII), or (XIII) that contain both different thiol-reactive ends (e.g., one end is a maleimide group and the other is a vinylsulfonyl group), conjugation can proceed at different pH or temperature, or with a catalyst, to distinguish the reaction of one end with a thiol group on a drug or antibody from the reaction of the other end. When one end is a maleimide group and the other is a vinylsulfonyl group, the reaction of the maleimide group with the thiol group on the drug or antibody (Michael addition) can proceed in a buffer solution of pH 5.5 or less (usually pH 4.5-7.0) at low temperature (2-15°C) and for a short time (30 minutes to 2 hours), whereas the reaction of the vinylsulfonyl group with the thiol group on the drug or antibody (Michael addition) must proceed in a buffer solution of pH 7.0 or more (usually pH 7.0-8.5) at high temperature (20-37°C) for at least 8 hours. Thus, the thiol group of the drug or antibody can first be reacted with the maleimide group of a linker of formula X), (XI), (XII), or (XIII) at low pH (e.g., less than 6) for less than 2 hours, and then a thiol-reduced antibody (containing a thiol) or a thiol-containing drug can be added to react with the vinylsulfonyl group at the other end of the linker conjugate at a higher pH (e.g., 7.5).

[0236] In a further embodiment, the conjugates of formula (VI), (VII), (VIII) or (IX) obtained under the method of the present patent invention are more than 75% conjugated to the cysteine ​​sites between the heavy and light chains of the antibody, and less than 15% are conjugated to the cysteine ​​sites (hinge region) between the heavy and heavy chains of the antibody. Typically, for formula (VI) or (VII), when the drug / antibody ratio (DAR) is set to 4, the percentage distribution of the number of drugs in the antibody is as follows: D0<1%, D2<10%, D4>75%, D6<10%, D8<10%; for formula (VIII) or (IX), when the drug / antibody ratio (DAR) is set to 4, the percentage distribution of the number of drugs in the antibody is as follows: D0<1%, D1<10%, D2>75%, D3<10%, D4<10%.

[0237] The resulting conjugate can be purified by standard biochemical methods, such as gel filtration on Sephadex G25 or Sephacryl S300 columns, adsorption chromatography, ion (cation or anion) exchange, or dialysis (ultrafiltration or hyperfiltration (UF) and diafiltration (DF)). In some cases, when a small antibody-like protein (e.g., <10 KD) is conjugated with a small molecule drug as a cell-binding molecule, it can be purified by chromatography, such as HPLC, medium pressure column chromatography, or ion exchange chromatography.

[0238] In general, conjugates of formula (VI), (VII), (VIII), or (IX) are preferably generated from drug / conjugate conjugates of formula (I), (II), (III), or (VI) as a one-pot reaction. When a thiol reduced from an antibody-like protein reacts with a thiol-reactive group at the terminus of a drug / conjugate conjugate of formula (I), (II), (III), or (VI), Ellman's reagent can be optionally used to monitor efficient reduction of disulfide bonds and conjugation of thiols through measurement of the number of free thiols in the reaction. UV spectroscopy at wavelengths ranging from 190 to 390 nm, preferably 240 to 380 nm, more preferably 240 to 330 nm, is preferably used to assist the reaction (through monitoring of conjugation). Thus, the conjugation reaction can be measured or carried out in a quartz cell or Pyrex flask in a temperature-controlled environment. The drug / protein (antibody) ratio (DAR) of the conjugate can also be measured by UV at wavelengths ranging from 240-380 nm, by measuring the integrated area of ​​each drug / protein fragment, by hydrophobic interaction chromatography (HIC-HPLC), or by capillary electrophoresis (CE), and / or LC-MS, LC-MS / MS, or CE-MS (a combination of liquid chromatography (LC) or CE with mass spectrometry (MS) via measuring both the integrated area of ​​LC or CE and the peak intensity of MS for each drug / protein fragment). In the conjugation method of the present invention, if the drug or drug / conjugate complex is not well soluble in the aqueous buffer, up to 30% of a water-miscible (miscible) organic solvent, such as DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropanol, dioxane, propylene glycol, or ethylenediol, can be added to the aqueous buffer as a co-solvent.

[0239] Aqueous solutions for modification of antibody-like proteins are buffered to a pH between 4-9, preferably 6.0-7.5, and may contain non-nucleophilic buffer salts useful for these pH ranges. Exemplary buffers include phosphate, acetate, triethanolamine HCl, HEPES, and MOPS buffers, and may further include additional components such as cyclodextrin, hydroxypropyl-β-cyclodextrin, polyethylene glycol, sucrose, and salts (e.g., NaCl, KCl). Other biological buffers used in conjugation methods are listed in the definitions section. The progress of the reaction can be monitored by measuring the decrease in absorbance at 252 nm or the increase in absorbance at 280 nm, or changes at other suitable wavelengths. After the reaction is complete, isolation of the modified cell-binding agent can be performed by conventional methods, such as gel filtration chromatography, ion exchange chromatography, adsorption chromatography, or column chromatography on silica gel or alumina, crystallization, preparative thin layer chromatography, ion exchange chromatography, or HPLC.

[0240] When disulfide exchange reactions are used to modify antibody-like proteins, the degree of modification can be assessed by measuring the absorbance of the nitropyridinethione, dinitropyridinedithione, pyridinethione, carboxyamidopyridinedithione, and dicarboxyamidopyridinedithione groups emitted through the UV spectrum. In conjugates without chromophore groups, the modification or conjugation reaction can be monitored by LC-MS, preferably UPLC-QTOF mass spectrometry, or capillary electrophoresis (CEMS). The side chain crosslinkers described herein have a variety of functional groups that can react with any drug, preferably a cytotoxic drug, with the appropriate substituent. For example, modified cell-binding molecules with amino or hydroxy substituents can react with drugs with N-hydroxysuccinimide (NHS) esters, and modified cell-binding molecules with thiol substituents can react with drugs with maleimide or haloacetyl groups. Additionally, modified cell-binding molecules with carbonyl substituents (ketones or aldehydes) can react with drugs with hydrazides or alkyloxyamines. One of skill in the art can readily determine which linker to use based on the known reactivity of the available functional groups on the linker.

[0241] In certain embodiments, examples of preferred conjugates of formulae (VI), (VII), (VIII), and (IX) that can be constructed according to the methods of the present invention are the compounds shown below, or one or more isotopes of the chemical elements, pharma- ceutically acceptable salts, hydrates, or hydrated salts; or polycrystalline structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers:

[0242] [ka] TIFF2024542073000135.tif224170TIFF2024542073000136.tif227170TIFF2024542073000137.tif195170TIFF2024542073000138.tif247170TIFF2024542073000139.tif237170TIFF2024542073000140.tif253170TIFF2024542073000141.tif209170TIFF2024542073000142.tif205170TIFF2024542073000143.tif169170TIFF2024542073000144.tif236170TIFF2024542073000145.tif245170TIFF2024542073000146.tif250170TIFF2024542073000147.tif249170TIFF2024542073000148.tif247170TIFF2024542073000149.tif237170TIFF2024542073000150.tif224170TIFF2024542073000151.tif225170TIFF2024542073000152.tif238170TIFF2024542073000153.tif245170TIFF2024542073000154.tif237170TIFF2024542073000155.tif251170TIFF2024542073000156.tif239170TIFF2024542073000157.tif225170TIFF2024542073000158.tif236170TIFF2024542073000159.tif249170TIFF2024542073000160.tif207170TIFF2024542073000161.tif241170TIFF2024542073000162.tif213170TIFF2024542073000163.tif243170TIFF2024542073000164.tif242170TIFF2024542073000165.tif246170TIFF2024542073000166.tif236170TIFF2024542073000167.tif232170TIFF2024542073000168.tif216170TIFF2024542073000169.tif252170TIFF2024542 073000170.tif242170TIFF2024542073000171.tif247170TIFF2024542073000172.tif220170T IFF2024542073000173.tif210170TIFF2024542073000174.tif215170TIFF2024542073000175. tif204170TIFF2024542073000176.tif235170TIFF2024542073000177.tif238170TIFF2024542 073000178.tif249170TIFF2024542073000179.tif237170TIFF2024542073000180.tif242170T IFF2024542073000181.tif241170TIFF2024542073000182.tif241170TIFF2024542073000183. tif251170TIFF2024542073000184.tif217170TIFF2024542073000185.tif236170TIFF2024542 073000186.tif216170TIFF2024542073000187.tif250170TIFF2024542073000188.tif161170.

[0243] In the formula, n is 1 to 10.

[0244] In another specific embodiment, preferred examples of drug / conjugate conjugates of formulas (I), (II), (III), and (IV) that can be used in the methods of the present invention to achieve 75% or more of the total drug being conjugated to the cysteine ​​site between the heavy and light chains (Fab) of the antibody are compounds 25, 30, 36, 45, 51, 58a, 68a, 68b, 68c, 72a, 72b, 73, 83, 88, 91, 96, 102, 115, 120, 121, 126, 130, 137, 140, 152, 157, 168, 178, 181a, 181b, 181c, 181d, 190, 1 92, 195, 202, 209, 215, 221, 221b, 227, 233, 241, 255, 267, 277, 283, 284, 290, 300, 306, 309, 310, 312 , 319, 322, 326, 328, 330, 332, 334, 335, 336, 337, 338, 361, 362, 372, 373, 374, 375, 384, 385, 390, 396, 399, 400, 402, 406, 409, 416, 417, 427, 432, 437, 441, 450, 455, 462, 464, 470, 478, 481, 484, 487, 581, 582, 587, 591, 595, 599. Other examples of preferred drug / conjugate conjugates of formula (I), (II), (III), and (IV) are shown in the Figures and Examples section as 488, 494, 498, 499, 500, 501, 504, 508, 511, 514, 518, 519, 521, 527, 531, 532, 534, 537, 542, 543, 544, 546, 550, 553, 560, 561, 562, 565, 570, 573, 577, 581, 582, 587, 591, 595, 599. Other examples of preferred drug / conjugate conjugates of formula (I), (II), (III), and (IV) are the following compounds; or a derivative having one or more isotopes; a pharma- ceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure thereof; or an optical isomer, racemate, diastereomer, or enantiomer thereof:

[0245] [ka] TIFF2024542073000190.tif216170TIFF2024542073000191.tif242170TIFF2024542073000192.tif246170TIFF20245420730001 93.tif226170TIFF2024542073000194.tif200170TIFF2024542073000195.tif236170TIFF2024542073000196.tif195170TIFF202 4542073000197.tif229170TIFF2024542073000198.tif246170TIFF2024542073000199.tif200170TIFF2024542073000200.tif2 25170TIFF2024542073000201.tif221170TIFF2024542073000202.tif200170TIFF2024542073000203.tif230170TIFF2024542073 000204.tif243170TIFF2024542073000205.tif225170TIFF2024542073000206.tif230170TIFF2024542073000207.tif231170TI FF2024542073000208.tif231170TIFF2024542073000209.tif217170TIFF2024542073000210.tif237170TIFF2024542073000211. tif227170TIFF2024542073000212.tif242170TIFF2024542073000213.tif206170TIFF2024542073000214.tif216170TIFF202454 2073000215.tif237170TIFF2024542073000216.tif250170TIFF2024542073000217.tif212170TIFF2024542073000218.tif51170

[0246] In the formula, n is 1 to 10.

[0247] In further embodiments, examples of binding molecules of formula (X), (XI), (XII), or (XIII) are as follows: [ka] TIFF2024542073000220.tif251170TIFF2024542073000221.tif145170

[0248] In further embodiments, examples of linker molecules of formula (XIV), (XV), (XVI), or (XVII) are as shown below: [ka] TIFF2024542073000223.tif236170

[0249] Many of the structures of the conjugate compounds of formula (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII) are incorporated in the Examples section and figures below. Those skilled in the art of drug / cytotoxic agent conjugation will readily appreciate that each of the conjugate compounds described herein or incorporated in the example conjugates of formula (VI), (VII), (VIII), or (IX) can be modified by methods for rapid conjugation. Those skilled in the art will also appreciate that many of the conjugate compounds known in the art can be used in place of the conjugate compounds described herein for homogeneous conjugation of the antibodies of the present invention.

[0250] antibody

[0251] The antibodies (mAbs) used in the present conjugation methods are preferably cell-binding antibodies or antibody-like protein molecules that bind to, complex with, or react with a portion of a cell population sought to be therapeutically or otherwise biologically modified.

[0252] For convenience in this section and elsewhere, unless the context requires otherwise, "antibodies" should be understood to include "antibody-like proteins and peptides." Suitable antibody-like proteins that may be present in the conjugates of the invention include, for example, peptides, polypeptides, antibodies, antibody fragments, enzymes, cytokines, chemokines, receptors, blood factors, peptide hormones, toxins, transcriptional antibody-like proteins, or multimeric antibody-like proteins structurally having interchain disulfide bonds.

[0253] Enzymes include carbohydrate-specific enzymes, proteolytic enzymes, and the like, including oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases, as disclosed in U.S. Patent No. 4,179,337.Specific enzymes of interest include asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase, bilirubin oxidase, glucose oxidase, glucuronidase, galactosidase, glucoserubrosidase, and glutaminase.

[0254] Blood antibody-like proteins include albumin, transferrin, Factor VII, Factor VIII or Factor IX, von Willebrand factor, insulin, ACTH, glucagen, somatostatin, somatotropin, thymosin, parathyroid hormone, chromohormones, somatomedins, erythropoietin, luteinizing hormone, hypothalamic releasing factor, antidiuretic hormone, prolactin, interleukins, interferons, e.g., IFN-α or IFN-β, colony stimulating factors, hemoglobin, cytokines, antibodies, antibody fragments, chorionic gonadotropin, follicle stimulating hormone, thyroid stimulating hormone, and tissue plasminogen activator.

[0255] Other antibody-like proteins of interest are the allergen antibody-like proteins disclosed in Dreborg et al Crit. Rev. Therap. Drug Carrier Syst. (1990) 6 315-365 as being less allergenic when conjugated with polymers such as poly(alkylene oxide) and therefore suitable for use as tolerogens. Among the allergens disclosed are ragweed antigen E, honeybee venom, mite allergen, etc.

[0256] Glycopolypeptides such as immunoglobulins, ovalbumin, lipase, glucocerebrosidase, lectins, tissue plasminogen activator, and glycosylated interleukins, interferons, and colony stimulating factors are of interest, as are immunoglobulins such as IgG, IgE, IgM, IgA, IgD and fragments thereof. Of particular interest are receptor and ligand binding antibody-like proteins, antibodies and antibody fragments used in clinical medicine for diagnostic and therapeutic purposes.

[0257] The antibody is preferably: (A): The group consisting of antibodies, antibody-like protein molecules, probodies, nanobodies, peptides, coated antibodies on polymeric micelles, antibody-liposomes, lipoprotein-based drug carriers, coated antibodies on nanoparticles, antibody dendrimers, and the above particles coated or conjugated with antibody-like proteins (antibodies), or combinations of the above; (B) antibody-like proteins, full-length antibodies (polyclonal antibodies, monoclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific, trispecific, or tetraspecific antibodies)); single-chain antibodies; antibody fragments that bind to target cells, monoclonal antibodies, single-chain monoclonal antibodies, monoclonal antibody fragments that bind to target cells, chimeric antibodies, chimeric antibody fragments that bind to target cells, domain antibodies, domain antibody fragments that bind to target cells, resurfaced antibodies, resurfaced single-chain antibodies, or resurfaced antibody fragments that bind to target cells, humanized antibodies or resurfaced antibodies, humanized single-chain antibodies, or humanized antibodies that bind to target cells. Antibody fragments, anti-idiotypic (anti-Id) antibodies, CDRs, diabodies, triabodies, tetrabodies, miniantibodies, probodies, probody fragments, small immune antibody-like proteins (SIPs), lymphokine antibody-like proteins, hormone-type antibody-like proteins, growth factor antibody-like proteins, colony stimulating factor antibody-like proteins, nutrient transport antibody-like proteins, high molecular weight antibody-like proteins, fusion antibody-like proteins, kinase inhibitor antibody-like proteins, gene targeting antibody-like proteins, antibody-like proteins coated on nanoparticles or polymers modified with antibodies or high molecular weight antibody-like proteins.

[0258] Antibody fragments include Fab, Fab', and F(ab'). 2, Fv [Parham, J. Immunol. 131, 2895-2902 (1983)], fragments obtained by Fab expression libraries, epitope-binding fragments of anti-idiotypic (anti-Id) antibodies, CDR's, bispecific antibodies, trispecific antibodies, cancer cell antigens, viral antigens, microbial antigens, or any of the above that immunospecifically bind to a protein generated by the immune system that is capable of recognizing, binding to a specific antigen, or expressing a desired biological activity (Miller et al (2003) J. of Immunology 170:4854-61); interferons (e.g., types I, II, III); peptides; lymphokines, e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, GM-CSF, or interferon gamma (IFN-γ); hormones, e.g., insulin, TRH (thyrotropin releasing hormone), MSH (cell stimulating hormone), or steroid hormones such as androgen, estrogen, or melanocyte stimulating hormone (MSH); growth factors and colony stimulating factors, e.g., epidermal growth factor (EFG), granulocyte macrophage colony stimulating factor (GM-CSF); transforming growth factors (TGF), e.g., TGFα, TGFβ; insulin and insulin-like growth factors (IGF-I, IGF-II), G-CSF, M-CSF, and GM-CSF [Burgess, Immunology Today, 5, 155-158 (1984)]; vaccine growth factor (VGF); fibroblast growth factor (FGF); small molecular weight proteins, polypeptides, peptides, and peptide hormones, such as bombesin, gastrin, and gastrin releasing peptide; platelet-derived growth factor; interleukins and cytokines, such as interleukin-2 (IL-2), interleukin-6 (IL-6), leukemia inhibitory factor, granulocyte-macrophage colony-stimulating factor (GM-CSF); vitamins such as folic acid; apoproteins and glycoproteins, such as transferrin [O'Keefe et al, J. Bio. Chem.260, 932-927 (1985)]; carbohydrate-binding proteins or lipoproteins such as lectins; cellular nutrient transport molecules; and small molecule inhibitors, e.g., inhibitors of prostate-specific membrane antigen (PSMA), small molecule tyrosine kinase inhibitors (TKIs), non-peptide, or other cell-binding molecules or substances, e.g., bioactive polymers (Dhar, et al, Proc. Natl. Acad. Sci. 2008, 105, 17356-61), dendrimers (Lee, et al, Nat. Biotechnol. 2005, 23, 1517-26; Almutairi, et al; Proc. Natl. Acad. Sci. 2009, 106, 685-90), nanoparticles (Liong, et al, ACS Nano, 2008, 19, 1309-12; Medarova, et al. al, Nat. Med. 2007, 13, 372-7; Javier, et al, Bioconjugate Chem. 2008, 19, 1309-12), liposomes (Medinai, et al, Curr. Phar. Des. 2004, 10, 2981-9), and viral capsids (Flenniken, et al, Viruses Nanotechnol. 2009, 327, 71-93).

[0259] Generally, monoclonal antibodies are preferred for cell surface binding molecules, provided that suitable monoclonal antibodies are available. Antibodies may be murine, human, humanized, chimeric, or of other species origin.

[0260] The production of antibodies used in the present invention includes in vivo or in vitro production processes or a combination thereof. Methods for preparing anti-receptor peptide polyclonal antibodies are well known, for example, as shown in U.S. Patent No. 4,493,795 (Nestor et al.). A typical method for preparing monoclonal antibodies is to fuse mouse spleen cells isolated from a specific antigen-immunized mouse with myeloma cells (Kohler, G; Milstein, C. 1975. Nature 256:495-497). Detailed procedures are described in antibodies-A Laboratory Manual, Harlow and Lane, eds., cold spring harbor laboratory press, New York (1988), the contents of which are incorporated herein by reference. In particular, monoclonal antibodies can be obtained by immunizing mice, rats, hamsters, or other mammals with the antigen of interest, which may be, for example, intact target cells, antigens isolated from target cells, whole viruses, weakened whole viruses, and viral proteins. Spleen cells are fused with myeloma cells using PEG 6000. The resulting hybridomas are screened for their sensitivity to HAT (hypoxanthine-aminopterin-thymine). Hybridomas producing monoclonal antibodies useful in the practice of the invention are identified by immunoreaction with specific target cell receptors or inhibition of receptor activity.

[0261] The monoclonal antibody used in the present invention can be obtained by initiating the culture of monoclonal hybridoma cells in a nutrient medium containing hybridoma cells that secrete antibodies with appropriate antigen specificity. The culture should be maintained for a time and under conditions sufficient for the hybridoma cells to secrete the antibodies into the culture medium. After collecting the antibody-containing culture supernatant, the antibody can be isolated by well-known techniques, such as protein A affinity chromatography; anion exchange chromatography, cation exchange chromatography, hydrophobic interaction chromatography, and molecular sieve chromatography (especially affinity chromatography and molecular sieve chromatography using antigen-crosslinked protein A); centrifugation, precipitation, or other standard methods for purifying proteins.

[0262] Media useful for the preparation of these compositions are well known in the art and commercially available, including synthetic media. An exemplary synthetic medium is Dulbecco's Minimum Essential Medium (DMEM; Dulbecco et al., Virol. 8:396 (1959)) supplemented with 4.5 g / L glucose, 0-20 mM glutamine, 0-20% fetal bovine serum, ppm amounts of certain heavy metals (e.g., Cu, Mn, Fe, or Zn) or / and heavy metals added in salt form, and an antifoaming agent (e.g., polyoxyethylene-polyoxypropylene block copolymer).

[0263] In addition to cell fusion techniques, cell lines for producing antibodies can also be constructed by the following methods: direct transformation of B lymphocytes with oncogenic DNA or transfection with oncogenic viruses, such as Epstein-Barr virus (EBV, also known as human herpesvirus 4 (HHV-4)) or Kaposi's sarcoma-associated virus (KSHV) (see U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890 for details). Monoclonal antibodies can be prepared with anti-receptor peptides or terminal carboxyl group-containing peptides based on known methods (for details, see Niman et al., Proc. Natl. Acad. Sci. USA, 80:4949-4953 (1983); Geysen et al., Proc. Natl. Acad. Sci. USA, 82:178-182 (1985); Lei et al., Biochemistry 34(20):6675-6688 (1995)). In general, anti-receptor polypeptides or polypeptide analogs can be used alone or conjugated to a cross-linked immunogenic carrier as immunogens for preparing monoclonal antibodies against anti-receptor polypeptides.

[0264] There are many other well-known methods for producing monoclonal antibodies as binding molecules of the present invention. Among them, the method for producing fully human antibodies has attracted particular attention. Phage display technology allows obtaining fully human antibodies that specifically bind to known antigens from a fully human antibody library by affinity selection. The literature provides detailed descriptions of the phage display technology itself, the construction of vectors, and the screening of libraries. For details, see Dente et al. Gene. 148(1):7-13 (1994); Little et al. Biotechnol Adv. 12(3):539-55 (1994); Clackson et al. Nature 352:264-628 (1991); Huse et al. Science 246:1275-1281 (1989).

[0265] Monoclonal antibodies obtained from other species (e.g., mice) other than humans using hybridoma technology can be humanized to avoid human anti-mouse antibodies when administered to humans. Among them, the well-known method for antibody humanization is the grafting and remodeling of complementarity determining regions. For details, see U.S. Patent Nos. 5,859,205 and 6,797,492; Liu et al., Immunol Rev. 222:9-27 (2008); Almagro et al., Front Biosci. 1;13:1619-33 (2008); Lazar et al., Mol Immunol. 44(8):1986-98 (2007); Li et al. Proc. Natl. Acad. Sci. USA. 103(10):3557-62 (2006). The disclosures of the above documents are incorporated by reference. Fully human antibodies can be prepared by immunizing transgenic mice, rabbits, monkeys, and other mammals that have most of the human immunoglobulin light and heavy chains with an antigen. Examples of such mice include Xenomouse (Abgenix, Inc.), HuMab-Mouse (Medarex / BMS), and VelociMouse (Regeneron). For details, see U.S. Patent Nos. 6,596,541, 6,207,418, 6,150,584, 6,111,166, 6,075,181, 5,922,545, 5,661,016, 5,545,806, 5,436,149, and 5,569,825. In the course of human treatment, the immunogenicity of chimeric antibodies constructed by integrating mouse antibody variable region genes and human antibody constant region genes in the human body is much lower than that of mouse antibodies (Kipriyanov et al., Mol Biotechnol. 26:39-60 (2004); Houdebine, Curr Opin Biotechnol. 13:625-9 (2002)), the disclosures of which are incorporated by reference. Furthermore, antibody affinity and specificity can be improved by site-specific mutagenesis of antibody variable regions (Brannigan et al., Nat Rev Mol Cell Biol. 3:964-70 (2002); Adams et al., J. Immunol Methods. 231:249-60 (1999)).The constant region of an antibody can be partially replaced to effectively enhance its affinity for immune effector cells, thereby enhancing the cytotoxic effect.

[0266] Immunospecific antibodies against malignant cell antigens can be obtained commercially or by several conventional techniques, such as chemical synthesis or recombinant expression techniques. Similarly, nucleotide sequences encoding immunospecific antibodies against malignant cell antigens can be obtained commercially from the GenBank database or other similar databases, from the published literature, or by routine cloning and sequencing.

[0267] Besides antibodies, polypeptides or proteins can also act as binding molecules, interacting with the corresponding receptors or epitopes on the surface of target cells by binding, blocking, attacking or other means. As long as these peptides or proteins can specifically bind to the epitopes or their corresponding receptors, they do not have to belong to the immunoglobulin family. These polypeptides are also isolated by techniques similar to phage display antibodies (Szardenings, J Recept Signal Transduct Res. 2003; 23(4): 307-49). Peptide fragments obtained from random peptide libraries are similar to the application of antibodies and antibody fragments. The polypeptide or protein molecule maintains its antigen binding specificity by connecting with some macromolecules or vehicles through binding molecules. These macromolecules include, but are not limited to, albumin, polymers, liposomes, nanoparticles, or dendrimers.

[0268] Antibodies that can be used to bind drugs using the conjugates of the present invention to treat cancer, autoimmune diseases, and infectious diseases include, but are not limited to, 3F8 (anti-GD2 antibody), abagovomab (anti-CA-125 antibody), abciximab (anti-CD41 antibody (integrin α-IIb)), adalimumab (anti-TNF-α antibody), adalimumab (anti-EpCAM antibody, CD326), afelimomab (anti-TNF-α); afutuzumab (anti-CD20 antibody), alacizumab pegol (Alacizumab pegol) (anti-VEGFR2 antibody), ALD518 (anti-IL-6 antibody), alemtuzumab (also known as campus, mab campus, anti-CD52 antibody), altumomab (anti-CEA antibody), anatumomab (anti-tag-72 antibody), anrukinzumab (IMA-638, anti-IL-13 antibody), apolizumab (anti-HLA-DR antibody), arcitumomab (anti-CEA antibody), acelizumab (anti-L -selectin (CD62L) antibody), Atlizumab (also known as Tocilizumab, Actemra, RoActemra, anti-IL-6 receptor antibody), Atorolimumab (anti-rhesus factor antibody), Bapineuzumab (anti-β-amyloid antibody), Basiliximab (Simulect, anti-CD25 (IL-2 receptor α chain) antibody), Bavituximab ximab (anti-phosphatidylserine antibody), Bectumomab (also known as LymphoScan, anti-CD22 antibody), Belimumab (also known as BENLYSTA, LymphoStat-B, anti-BAFF antibody), Benralizumab (anti-CD125 antibody), Bertilimumab (anti-CCL11 (eotaxin-1) antibody), Besilesomab (also known as Scintimun, anti-CEA-related antigen antibody), Bevacizumab (also known as Avastin, anti-VEGF antibody), Biciromab (also known as FibriScint, anti-fibrin II beta chain antibody), Bivatuzumab (anti-CD44v6 antibody), Blinatumomab (also known as BiTE, anti-CD19 antibody), Brentuximab (cAC10, anti-CD30 TNFRSF8 antibody), Briakinumab (anti-IL-12, IL-23 antibody), Canakinumab (also known as Ilaris, anti-IL-1 antibody),Cantuzumab (also known as C242, anti-CanAg antibody), Capromab, Catumaxomab (also known as removeb, anti-EpCAM, anti-CD3 antibody), CC49 (anti-TAG-72 antibody), Cedelizumab (anti-CD4 antibody), Certolizumab pegol (also known as CIMZIA, anti-TNF-α antibody), Cetuximab (also known as Erbitux, IMC-C225, anti-EGFR antibody), Sitanuzumab (anti-EpCAM antibody), Cixutumumab (anti-IGF-1 antibody), Clenoliximab (anti-CD 4 antibodies), Clivatuzumab (anti-MUC1 antibody), Conatumumab (anti-TRAIL-R2 antibody), CR6261 (anti-influenza A hemagglutinin antibody), Dacetuzumab (anti-CD40 antibody), Daclizumab (also known as Zenapax, anti-CD25C (IL-2 receptor α chain) antibody), Daratumumab (anti-CD38 (cyclic ADP ribose hydrolase) antibody), Denosumab (also known as Prolia, anti-RANKL antibody), (anti-B-lymphoma cell antibody), Dorlimomab, Dorlixizumab, Ecromeximab (anti-GD3 ganglioside antibody), Eculizumab (also known as Soliris, anti-C5 antibody), Edobacomab (anti-endotoxin antibody), Edrecolomab (also known as Panorex, MAb17-A1, anti-EpCAM antibody), Efalizumab (also known as Raptiva, anti-LFA-1 (CD11a) antibody), Efungumab (also known as Mycograb, anti-Hsp90 antibody), Elotuzumab Elotuzumab (anti-SLAMF7 antibody), Elsilimomab (anti-IL-6 antibody), Enlimomab pegol (anti-ICAM-1 (CD54) antibody), Epitumomab (anti-episialin antibody), Epratuzumab (anti-CD22 antibody), Erlizumab (anti-ITGB2 (CD18) antibody), Ertumaxomab (also known as Rexomun, anti-HER2 / neu, CD3 antibody), Etaracizumab (also known as Abegrin, anti-integrin αvβ3),Exibirumab (anti-hepatitis B surface antigen antibody (HBs antibody)), Fanolesomab (also known as NeutroSpec, anti-CD15 antibody), Faralimomab (anti-interferon receptor antibody), Farletuzumab (anti-folate receptor 1 antibody), Felvizumab (antibody against respiratory syncytial virus), Fezakinumab (anti-IL-22 antibody), Figitumumab (anti-IGF-1 receptor antibody), Fontolizumab (anti-IFN-γ antibody), Foravirumab (anti-rabies virus glycoprotein antibody), Fresolimumab (anti-TGF-β antibody), Galiximab (anti-CD80 antibody), Gantenerumab (anti-β-amyloid antibody), Gavilimomab (anti-CD147 (basigin) antibody), Gemtuzumab (anti-CD33 antibody), Girentuximab (anti-carbonic anhydrase 9 antibody), Glembatumumab (also known as CR011, anti-GPNMB antibody), Golimumab (also known as Simponi, anti-TNF-α antibody), Gomiliximab (anti-CD23C (IgE receptor) antibody), Ibalizumab (anti-CD4 antibody), Ibritumomab (anti-CD20 antibody), Igovomab (also known as Indimacis-125, anti-CA-125 antibody), Imciromab (also known as Myoscint , anti-cardiac myosin antibody), Infliximab (also known as Remicade, anti-TNF-α antibody), Intetumumab (anti-CD51 antibody), Inolimomab (anti-CD25 (IL-2 receptor α chain) antibody), Inotuzumab (anti-CD22 antibody), Ipilimumab (anti-CD152 antibody), Iratumumab (anti-CD30 (TNFRSF8) antibody), Keliximab (anti-CD4 antibody), Labetuzumab (also known as CEA-Cide, anti-CEA antibody),Lebrikizumab (anti-IL-13 antibody), Remalesomab (anti-NCA-90 (granulocyte antigen) antibody), Lerdelimumab (anti-TGFβ-2 antibody), Lexatumumab (anti-TRAIL-R2 antibody), Ribivirumab (anti-Hepatitis B surface antigen antibody), Lintuzumab (anti-CD33 antibody), Lucatumumab (anti-CD40 antibody), Lumiliximab (anti-CD23 (IgE receptor) antibody), Mapatumumab (anti-TRAIL-R1 antibody), Maslimomab ( Anti-T cell receptor antibody), Matuzumab (anti-EGFR antibody), Mepolizumab (also known as Bosatria, anti-IL-5 antibody), Metelimumab (anti-TGFβ-1 antibody), Milatuzumab (anti-CD74 antibody), Minretumomab (anti-TAG-72 antibody), Mitumomab (also known as BEC-2, anti-ganglioside antibody-GD3), Morolimumab (anti-rhesus factor antibody), Motavizumab (also known as Numax, anti-RS virus antibody), Muromonab-CD3 (also known as Orthoclone OKT3, anti-CD3 antibody), Nacolomab (anti-C242 antibody), Naptumomab (anti-5T4 antibody), Natalizumab (also known as Tysabri, anti-integrin α4 antibody), Nebacumab (anti-endotoxin antibody), Necitumumab (anti-EGFR antibody), Nerelimomab (anti-TNF-α antibody), Nimotuzumab (also known as :Theracim, Theraloc, anti-EGFR antibody), Nofetumomab, Ocrelizumab (anti-CD20 antibody), Odulimomab (also known as Afolimomab, anti-LFA-1 (CD11a) antibody), Ofatumumab (also known as Arzerra, anti-CD20 antibody), Olaratumab (anti-PDGF-Rα antibody), Omalizumuba (also known as Xolair,Anti-IgEFc region antibody), Ozumab (anti-EpCAM antibody), Oregovomab (also known as OvaRex, anti-CA-125 antibody), Otelixizumab (anti-CD3 antibody), Pagibaximab (anti-LTA antibody), Palivizumab (also known as Synagis, Abbosynagis, anti-RS virus antibody), Panimumab (also known as Vectibix, ABX-EGF, anti-EGFR antibody), Panobacumab (anti-Pseudomonas aeruginosa antibody), Pascolizumab (anti-IL-4 antibody), Pemtumomab (also known as Theragyn, anti-MUC1 antibody), Pertuzumab (also known as Omnitarg, 2C4, anti-HER2 / neu antibody), Pexelizumab (anti-C5 antibody), Pintumomab (anti-adenocarcinoma antigen antibody), Priliximab (anti-CD4 antibody), Pritumumab (anti-vimentin antibody), PRO140 (anti-CCR5 antibody), Racotumomab (ra cotumomab (also known as 1E10, anti-(N-glycolylneuraminic acid (NeuGc, NGNA)-ganglioside (GM3) antibody), Rafivirumab (anti-rabies virus glycoprotein antibody), Ramucirumab (anti-VEGFR2 antibody), Ranibizumab (also known as Lucentis, anti-VEGF-A antibody), Raxibacumab (anti-anthrax toxin, protective antigen antibody), Regavirumab (anti-CMV glycoprotein B antibody), Reslizumab lizumab (anti-IL-5 antibody), rilotumumab (anti-HGF antibody), rituximab (also known as MabThera, Rituxanmab, anti-CD20 antibody), robatumumab (anti-IGF-1 receptor antibody), rontalizumab (anti-IFN-α antibody), rovelizumab (also known as LeukArrest, anti-CD11, CD18 antibody), ruplizumab (also known as Antova, anti-CD154 (CD40L) antibody),Satumomab (anti-TAG-72 antibody), Sevirumab (anti-CMV antibody), Sibrotuzumab (anti-FAP antibody), Sifalimumab (anti-IFN-α antibody), Siltuximab (anti-IL-6 antibody), Siplizumab (anti-CD2 antibody), (Smart) MI95 (anti-CD33 antibody), Solanezumab (, Anti-β-amyloid antibody), Sonepcizumab (anti-sphingosine-1-phosphate antibody), Sontuzumab (anti-episialin antibody), Stamulumab (anti-myostatin antibody), Sulesomab (also known as LeukoScan, (anti-NCA-90 (granulocyte antigen) antibody)), Tacatuzumab (anti-α-phenotype antibody), tocoprotein antibody), tadocizumab (anti-integrin αIIbβ3 antibody), talizumab (anti-IgE antibody), tanezumab (anti-NGF antibody), taplitumomab (anti-CD19 antibody), tefibazumab (also known as Aurexis, anti-clumping factor A antibody), terimomab, tenatumomab natumomab (anti-tenascin C antibody), teneliximab (anti-CD40 antibody), teplizumab (anti-CD3 antibody), TGN1412 (anti-CD28 antibody) ), Ticilimumab (also known as Tremelimumab, anti-CTLA-4 antibody), Tigatuzumab (anti-TRAIL-R2 antibody), TNX-650 (anti-IL-13 antibody), Tocilizumab (Also known as Atlizumab, Actemra, RoActemra, (anti-IL-6 receptor antibody), Toralizumab (anti-CD154 (CD40L) antibody), Tositumomab (anti-CD20 antibody), Trastuzumab (also known as Herceptin, anti-HER2 / neu antibody), Tremelimumab (anti-CTLA-4 antibody), Tucotuzumabcelmoleukin (anti-EpCAM antibody), tuvirumab (anti-hepatitis B antibody), urtoxazumab (anti-Escherichia coli antibody), ustekinumab (also known as Stelara, anti-IL-12, IL-23 antibody), vapaliximab (anti-AOC3 (VAP-1) antibody), vedolizumab (anti-integrin α4β7 antibody), veltuzumab (anti-CD20 antibody), vepalimomab (anti-AOC3 (VAP-1) antibody), visilizumab (also known as Nuvion, anti-CD3 antibody), vitaxin (anti-angiogenic integrin avb3 antibody), volociximab (anti-integrin phospho-α5β1), Votumumab (also known as HumaSPECT, anti-tumor antigen CTAA16.88 antibody), Zalutumumab (also known as HuMax-EGFr, (anti-EGFR antibody), Zanolimumab (also known as HuMax-CD4, anti-CD4 antibody), Ziralimumab (anti-CD147 (basic immunoglobulin) antibody), Zolimomab (anti-CD5 antibody), Etanercept (registered trademark "Enbrel"), Alefacept (registered trademark "Amevive"), Abatacept (registered trademark "Orencia"), Rilonacept (Arcalyst), 14F7 [anti-IRP-2 (iron regulatory protein 2) antibody], 14G2a (Nat.Cancer Inst.), J591 (anti-ganglioside GD2 antibody for melanoma and solid tumors, from Weill Cornell Medical School), J591 (anti-PSMA antibody for treating prostate cancer, from Weill Cornell Medical School), 225.28S [anti-HMW-MAA (high molecular weight melanoma associated antigen) antibody for melanoma, from Sorin Radiofarmaci SRL (Milan, Italy)], COL-1 (anti-CEACAM3 antibody, CGM1, for colorectal and gastric cancer, from Nat. Cancer Inst.), CYT-356 (Oncoltad®, prostate cancer), HNK20 (Ora VaxInc. for respiratory syncytial virus), ImmuRAIT (IMMUNOMEDICS for non-Hodgkin's lymphoma), Lym-1 (anti-HLA-DR10 antibody, Peregrine Pharm for oncology), MAK-195F [anti-TNF (tumor necrosis factor; TNFA, TNF-α; TNFSF2) antibody for sepsis, toxic shock from Abbott / Knoll], MEDI-500 [also known as T10B9, anti-CD3 antibody, TRαβ (T-cell receptor α / β), for graft-versus-host disease from MedImmune Inc], RING SCAN [Neoprobe Corp. for breast, colon and colorectal cancers)], Avicidin (anti-EPCAM (epithelial cell adhesion molecule) antibody), anti-TACSTD1 (tumor-associated calcium signal transducer 1) antibody, anti-GA733-2 (gastrointestinal tumor-associated protein 2) antibody, anti-EGP-2 (epithelial glycoprotein 2) antibody; anti-KSA antibody; KS1 / 4 antigen; M4S; tumor antigen 17-1A; CD326 for colon, ovarian, prostate and non-Hodgkin's lymphoma from NeoRx Corp.; LYMPHOCIDE (IMMUNOMEDICS, NJ), smart ID10 (Protein Design Labs), Oncolym (Techniclone Inc, CA), Allomune (BioTransplant, CA), anti-VEGF antibody (Genentech, CA); CEAcide (Immunomedics, NJ), IMC-1C11 (ImClone Systems, NJ), and cetuximab (ImClone, NJ).

[0269] Other antibodies that function as cell binding molecules / ligands include, but are not limited to, antibodies against the following antigens: aminopeptidase N (CD13), annexin A1, B7-H3 (CD276, various cancers), CA125 (ovarian), CA15-3 (carcinoma), CA19-9 (carcinoma), L6 (carcinoma), Lewis Y (carcinoma), Lewis X (carcinoma), alpha-fetoprotein (carcinoma), CA242 (colorectal), placental alkaline phosphatase (carcinoma), prostate specific antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (carcinoma), CD2 (prostate cancer), and IL-16. rheumatoid arthritis, NHL lymphoma, multiple myeloma), CD3ε (T-cell lymphoma, lung cancer, breast cancer, gastric cancer, ovarian cancer, autoimmune diseases, malignant ascites), CD19 (B-cell malignancies), CD20 (non-Hodgkin's lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, systemic lupus erythematosus), CD30 (Hodgkin's lymphoma), CD33 (leukemia, autoimmune diseases), CD38 (multiple myeloma), CD40 (lymphoma, multiple myeloma, leukemia (CLL)), CD51 (metastatic melanoma, sarcoma), CD52 (leukemia), CD56 (small cell lung cancer, ovarian cancer, Merkel cell carcinoma and liquid tumors, multiple myeloma), CD66e (cancer), CD70 (metastatic renal cell carcinoma and non-Hodgkin's lymphoma), CD74 (multiple myeloma), CD80 (lymphoma), CD98 (cancer), mucin (carcinoma), CD221 (solid tumors), CD227 (breast cancer, ovarian cancer), CD262 (non-small cell lung cancer and other cancers), CD309 (ovarian cancer), CD326 (solid tumors), CEACAM3 (colorectal cancer, gastric cancer), CEACAM5 (carcinoembryonic antigen; CEA, CD66e) (breast cancer, colorectal cancer and lung cancer), DLL4 (Δ-like-4), EGFR (epidermal growth factor receptor, various cancers), CTLA4 (melanoma), CXCR4 (CD184, hemoglobin, solid tumors), endoglin (CD105, solid tumors), EPCAM (epithelial cell adhesion molecule, bladder, head, neck, colon cancer, NHL prostate cancer, and ovarian cancer), ERBB2 (epidermal growth factor receptor 2; lung cancer, breast cancer, prostate cancer), FCGR1 (autoimmune disease), FOLR (folate receptor, ovarian cancer), GD2 ganglioside (cancer), G-28G (cell surface antigen glycolipid, melanoma), GD3 idiotype (cancer), heat shock protein (cancer), HER1 (lung cancer, gastric cancer), HER2 (breast cancer, lung cancer, and ovarian cancer),HLA-DR10 (NHL), HLA-DRB (NHL, B-cell leukemia), human chorionic gonadotropin (carcinoma), IGF1R (insulin-like growth factor-1 receptor, solid tumors, blood cancers), IL-2 receptor (interleukin-2 receptor, T-cell leukemia and lymphoma), IL-6R (interleukin-6 receptor, multiple myeloma, RA, Castleman's disease, IL6-dependent tumors), integrins (αVβ3, α5β1, α6β4, αIIβ3, α5β5, αV for various cancers) β5), MAGE-1 (carcinoma), MAGE-2 (carcinoma), MAGE-3 (carcinoma), MAGE-4 (carcinoma), anti-transferrin receptor (carcinoma), p97 (melanoma), MS4A1 (transmembrane 4-domain family A member 1, non-Hodgkin's B-cell lymphoma, leukemia), MUC1 or MUC1-KLH (breast, ovarian, cervical, bronchial and gastrointestinal cancer), MUC16 (CA125) (ovarian cancer), CEA (colon), gp100 (melanoma), MART1 (melanoma), MPG (melanoma) ), MS4A1 (transmembrane 4-domain family A member 1, small cell lung cancer, NHL), nucleolin, neuronal oncogene product (carcinoma), P21 (carcinoma), anti-(paratope of N-glycolylneuraminic acid (breast cancer, melanoma cancer), PLAP-like testicular alkaline phosphatase (ovarian cancer, testicular cancer), PSMA (prostate cancer), PSA (prostate), ROBO4, TAG72 (tumor-associated glycoprotein 72, leukemia (AML), gastric cancer, colorectal cancer, ovarian cancer), transmembrane protein of T cells (cancer) , Tie (CD202b), TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, cancer), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, renal cell carcinoma), TRAIL-R1 (TNF-related apoptosis ligand receptor 1, lymphoma, NHL, colorectal cancer, lung cancer), VCAM-1 (CD106, melanoma), VEGF, VEGF-A,VEGF-2 (CD309) (various cancers). Other tumor-associated antigens recognized by antibodies have been reported (Gerber, et al, mAbs 1:3, 247-253 (2009); Novellino et al, Cancer Immunol Immunother. 54 (3), 187-207 (2005). Franke et al, Cancer Biother Radiopharm. 2000, 15, 459-76).

[0270] The antibody-like protein is preferably an IgG antibody that can be directed against tumor cells, virus-infected cells, microorganism-infected cells, parasite-infected cells, autoimmune cells, activated cells, myeloid cells, activated T cells, B cells, or melanocytes. More specifically, the antibody can bind to abnormal cells expressing any one of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CD16a, CD16b, CDw17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD63, CD64, CD65, CD66, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD76, CD77, CD78, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD87, CD88, CD89, CD90, CD82, CD83, CD D22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD32a, CD32b, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, C D42, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD49c, CD49d, CD49f, CD50, CD51, CD52, CD53, CD54 , CD55, CD56, CD57, CD58, CD59, CD60, CD60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD65, CD65s, CD66, CD66a, CD66b, CD 66c, CD66d, CD66e, CD66f, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD74, CD75, CD75s, CD76, CD77, CD78, CD79, CD79a, CD79b, CD 80, CD81, CD82, CD83, CD84, CD85, CD85a, CD85b, CD85c, CD85d, CD85e, CD85f, CD85g, CD85g, CD85i, CD85j, CD85k, CD85m, CD86, CD87, CD 88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107, CD107a,CD107b、CD108、CD109、CD110、CD111、CD112、CD113、CD114、CD115、CD116、CD117、CD118、CD119、CD120a、CD120b、CD121、CD121a、CD121b、CD122、CD123、CD123a、CD124、CD125、CD126、CD127、CD128、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、CD139、CD140、CD140a、CD140b、CD141、CD142、CD143、CD144、CD145、CDw145、CD146、CD147、CD148、CD149、CD150、CD151、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、CD156d、CD157、CD158、CD158a、CD158b1、CD158b2、CD158c、CD158d、CD158e1、CD158e2、CD158f2、CD158g、CD158h、CD158i、CD158j、CD158k、CD159、CD159a、CD159b、CD159c、CD160、CD161、CD162、CD163、CD164、CD165、CD166、CD167、CD167a、CD167b、CD168、CD169、CD170、CD171、CD172、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177、CD178、CD179、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186、CDw186、CD187、CD188、CD189、CD190、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CD198、CDw198、CDw199、CD200、CD201、CD202(a,b)、CD203、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210、CDw210a、CDw210b、CD211、CD212、CD213、CD213a1、CD213a2、CD214、CD215、CD216、CD217、CD218、CDw218a、CD218、CD21b9、<h2 style=";text-align:left;direction:ltr">CD220、CD221、CD222、CD223、CD224、CD225、CD226、CD227、CD228、CD229、CD 230、CD231、CD232、CD233、CD234、CD235a、CD235b、CD236、CD236R、CD238、C D239, CD240, CD240ce, CD240d, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD250, CD251, CD252, CD253, CD254, CD255, CD256, CD2 57, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD265, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD 278, CD279, CD281, CD282, CD283, CD284, CD285, CD286, CD287, CD288, CD289, CD290, CD291, CD292, CD293, CD294, CD295, CD296, CD297, CD298, CD299, C D300、CD300a、CD300b、CD300c、CD301、CD302、CD303、CD304、CD305、CD306、 CD307、CD307a、CD307b、CD307c、CD307d、CD307e、CD307f、CD308、CD309、CD3 10、CD311、CD312、CD313、CD314、CD315、CD316、CD317、CD318、CD319、CD320 、CD321、CD322、CD323、CD324、CD325、CD326、CD327、CD328、CD329、CD330、CD 331、CD332、CD333、CD334、CD335、CD336、CD337、CD338、CD339、CD340、CD34 1、CD342、CD343、CD344、CD345、CD346、CD347、CD348、CD349、CD350、CD351、C D352, CD353, CD354, CD355, CD356, CD357, CD358, CD359, CD360, CD361, CD362, CD363, CD364, CD365, CD366, CD367, CD368, CD369, CD370, CD371, CD372CD373, CD374, CD375, CD376, CD377, CD378, CD379, CD381, CD382, CD383, CD384, CD385, CD386, CD387, CD388, CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB, APO2, ASLG659, BMPR1B, 4-1BB, 5AC, 5T4 (trophoblast glycoprotein, TPBG, 5T4, Wnt activation inhibitor 1 or WAIF1) , adenocarcinoma antigen, AGS-5, AGS-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, α integrin, αvβ6, aminopeptidase N, amyloid beta, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3 (VAP-1), B7-H3, anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cells, bcr-abl, bombesin, BORIS, C5, C242 anti Hara, CA125 (carbohydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, canine IL31, carbonic anhydrase IX, cardiac myosin, CCL11 (CC motif chemokine 11), CCR4 (CC chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (factor D), Ch4D5, cholecystokinin 2 (CCK2R), CLDN18 (claudin -18), CLDN18.1 (claudin-18.1), CLDN18.2 (claudin-18.2), clumping factor A, cMet, CRIPTO, FCSF1R (colony-stimulating factor 1 receptor, CD115), CSF2 (colony-stimulating factor 2, granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, CXC chemokine receptor type 4, cADP-ribose hydrolase, Cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL3 (delta-like ligand 3), DLL4 (delta-like ligand 4),DPP4 (dipeptidyl peptidase 4), DR5 (death receptor 5), Escherichia coli Shiga toxin type 1, Escherichia coli Shiga toxin type 2, ED-B, EGFL7 (EGF-like domain containing protein 7), EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, episialin, ERBB2 (epidermal growth factor receptor 2), ERBB3, ERG (TMPRS S2ETS fusion gene), E. coli, ETV6-AML, FAP (fibroblast activation protein alpha), fibroblast surface antigen, FCGR1, alpha-fetoprotein, fibrin II, beta chain, fibronectin ectodomain B, FOLR (folate receptor), folate receptor alpha, folate hydrolase, respiratory syncytial virus Fos-related antigen 1F protein, Frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28 (cell surface glycolipid antigen), GD3 idiotype, GloboH, glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor alpha chain, growth differentiation factor, GP100, GPNMB (transmembrane protein NMB), GUCY2C (guanylate cyclase 2C, guanylate cyclase C (GC-C), intestinal guanylate cyclase, guanylate cyclase-C receptor, heat-stable enterotoxin receptor (hSTAR)), heat shock protein, hemocyte agglutinins, hepatitis B surface antigen, hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2 / neu, HER3 (ERBB-3), IgG4, HGF / SF (stem cell growth factor / scatter factor), HHGFR, HIV-1, histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human scatter factor receptor kinase, HPV E6 / E7, Hsp90, hTERT, ICAM-1 (intercellular adhesion molecule 1), idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGHE, interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19,IL-20、IL-21、IL-22、IL-23、IL-27 and IL-28。 ) IL-31RA ILGF2(α4 and α IIIb β 3 、αvβ3、α 4 β 7 、α5β1、α6β4、α7β7、αI Iβ3, α5β5, αvβ5), interferon-gamma-inducible protein, ITAGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1 (lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGEA1, MAGEA3, MAGE4, ​​MART1, MCP-1, MIF (macrophage migration inhibitory factor or glycosylation inhibitory factor (GIF)), MS4A1 (transmembrane 4 domain subfamily A member 1), MSLN (mesothelin), MUC1 (mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemotactic protein 1), MelanA / MART1, ML-IAP, MPG, MS4A1 (transmembrane 4 domain subfamily A), MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, neuronal apoptosis-regulating proteinase 1, NOGO-A, Notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (oxidized low-density lipoprotein), OY-TES1, P21, non-mutant p53, P9 7, Page4, PAP, anti-(N-glycolylneuraminic acid) paratope, PAX3, PAX5, PCSK9, PDCD1 (PD-1, programmed cell death protein 1), PDGF-Rα, (platelet-derived growth factor receptor α), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor β, sodium phosphate cotransporter, PMEL17, polysialic acid, proteinase 3 (PR1), prostate cancer, PS (phosphatidylserine), prostate cancer cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), rhesus factor, RANKL, PhoC,Ras mutant, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma metastasis breakpoint, SART3, sclerostin, SLAMF7 (SLAM family member 7), selectin P, SDC1 (syndecan 1), sLe(a), somatomedin C, SIP (sphingosine-1-phosphate), somatostatin, sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial antigen of the prostate 1), STEAP2, STn, TAG-72 (tumor-associated glycoprotein 72), survivin, T cell receptor, T cell transmembrane protein, TEM1 (tumor epithelial marker 1), TENB2, tenascin C (TN-C), TGF-α, TGF-β (transforming growth factor beta), TGF-β1, TGF-β2 (transforming growth factor beta 2), Tie (CD202b), Tie2, TIM-1 (CDX- 014), TN, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis-inducing ligand receptor 1), TRAILR2 (cell death receptor 5 (DR5)), tumor-associated calcium signal transducer 2, tumor-specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-1 (Trop1), TRP-2 (Trop2), tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or cells expressing vimentin, WT1, XAGE1, or any insulin growth factor receptor, or any epidermal growth factor receptor.

[0271] Many tumor-associated antigens (TAA) or tumor cell receptors are known in the art and can be prepared for use in generating antibodies using methods and information well known in the art. In an attempt to discover effective cellular targets for cancer diagnosis and treatment, researchers have sought to identify transmembrane or tumor-associated polypeptides or glycoproteins that are specifically expressed on the surface of one or more specific types of cancer cells compared to one or more normal non-cancerous cell surfaces. In many cases, such tumor-associated polypeptides are more abundantly expressed on the surface of cancer cells compared to the surface of non-cancerous cells. Identification of such tumor-associated cell surface antigen polypeptides provides the ability to specifically target cancer cells for their destruction via the ADCs of the present application. Examples of TAAs and cognate antibodies known in the art are as follows:

[0272] (1) BMPR1B (bone morphogenetic protein receptor type IB) Nucleotide: Genbank Accession No. NM_001203; Genbank Version No. NM_001203.2 GI: 169790809. Polypeptide: Genbank Accession No. NP_001194; Genbank Version No. NP_001194.1 GI: 4502431. Cross References: Attisano L, et al, Cell. 75(4):671-80 (1993); ten Dijke, P., et al Science 264 (5155): 101-104 (1994), Ide H., et al, Oncogene 14 (11):1377-1382 (1997); WO2004 / 063362 (claim 2); WO2003 / 042661 (claim 12); US2003 / 134790-A1 (pages 38-39); WO2002 / 102235 (claim 13; page 296); WO2003 / 055443 (pages 91-92); WO2002 / 99122 (Example 2; pages 528-530); WO2003 / 029421 (claim 6); WO2003 / 024392 (claim 2; figure 112); WO2002 / 98358 (claim 1; page 183); WO2002 / 54940 (pages 100-101); WO2002 / 59377 (pages 349-350); WO2002 / 30268 (claim 27; page 376); 15 WO2001 / 48204 (example; figure 4); NP_001194 bone morphogenetic protein receptor, type IB / pid=NP_001194.1; MIM:603248; AY065994

[0273] (2) E16 (LAT1, SLC7A5): Nucleotide: Genbank Accession No. NM_003486; Genbank Version No. NM_003486.5 GI:71979931. Polypeptide: Genbank Accession No. NP_003477; Genbank Version No. NP_003477.4 GI:71979932. Cross References: Prasad, PD et al, Biochem. Biophys. Res. Commun. 255 (2), 283-288 (1999), Mastroberardino, L., et al, Nature 395 (6699):288-291 (1998), Pfeiffer R, et al, EMBO J. 18(1):49-57 (1999); Gaugitsch, HW, et al, J. Biol. Chem. 267 (16):11267-11273 (1992); WO2004 / 048938 (Example 2); WO2004 / 032842 (Example IV); WO2003 / 042661 (Claim 12); WO2003 / 016475 (Claim 1); WO2002 / 78524 (Example 2); WO2002 / 99074 (claim 19; pages 127-129); WO2002 / 86443 (claim 27; pages 222, 393); WO2003 / 003906 (claim 10; page 293); WO2002 / 64798 (claim 33; pages 93-95); WO2000 / 14228 (claim 5; pages 133-136); US2003 / 224454 (figure 3); 25 WO2003 / 025138 (claim 12; page 150); NP_003477 solute carrier family 7 (cationic amino acid transporters, y+ system), member 5 / pid=NP_003477.3 - Homo sapiens; MIM:600182; NM_015923.

[0274] (3) STRAP1 (six-transmembrane epithelial antigen of the prostate): Nucleotide: Genbank Accession No. NM_012449; Genbank Version No. NM_012449.2 GI: 22027487. Polypeptide: Genbank Accession No. NP_036581; Genbank Version No. NP_036581.1 GI: 9558759. Cross References: Tang, D. et al, Cancer Res. 61 (15), 5857-5860 (2001); Hubert, RS, et al, Proc. Natl. Acad. Sci. USA 96 (25):14523-14528 (1999); WO2004 / 065577 (Claim 6); WO2004 / 027049 (Fig. 1L); EP1394274 (Example 11); WO2004 / 016225 (Claim 2); WO2003 / 042661 (Claim 12); US2003 / 157089 (Example 5); US2003 / 185830 (Example 5); US Patent Publication No. 2003 / 064397 (Fig. 2); WO2002 / 89747 (Example 5; pages 618-619); WO2003 / 022995 (Example 9; Figure 13A, 35 Example 53; page 173, Example 2; Figure 2A); Six-transmembrane epithelial antigen of the prostate. MIM:604415.

[0275] (4) 0772P(CA125, MUC16): Nucleotide: Genbank Accession No. AF361486; Genbank Version No. AF361486.3 GI:34501466. Polypeptide: Genbank Accession No. AAK74120; Genbank Version No. AAK74120.3 GI:34501467. Cross References: Yin, BW,Lloyd, KO J. Biol. Chem. 276 (29): 27371-5 (2001); Bouanene H, Miled A. Bull Cancer. 96(5):597-601 (2009); Felder M, et al, Mol Cancer. 2014, 13:129; WO2004 / 045553 (claim 14); WO2002 / 92836 (claim 6; Figure 12); WO2002 / 83866 (claim 15; pages 116-121); US2003 / 124140 (example 16); GI:34501467;

[0276] (5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin): Nucleotide: Genbank Accession No. NM_005823; Genbank Version No. NM_005823.5 GI: 293651528. Polypeptide: Genbank Accession No. NP_005814; Genbank Version No. NP_005814.2 GI: 53988378. Cross reference: Hassan R, et al, Clin Cancer Res. 10(12Pt 1): 3937-42(2004), Yamaguchi, N., et al Biol. Chem. 269(2), 805-808(1994), Scholler, N., et al, Natl. Acad. Sci. USA 96(20):11531-11536 (1999), Chang, K., Pastan, I., Proc. Natl. Acad. Sci. USA 93(1):136-140 (1996), Kojima T., et al, J. Biol. Chem. 270(37):21984-21990 (1995); WO2003 / 101283 (Claim 14); (WO2002 / 102235 (Claim 13) WO2002 / 101075 (Claim 4; pages 308-309); WO2002 / 71928 pages 320-321); WO94 / 10312 (pages 52-57); IM:601051.

[0277] (6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b) Nucleotide: Genbank Accession No. NM_006424; Genbank Version No. NM_006424.2 GI: 110611905. Polypeptide: Genbank Accession No. NP_006415; Genbank Version No. NP_006415.2 GI: 110611906. Cross-references: Hiroko Segawa, et al, J. Biol. Chem. 277 (22):19665-19672 (2002), Xu H, et al, Genomics 62 (2):281-284 (1999), Field, JA, et al Biochem. Biophys. Res. Commun. 258(3):578-582(1999); WO2004 / 022778 (Claim 2); EP1394274 (Example 11) WO2002 / 102235 (Claim 13; Page 326); EP0875569 (Claim 1; Pages 17-19); WO2001 / 57188 ​​(Claim 20; page 329); WO2004 / 032842 (Example IV); WO2001 / 75177 (Claim 24; pages 139-140); MIM:604217.

[0278] (7) Sema5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, 25 Sema domains, 7 thrombospondin repeats (type 1 and type 1-like), transmembrane domain (trademark, and short cytoplasmic domain, (Semaphorin) 5B) Nucleotide: Genbank Accession No. AB040878; Genbank Version No. AB040878.1 GI:7959148. Polypeptide: Genbank Accession No. BAA95969; Genbank Version No. BAA95969.1 GI:7959149. Cross references: Nagase T., et al DNA Res. 7 (2):143-150 (2000); WO2004 / 000997 (Claim 1); WO2003 / 003984 (Claim 1); WO2002 / 06339 (Claim 1; page 50); WO2001 / 88133 (Claim 1; 41-43, pages 48-58); WO2003 / 054152 (Claim 20); WO2003 / 101400 (Claim 11); Accession number: 30 Q9P283; Genew; HGNC:10737.

[0279] (8) PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene): Nucleotide: Genbank Accession No. AY358628; Genbank Version No. AY358628.1 GI:37182377. Polypeptide: Genbank Accession No. AAQ88991; Genbank Version No. AAQ88991.1 GI:37182378. Cross references: Ross et al Cancer Res. 62:2546-2553(2002); US2003 / 129192 (Claim 2); US2004 / 044180 (Claim 12); US2004 / 044179 (Claim 11); US2003 / 096961 (Claim 11); US2003 / 232056 (Example 5); WO2003 / 105758 16 (Claim 12); US2003 / 206918 (Example 5); EP1347046 (Claim 1); WO2003 / 025148 (Claim 20); GI:37182378.

[0280] (9) ETBR (Endothelin type B receptor) Nucleotide: Genbank accession no. AY275463; Genbank version no. AY275463.1 GI:30526094. Polypeptide: Genbank accession no. AAP32295; Genbank version no. AAP32295.1 GI:30526095. Cross-reference: Nakamuta M., et al Biochem. Biophys. Res. Commun. 177, 34-39(1991); Ogawa Y., et al Biochem. Biophys. Res. Commun. 178, 248-255(1991); Arai H., et al Jpn. Circ. J. 56, 1303-1307(1992); Arai H., et al J. Biol. Chem. 268, 3463-3470(1993); Sakamoto A., Yanagisawa M., et al Biochem. Biophys. Res. Commun. 178, 656-663(1991); Elshourbagy N. A., et al J. Biol. Chem. 268, 3873-3879(1993); Haendler B., et al J. Cardiovasc. Pharmacol. 20, S1-S4(1992); Tsutsumi M., et al Gene 228, 43-49(1999); Strausberg R. L., et al Proc. Natl. Acad. Sci. U.S.A. 99, 16899-16903(2002); Bourgeois C., et al J. Clin. Endocrinol. Metab. 82, 3116-3123(1997); Okamoto Y., et al Biol. Chem. 272, 21589-21596(1997); Verheij J. B., et al Am. J. Med. Genet. 108, 223-225(2002); Hofstra R. M. W., et al Eur. J. Hum. Genet. 5, 180-185(1997); Puffenberger E. G., et al Cell 79, 1257-1266(1994); Attie T., et al, Hum. Mol. Genet. 4, 2407-2409(1995); Auricchio A., et al Hum. Mol. Genet. 5:351-354(1996); Amiel J., et al Hum. Mol.Genet. 5, 355-357(1996); Hofstra RMW, et al Nat. Genet. 12, 445-447(1996); Svensson PJ, et al Hum. Genet. 103, 145-148(1998); Fuchs S., et al Mol. Med. 7, 115-124(2001); Pingault V., et al Hum. Genet. 111, 198-206(2002); WO2004 / 045516 (claim 1); WO2004 / 048938 (example 2); WO2004 / 040000 (claim 151); WO2003 / 087768 (claim 1); 20 WO2003 / 016475 (claim 1); WO2003 / 016475 (claim 1); WO2002 / 61087 (FIG. 1); WO2003 / 016494 (fig. 6); WO2003 / 025138 (claim 12; p. 144); WO2001 / 98351 (claim 1; p. 124-125); EP0522868 (claim 8; figure 2); WO2001 / 77172 (claim 1; p. 297-299); US2003 / 109676; US Pat. No. 6,518,404 (fig. 3); US Pat. No. 5,773,223 (claim 1a; cols. 31-34); WO2004 / 001004.

[0281] (10) MSG783 (RNF124, hypothetical protein FLJ20315) Nucleotide: Genbank Accession No. NM_017763; Genbank Version No. NM_017763.4 GI: 167830482. Polypeptide: Genbank Accession No. NP_060233; Genbank Version No. NP_060233.3 GI: 56711322. Cross references: WO2003 / 104275 (claim 1); WO2004 / 046342 (example 2); WO2003 / 042661 (claim 12); WO2003 / 083074 (claim 14; page 61); WO2003 / 018621 (claim 1); WO2003 / 024392 (claim 2; figure 93); WO2001 / 66689 (example 6); LocusID:54894.

[0282] (11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six-transmembrane epithelial antigen of the prostate 2, six-transmembrane prostate protein) Nucleotide: Genbank accession no. AF455138; Genbank version no. AF455138.1 GI:22655487. Polypeptide: Genbank accession no. AAN04080; Genbank version no. AAN04080.1 GI:22655488. CROSS REFERENCE: Porkka, K P., et al, Lab. Invest. 82 (11):1573-1582 (2002); WO2003 / 087306; US2003 / 064397 (Claim 1; Figure 1); WO2002 / 72596 (Claim 13; pages 54-55); WO2001 / 72962 (Claim 1; Figure 4B); WO2003 / 104270 (Claim 11); WO2003 / 104270 (Claim 16); US2004 / 005598 (Claim 22); WO2003 / 042661 (Claim 12); US2003 / 060612 (Claim 12; Figure 10); WO2002 / 26822 (Claim 23; Figure 2); WO2002 / 16429 (claim 12; figure 10); GI:22655488.

[0283] (12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation 5 channel, subfamily M, member 4) Nucleotide: Genbank Accession No. NM_017636; Genbank Version No. NM_017636.3 GI:304766649. Polypeptide: Genbank Accession No. NP_060106; Genbank Version No. NP_060106.2 GI:21314671. Cross reference: Xu, XZ, et al Proc. Natl. Acad. Sci. USA 98 (19):10692-10697 (2001), Launay P., et al Cell 109 (3):397-407 (2002), Nilius B., et al J. Biol. Chem. 278 (33):30813-30820 (2003); US2003 / 143557 (Claim 4); WO2000 / 40614 (Claim 14; pages 100-103); WO2002 / 10382 (Claim 1; Figure 9A); WO2003 / 042661 (Claim 12); WO2002 / 30268 (Claim 27; 391 pages); US2003 / 219806 (Claim 4); WO2001 / 62794 (claim 14; Fig. 1A-D); MIM:606936.

[0284] (13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor) Nucleotide: Genbank accession no. NM_003212; Genbank version no. NM_003212.3 GI:292494881. Polypeptide: Genbank accession no. NP_003203; Genbank version no. NP_003203.1 GI:4507425. Cross references: Ciccodicola, A., et al EMBO J. 8 (7):1987-1991 (1989), Dono R., et al, Am. J. Hum. Genet. 49 (3):555-565 (1991); US2003 / 224411 (Claim 1); 1); WO2003 / 034984 (Claim 12); WO2002 / 88170 (Claim 2; Page 52-53); WO2003 / 024392 (Claim 2; FIG. 58); WO2002 / 16413 (Claim 1; Page 94-95, 105); WO2002 / 22808 (Claim 2; FIG. 1); US Pat. No. 5,854,399 (Example 2; Col 17-18); US Pat. No. 5,792,616 (FIG. 2); MIM:187395.

[0285] (14) CD21 (CR2 (complement receptor 2) or C3DR (C3d / Epstein-Barr virus receptor) or Hs.73792) Nucleotide: Genbank Accession No. M26004; Genbank Version No. M26004.1 GI:181939. Polypeptide: Genbank Accession No. AAA35786; Genbank Version No. AAA35786.1 GI:181940. Cross references: Fujisaku et al J. Biol. Chem. 264 (4):2118-2125(1989); Weis JJ, et al J. Exp. Med. 167, 1047-1066(1988); Moore M., et al Proc. Natl. Acad. Sci. USA 84, 9194-9198(1987); Barel M., et al Mol. Immunol. 35, 1025-1031(1998); Weis JJ, et al Proc. Natl. Acad. Sci. USA 83, 5639-5643(1986); Sinha SK, et al J. Immunol. 150, 5311-5320(1993); WO2004 / 045520 (Example 4); US2004 / 005538 (Example 1); WO2003 / 062401 (Claim 9); WO2004 / 045520 (Example 4); WO91 / 02536 (Figures 9.1-9.9); WO2004 / 020595 (Claim 1); Accession Nos: P20023; Q13866; Q14212; EMBL; M26004; AAA35786.1.

[0286] (15) CD79b (CD79B, CD793, IGb (immunoglobulin-related beta), B29) Nucleotide: Genbank accession no. NM_000626; Genbank version no. NM_000626.2 GI:90193589. Polypeptide: Genbank accession no. NP_000617; Genbank version no. NP_000617.1 GI:11038674. Cross-references: Gordon MS., et al Proc. Natl. Acad. Sci. USA 100 (7):4126-4131 (2003), Cragg MS., et al Blood 100 (9):3068-3076 (2002), Muller et al Eur. J. Immunol. 22 (6):1621-1625(1992); WO2004 / 016225 (Claim 2, Figure 140); WO2003 / 087768, US2004 / 101874 (Claim 1, page 102); WO2003 / 062401 (Claim 9); WO2002 / 78524 (Example 2); US2002 / 150573 (Claim 35) 5, 15 pages); US Pat. No. 5,644,033; WO2003 / 048202 (claim 1, pages 306 and 309); WO 99 / 58658, US Pat. No. 6,534,482 (claim 13, Figure 17A / B); WO2000 / 55351 (claim 11, pages 1145-1146); MIM:147245

[0287] (16)FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain-containing phosphatase anchor protein 5La), SPAP1B, SPAP1C) Nucleotide: Genbank Accession No. NM_030764; Genbank Version No. NM_030764.3 GI:227430280. Polypeptide: Genbank Accession No. NP_110391; Genbank Version No. NP_110391.2 GI:19923629. Cross-reference: AY358130); Clark HF., et al Genome Res. 13 (10):2265-2270 (2003), Guselnikov SV., et al Immunogenetics 54 (2):87-95 (2002), Miller I., et al Blood 99 (8):2662-2669 (2002), Davis RS., et al Proc. Natl. Acad. Sci. USA 98 (17):9772-9777 (2001), Xu, MJ, et al Biochem. Biophys. Res. Commun. 280 (3):768-775(2001); WO2004 / 016225 (claim 2); WO2003 / 077836; WO2001 / 38490 (Claim 5; Figure 18D-1-18D-2); WO2003 / 097803 (Claim 12); 10 WO2003 / 089624 (Claim 25); MIM:606509.

[0288] (17)HER2(ErbB2): Nucleotide: Genbank Accession No. M11730; Genbank Version No. M11730.1 GI: 183986. Polypeptide: Genbank Accession No. AAA75493; Genbank Version No. AAA75493.1 GI: 306840. Cross-reference: Coussens L., et al Science 230(4730):1132-1139(1985); Yamamoto T., et al Nature 319, 230-234(1986); Semba K., et al Proc. Natl. Acad. Sci. U.S.A. 82, 6497-6501(1985); Swiercz J. M., et al J. Cell Biol. 165, 869-880(2004); Kuhns J. J., et al J. Biol. Chem. 274, 36422-36427(1999); Cho H.-S., et al Nature 421, 756-760(2003); Ehsani A., et al Genomics 15, 426-429(1993); WO2004 / 048938 (Example 2); WO2004 / 027049 (Figure 11); WO2004 / 009622; WO2003 / 081210; WO2003 / 089904 (Claim 9); WO2003 / 016475 (Claim 1); US2003 / 118592; WO2003 / 008537 (Claim 1); WO2003 / 055439 (Claim 29; FIG. 1A-B); WO2003 / 025228 (Claim 37; Figure 5C); 20 WO2002 / 22636 (Example 13; pages 95-107); WO2002 / 12341 (Claim 68; Figure 7); WO2002 / 13847 (pages 71-74); WO2002 / 14503 (pages 114-117); WO2001 / 53463 (Claim 2; pages 41-46); WO2001 / 41787 (page 15); WO2000 / 44899 (Claim 52; Figure 7); WO2000 / 20579 (Claim 3; Figure 2); U.S. Pat. No. 5,869,445 (Claim 3; columns 31-38); WO9630514 (Claim 2; pages 56-61); EP1439393 (Claim 7); WO2004 / 043361 (Claim 7); WO2004 / 022709; WO2001 / 00244 25 (Example 3; FIG. 4); Accession: P04626; EMBL; M11767; AAA35808.1.EMBL; M11761; AAA35808.1. Antibodies: Abbott: US20110177095, for example, antibodies comprising CDRs having at least 80% overall sequence identity to the CDRs having the amino acid sequences of SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:104 and / or SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2), and SEQ ID NO:8 (CDR-L3), wherein the anti-HER2 antibody or anti-HER2 binding fragment has reduced immunogenicity compared to an antibody having a VH of SEQ ID NO:1 and a VL of SEQ ID NO:2. Biogen: US20100119511 ; e.g., ATCC Accession Nos: PTA-10355, PTA-10356, PTA-10357, PTA-10358 For example, a purified antibody molecule that binds to HER2, comprising all six CDRs from an antibody selected from the group consisting of BIIB71F10 (SEQ ID NOs: 11, 13), B11B69A09 (SEQ ID NOs: 15, 17), BIIB67F10 (SEQ ID NOs: 19, 21), BIIB67F11 (SEQ ID NOs: 23, 25), BIIB66A12 (SEQ ID NOs: 27, 29), BIIB66C01 (SEQ ID NOs: 31, 33), BIIB65C10 (SEQ ID NOs: 35, 37), BIIB65H09 (SEQ ID NOs: 39, 41), and B11B65B03 (SEQ ID NOs: 43, 45), or CDRs that are identical to said CDRs or have no more than two changes from said CDRs. Herceptin (Genentech): U.S. Patent No. 6,054,297, ATCC Accession No. CRL-10463 (Genentech) Pertuzumab (Genentech): US20110117097. See, e.g., SEQ ID NOs: 15 and 16, SEQ ID NOs: 17 and 18, SEQ ID NOs: 23 and 24, and ATCC Accession Nos. HB-12215, HB-12216, CRL 10463, HB-12697. US20090285837, US20090202546. See, e.g., ATCC Accession Nos. HB-12215, HB-12216, CRL 10463, HB-12698. US20060088523. See, e.g., ATCC Accession Nos. HB-12215, HB-12216. An antibody comprising, e.g., the variable light and variable heavy amino acid sequences of SEQ ID NOs: 3 and 4, respectively. For example, an antibody comprising a light chain amino acid sequence selected from SEQ ID NO: 15 and 23, and a heavy chain amino acid sequence selected from SEQ ID NO: 16 and 24 (US20060018899). For example, ATCC Accession Nos: (7C2) HB-12215, (7F3) HB-12216, (4D5) CRL-10463, (2C4) HB-12697. For example, an antibody comprising the amino acid sequence of SEQ ID NO: 23, or a deamidated and / or oxidized variant thereof. US2011 / 0159014. For example, an antibody having a light chain variable domain comprising the hypervariable region of "SEQ ID NO: 1". For example, an antibody having a heavy chain variable domain comprising the hypervariable region of SEQ ID NO: 2. Glycotope: TrasGEX Antibody http: / / www.glycotope.com / pipeline. See e.g. International Collaborating Cancer Institute and Shanghai Hospital Cancer Center: HMTI-Fc Ab-Gao J., et al BMB Rep.: 42(10):636-41(2009). Symphogen: US20110217305, Union Stem Cell &Gene Engineering, China - Liu HQ. et al. Xi Bao Yu Fen Zi Mian YiXue Za Zhi; 26(5):456-8(2010).

[0289] (18)NCA(CEACAM6): Nucleotide: Genbank Accession No. M18728; Genbank Version No. M18728.1 GI: 189084. Polypeptide: Genbank Accession No. AAA59907; Genbank Version No. AAA59907.1 GI: 189085. Cross References: Barnett T., et al Genomics 3, 59-66(1988); Tawaragi Y., et al Biochem. Biophys. Res. Commun. 150, 89-96(1988); Strausberg RL, et al Proc. Natl. Acad. Sci. USA 99:16899-16903(2002); WO2004 / 063709; EP1439393 (Claim 7); WO2004 / 044178 (Example 4); WO2004 / 031238; WO2003 / 042661 (Claim 12); WO2002 / 78524 (Example 2); WO2002 / 86443 (Claim 27; Page 427); WO2002 / 60317 (Claim 2); Accession: P40199; Q14920; EMBL; M29541; AAA59915.1. EMBL; M18728.

[0290] (19)MDP(DPEP1): Nucleotide: Genbank Accession No. BC017023; Genbank Version No. BC017023.1 GI:16877538. Polypeptide: Genbank Accession No. AAH17023; Genbank Version No. AAH17023.1 GI:16877539. Cross references: Strausberg RL., et al Proc. Natl. Acad. Sci. USA 99 (26):16899-16903 (2002); WO2003 / 016475 (claim 1); WO2002 / 64798 (claim 33; pages 85-87); JP05003790 (Figures 6-8); WO99 / 46284 (Figure 9); MIM:179780.

[0291] (20)IL20R-alpha (IL20Ra, ZCYTOR7): Nucleotide: Genbank Accession No. AF184971; Genbank Version No. AF184971.1 GI:6013324. Polypeptide: Genbank Accession No. AAF01320; Genbank Version No. AAF01320.1 GI:6013325. Cross references: Clark HF, et al Genome Res. 13, 2265-2270(2003); Mungall AJ, et al Nature 425, 805-811(2003); Blumberg H., et al Cell 104, 9-19(2001); Dumoutier L., et al J. Immunol. 167, 3545-3549(2001); Parrish-Novak J., et al J. Biol. Chem. 277, 47517-47523(2002); Pletnev S., et al 10 Biochemistry 42:12617-12624 (2003); Sheikh F., et al J. Immunol. 172, 2006-2010(2004); EP1394274 (Example 11); US2004 / 005320 (Example 5); WO2003 / 029262 (pages 74-75); WO2003 / 002717 (claim 2; page 63); WO2002 / 22153 (pages 45-47); US2002 / 042366 (pages 20-21); WO2001 / 46261 (pages 57-59); WO2001 / 46232 (pages 63-65); WO98 / 37193 (claim 1; pages 55-59); Accession: Q9UHF4; Q6UWA9; Q96SH8; EMBL; AF184971; AAF01320.1.

[0292] (21) Brevican (BCAN, BEHAB): Nucleotide: Genbank Accession No. AF229053; Genbank Version No. AF229053.1 GI:10798902. Polypeptide: Genbank Accession No. AAG23135; Genbank Version No. AAG23135.1 GI:10798903. Cross References: Gary SC, et al Gene 256, 139-147(2000); Clark HF, et al Genome Res. 13, 2265-2270(2003); Strausberg RL, et al Proc. Natl. Acad. Sci. USA 99, 16899-16903(2002); US2003 / 186372 (claim 11); US2003 / 186373 (claim 11); US2003 / 119131 (claim 1; Figure 52); US2003 / 119122 (claim 1; Figure 52); US2003 / 119126 (claim 1); US2003 / 119121 (claim 1; Figure 52); US2003 / 119129 (claim 1); US2003 / 119130 (claim 1); US2003 / 119128 (Claim 1; Fig. 52); US2003 / 119125 (Claim 1); WO2003 / 016475 (Claim 1); WO2002 / 02634 (Claim 1)

[0293] (22) EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5): Nucleotide: Genbank Accession No. NM_004442; Genbank Version No. NM_004442.6 GI: 111118979. Polypeptide: Genbank Accession No. NP_004433; Genbank Version No. NP_004433.2 GI: 21396504. Cross-reference: Chan, J., Watt, VM, Oncogene 6 (6), 1057-1061 (1991), Fox GM., et al, Oncogene 10 (5):897-905 (1995), Flanagan JG., et al, Annu. Rev. Neurosci. 21:309-345 (1998), Wilkinson DG, Int. Rev. Cytol. 196:177-244 (2000); WO2003042661 (Claim 12); WO200053216 (Claim 1; page 41); WO2004065576 (Claim 1); WO2004020583 (Claim 9); WO2003004529 (pages 128-132); WO200053216(Claim 1; page 42); MIM:600997.

[0294] (23)ASLG659(B7h): Nucleotide: Genbank accession number AX092328; Genbank version number AX092328.1 GI:13444478. CROSS REFERENCES: US2004 / 0101899 (Claim 2); WO2003104399 (Claim 11); WO2004000221 (Figure 3); US2003 / 165504 (Claim 1); US2003 / 124140 (Example 2); US2003 / 065143 (Figure 60); WO2002 / 102235 (Claim 13; page 299); US2003 / 091580 (Example 2); WO2002 / 10187 (Claim 6; Figure 10); WO2001 / 94641 (Claim 12; Figure 7b); WO2002 / 02624 (Claim 13; Figures 1A-1B); US2002 / 034749 (Claim 54; pages 45-46); WO2002 / 06317 (Example 2; pages 320-321, claim 34; pages 321-322); WO2002 / 71928 (pages 468-469); WO2002 / 02587 (Example 1; Figure 1); WO2001 / 40269 (Example 3; pages 190-192); WO2000 / 36107 (Example 2; pages 205-207); WO2004 / 053079 (claim 12); WO2003 / 004989 (claim 1); WO2002 / 71928 (pages 233-234, pages 452-453); WO 01 / 16318.

[0295] (24)PSCA (Prostate Stem Cell Antigen Precursor): Nucleotide: Genbank Accession No. AJ297436; Genbank Version No. AJ297436.1 GI:9367211. Polypeptide: Genbank Accession No. CAB97347; Genbank Version No. CAB97347.1 GI:9367212. Cross-references: Reiter RE, et al Proc. Natl. Acad. Sci. USA 95, 1735-1740(1998); Gu Z., et al Oncogene 19, 1288-1296(2000); Bahrenberg G., et al, Biochem. Biophys. Res. Commun. 275(3):783-788(2000); WO2004 / 022709; EP1394274 (Example 11); US2004 / 018553 (Claim 17); WO2003 / 008537 (Claim 1); WO2002 / 81646 (Claim 1; page 164); WO2003 / 003906 (Claim 10; page 288); WO2001 / 40309 (Example 1; Figure 17); US2001 / 055751 (Example 1; FIG. 1 b); WO2000 / 32752 (Claim 18; Fig. 1); WO98 / 51805 (Claim 17; p. 97); WO98 / 51824 (Claim 10; p. 94); WO98 / 40403 (Claim 2; Fig. 1B); Accession: 043653; EMBL; AF043498; AAC39607.1

[0296] (25)GEDA: Nucleotide: Genbank Accession No. AY260763; Genbank Version No. AY260763.1 GI:30102448. Polypeptide: Genbank Accession No. AAP14954; Genbank Version No. AAP14954.1 GI:30102449. Cross References: AP14954 Lipoma HMGIC Fusion Partner-Like Protein / pid=AAP14954.1 - Homo sapiens (Human); WO2003 / 054152 (Claim 20); WO2003 / 000842 (Claim 1); WO2003 / 023013 (Example 3, Claim 20); US2003 / 194704 (Claim 45); GI:30102449.

[0297] (26)BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3): Nucleotide: Genbank Accession No. AF116456; Genbank Version No. AF116456.1 GI:4585274. Polypeptide: Genbank Accession No. AAD25356; Genbank Version No. AAD25356.1 GI:4585275. Cross reference: BAFF receptor / pid=NP_443177.1 - Homo sapiens: Thompson, JS, et al Science 293 (5537), 2108-2111 (2001); WO2004 / 058309;WO2004 / 011611; WO2003 / 045422 (Examples; pages 32-33);WO2003 / 014294 (Claim 35; Figure 6B); WO2003 / 035846 (Claim 70; pages 615-616); WO2002 / 94852 (columns 136-137);WO2002 / 38766 (Claim 3; page 133); WO2002 / 24909 (Example 3; Figure 3); MIM:606269; NP_443177.1; NM_052945_1; AF132600

[0298] (27)CD22 (B cell receptor CD22-B isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814): Nucleotide: Genbank Accession No. AK026467; Genbank Version No. AK026467.1 GI:10439337. Polypeptide: Genbank Accession No. BAB15489; Genbank Version No. BAB15489.1 G1:10439338. Cross-references: Wilson et al J. Exp. Med. 173:137-146(1991); WO2003 / 072036 (Claim 1; Figure 1); IM:107266; ​​NP_001762.1; NM_001771_1.

[0299] (27A)Cd22 (Cd22 molecule): Nucleotide: Genbank Accession No. X52785; Genbank Version No. X52785.1 G1:29778. Polypeptide: Genbank Accession No. CAA36988; Genbank Version No. CAA36988.1 G1:29779. Cross-reference: Stamenkovic I. et al., Nature 345 (6270), 74-77 (1990). Additional information: Official symbol: CD22; Other aliases: SIGLEC-2, SIGLEC2; Other names: B cell receptor CD22; Cell adhesion molecule of B lymphocytes; BL-CAM; CD22 antigen; T cell surface antigen Leu-14; Sialic acid-binding Ig-like lectin 2; Sialic acid-binding Ig-like lectin 2 Antibodies: G5 / 44 (inotuzumab): DiJoseph J F., et al Cancer Immunol Immunother. 54(1):11-24 (2005). Epratuzumab - Goldenberg DM., et al Expert Rev Anticancer Ther. 6(10): 1341-53(2006).

[0300] (28) CD79a (CD79A, CD79alpha), a B cell-specific protein that binds covalently to immunoglobulin-related alpha, Ig beta (CD79B), forms a complex with IgM35 molecules on the surface, and transmits signals involved in B cell differentiation), Pl: 4.84, MW: 25028 Tm: 2 [P] gene chromosome: 19q13.2): Nucleotide: Genbank Accession No. NM_001783; Genbank Version No. NM_001783.3 GI:90193587. Polypeptide: Genbank Accession No. NP_001774; Genbank Version No. NP_001774.1 GI:4502685. Cross-references: WO2003 / 088808, US2003 / 0228319; WO2003 / 062401 (claim 9); US2002 / 150573 (claim 4, pages 13-14); WO99 / 58658 (claim 13, Figure 16); WO92 / 07574 (Figure 1); US Pat. No. 5,644,033; Ha et al J. Immunol. 148(5):1526-1531 (1992); Muller et al Eur. J. Immunol. 22:1621-1625(1992); Hashimoto et al Immunogenetics 40(4):287-295 (1994); Preud'homme et al Clin. Exp. 5 Immunol. 90(1):141-146(1992); Yu et al J. Immunol. 148(2) 633-637(1992); Sakaguchi et al EMBO J. 7(11):3457-3464(1988).

[0301] (29) CXCR5 (Burkitt's lymphoma receptor 1, a G protein-coupled receptor activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, and plays a role in HIV-2 infection and possibly the pathogenesis of AIDS, lymphoma, myeloma, and leukemia); 372Aa, Pl:8.54MW:41959TM:7[P] gene chromosome: 11q23.3: Nucleotide: Genbank Accession No. NM_001716; Genbank Version No. NM_001716.4 GI:342307092. Polypeptide: Genbank Accession No. NP_001707; Genbank Version No. NP_001707.1 GI:4502415. CROSS REFERENCES: WO2004 / 040000; WO2004 / 015426; US2003 / 105292 (Example 2); US Patent No. 6,555,339 (Example 2); WO2002 / 61087 (Figure 1); WO2001 / 57188 ​​(Claim 20, p. 269); WO2001 / 72830 (p. 12-13); WO2000 / 22129 (Example 1, p. 152-153; Example 2, p. 254-256); WO99 / 28468 (Claim 1, p. 38); US Patent No. 5,440,021 (Example 2, columns 49-52); WO94 / 28931 (p. 56-58); WO92 / 17497 (Claim 7, Figure 5); Dobner et al Eur. J. Immunol. 22:2795-2799 (1992); Barella et al Biochem. J. 309:773-779 (1995).

[0302] (30) HLA-DOB (beta subunit of MHC class II molecule (La antigen) that binds and presents peptides to CD4 + T lymphocytes); 273 Aa, Pl: 6.56, MW: 30820. TM: 1 [P] gene chromosome: 6p21.3): Nucleotide: Genbank Accession No. NM_002120; Genbank Version No. NM_002120.3 GI: 118402587. Polypeptide: Genbank Accession No. NP_002111; Genbank Version No. NP_002111.1 GI: 4504403. Cross references: Tonnelle C. et al., EMBO J. 4(11):2839-2847 (1985); Johnson A. K. et al., Immunogenetics 29(6):411-413 (1989); Beck S. et al., J. Mol. Biol. 228:433-441 (1992); Strausberg R. L. et al., Proc. Natl. Acad. Sci. USA 99:16899-16903 (2002); Servenius B. et al., J. Chem. 262:8759-8766 (1987); Beck S. et al., J. Mol. Biol. 255:1-13 (1996); Naruse T. K. et al., Tissue Antigens 59:512-519 (2002); WO99 / 58658 (claim 13, figure 15). US Patent No. 6,153,408 (columns 35-38); US Patent No. 5,976,551 (columns 168-170); US Patent No. 6,011,146 (columns 145-146); Kasahara M. et al., Immunogenetics 30(1):66-68 (1989); Larhammar D. et al., J. Biol. 260 (26):14111-14119 (1985).

[0303] (31) P2X5 (P2X ligand-gated ion channel 5 is an ion channel regulated by extracellular ATP and may be involved in synaptic transmission and neurogenesis, and its deficiency may contribute to the pathophysiology of idiopathic detrusor instability); 422 Aa), Pl: 7.63, MW: 47206 TM: 1 [P] gene chromosome: 17p13.3): Nucleotide: Genbank Accession No. NM_002561; Genbank Version No. NM_002561.3 GI:325197202. Polypeptide: Genbank Accession No. NP_002552; Genbank Version No. NP_002552.2 GI:28416933. Cross References: Le KT. et al. FEBS Lett. 418(1-2):195-199 (1997); WO2004 / 047749; WO2003 / 072035 (claim 10); Touchman JW. et al., Genome Res. 10:165-173 (2000); WO2002 / 22660 (claim 20); WO2003 / 093444 (claim 1); WO2003 / 087768 (claim 1); WO2003 / 029277 (page 82)

[0304] (32) CD72 (B cell differentiation antigen CD72, Lyb-2). 359 Aa, Pl: 8.66, MW: 40225, TM: 1 5 [P] gene chromosome: 9p13.3): Nucleotide: Genbank Accession No. NM_001782; Genbank Version No. NM_001782.2 GI: 194018444. Polypeptide: Genbank Accession No. NP_001773; Genbank Version No. NP_001773.1 GI: 4502683. Cross-references: WO2004042346 (claim 65); WO2003 / 026493 (pages 51-52, 57-58); WO2000 / 75655 (pages 105-106); Von Hoegen et al., J. Immunol. 144 (12):4870-4877 (1990); Strausberg RL et al., Proc. Natl. Acad. Sci. USA 99:16899-16903 (2002).

[0305] (33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine-rich repeat (LRR) family, regulates B cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosus); 661 Aa, pl: 6.20, MW: 74147 TM: 1 [P] gene chromosome: 5q12): Nucleotide: Genbank Accession No. NM_005582; Genbank Version No. NM_005582.2 GI: 167555126. Polypeptide: Genbank Accession No. NP_005573; Genbank Version No. NP_005573.2 GI: 167555127. Cross references: US2002 / 193567; WO97 / 07198 (claim 11, pages 39-42); Miura Y et al., Genomics 38(3):299-304 (1996); Miura Y et al., Blood 92:2815-2822 (1998); WO2003 / 083047; WO97 / 44452 (claim 8, pages 57-61); WO2000 / 12130 (pages 24-26).

[0306] (34)FcRH1 (Fc receptor-like protein 1, a putative receptor for immunoglobulin Fc domains containing C2-type Ig-like domains and ITAM domains, may play a role in the differentiation of B lymphocytes 20); 429 Aa, Pl: 5.28, MW: 46925 TM: 1 [P] gene chromosome: 1q21-1q22) Nucleotide: Genbank Accession No. NM_052938; Genbank Version No. NM_052938.4 GI:226958543. Polypeptide: Genbank Accession No. NP_443170; Genbank Version No. NP_443170.1 GI:16418419. Cross references: WO2003 / 077836; WO2001 / 38490 (Claim 6, Figure 18E-1-18-E-2); Davis RS et al Proc. Natl. Acad. Sci USA 98(17):9772-9777(2001); WO2003 / 089624 (Claim 8); EP1347046 (Claim 1); WO2003 / 089624 (Claim 7).

[0307] (35)IRTA2 (Immunoglobulin superfamily receptor translocation associated 2, a putative immune receptor that may play a role in B cell development and lymphomagenesis, dysregulation of the gene due to the translocation occurs in some B cell malignancies); 977 Aa, pl: 6.88, MW: 106468, TM: 1 [P] gene chromosome: 1q21): Nucleotide: Genbank Accession No. AF343662; Genbank Version No. AF343662.1 GI: 13591709. Polypeptide: Genbank Accession No. AAK31325; Genbank Version No. AAK31325.1 GI: 13591710. Cross references: AF343663, AF343664, AF343665, AF369794, AF397453, AK090423, AK090475, AL834187, AY358085; mouse: AK089756, AY158090, AY506558; NP_112571.1; WO2003 / 024392 (claim 2, figure 97); Nakayama Y et al Biochem. Biophys. Res. Commun. 277(1):124-127(2000); WO2003 / 077836; WO2001 / 38490 (claim 3, figures 18B-1-18B-2).

[0308] (36) TENB2 (TMEFF2, tomoregulin, TPEF, HPP1, TR, putative transmembrane 35 proteoglycan, related to the EGF / heregulin family of growth factors and follistatin); 374 Aa): Nucleotide: Genbank Accession No. AF179274; Genbank Version No. AF179274.2 GI: 12280939. Polypeptide: Genbank Accession No. AAD55776; Genbank Version No. AAD55776.2 GI: 12280940. Cross references: NCBI Accession: AAD55776, AAF91397, AAG49451; NCBI RefSeq: NP_057276; NCBI Gene: 23671; OmiM: 605734; SwissProt Q9UIK5; AY358907, CAF85723, CQ782436; WO2004 / 074320; JP2004113151; WO2003 / 042661; WO2003 / 009814; EP1295944 (pages 69-70); WO2002 / 30268(page 329); WO2001 / 90304; US2004 / 249130; US2004 / 022727; WO2004 / 063355; US2004 / 197325; US2003 / 232350; US2004 / 005563; US2003 / 124579; Horie M et al Genomics 67:146-152(2000); Uchida et al., Biochem. Biophysics. Rev. 266:593-602(1999); Liang G et al Cancer Res. 60:4907-12 (2000); Glynne-Jones E et al Int J Cancer ; 94(2):178-84(2001).

[0309] (37) PSMA-FOLH1 (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1): Nucleotide: Genbank Accession No. M99487; Genbank Version No. M99487.1 G1: 190663. Polypeptide: Genbank Accession No. AAA60209; Genbank Version No. AAA60209.1 GI: 190664. Cross-reference: Israeli RS, et al. Cancer Res. 53 (2), 227-230 (1993) Additional information: Official symbol: FOLH1;Other aliases: GIG27, FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP.Other names: N-acetylated alpha-linked acidic dipeptidase 1; N-acetylated alpha-linked acidic dipeptidase I; NAALADase I;Cell proliferation inhibitory gene 27 protein;Folyl poly-gamma-glutamate carboxypeptidase;Glutamate carboxylase II;Glutamate carboxypeptidase 2;Glutamate carboxypeptidase II;Membrane glutamate carboxypeptidase.Prostate-specific membrane antigen variant F;Pteroylpolygamma-glutamate carboxypeptidase. Antibodies: U.S. Patent No. 5,010,000 U.S. Patent No. 7,666,425. The antibodies are produced by hybridomas having the following ATCC reference numbers: ATCC Accession No. HB-12101, ATCC Accession No. HB-12109, ATCC Accession No. HB-12127 and ATCC Accession No. HB-12126. Proscan: A monoclonal antibody selected from the group consisting of 8H12, 3E11, 17G1, 29B4, 30C1, and 20F2 (U.S. Patent No. 7,811,564; Moffett S., et al Hybridoma (Larchmt) 26(6):363-72(2007)). Cytogen: Monoclonal antibodies 7E11-C5 (ATCC Accession No. HB 10494) and 9H10-A4 (ATCC Accession No. HB11430) - U.S. Patent No. 5,763,202. Carbohydrate mimetics: NUH2 - ATCC Accession No. HB 9762 (U.S. Patent No. 7,135,301). Human Genome Sciences: HPRAJ70 - ATCC Accession No. 97131 (U.S. Patent No. 6,824,993); Amino acid sequence encoded by the cDNA clone (HPRAJ70) deposited with the American Type Culture Collection (“ATCC”) Accession No. 97131. Medarex: Anti-PSMA antibody lacking fucosyl residues - US Patent No. 7,875,278. Mouse anti-PSMA antibodies include 3F5.4G6, 3D7.1.1, 4E10-1.14, 3E11, 4D8, 3E6, 3C9, 2C7, 1G3, 3C4, 3C6, 4D4, 1G9, 5C8B9, 3G6, 4C8B9, and monoclonal antibodies. Hybridomas secreting 3F5.4G6, 3D7.1.1, 4E10-1.14, 3E11, 4D8, 3E6, 3C9, 2C7, 1G3, 3C4, 3C6, 4D4, 1G9, 5C8B9, 3G6, or 4C8B9 have been publicly deposited and are described in U.S. Patent No. 6,159,508. Related hybridomas have been publicly deposited and are described in U.S. Patent No. 6,107,090. Additionally, humanized anti-PSMA antibodies, including humanized versions of J591, are described in further detail in PCT Publication WO 02 / 098897. Other mouse anti-human PSMA antibodies have also been described in the art, such as mAb 107-1A4 (Wang, S. et al. Int. J. Cancer 92:871-876 (2001)) and mAb 2C9 (Kato, K. et al. Int. J. Urol. 10:439-444 (2003)). Examples of human anti-PSMA monoclonal antibodies include the 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 antibodies, which were isolated and structurally characterized as first described in PCT Publication Nos. WO 01 / 09192 and WO 03 / 064606, and U.S. Provisional Application No. 60 / 654,125, entitled "Human Monoclonal Antibodies Directed Against Prostate-Specific Membrane Antigen (PSMA)," filed February 18, 2005. The V.sub.H amino acid sequences of 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5 and 1C3 are set forth in SEQ ID NOs: 1-9, respectively. The V.sub.L amino acid sequences of 4A3, 7F12, 8C12, 8A11, 16F9, 2A10, 2C6, 2F5, and 1C3 are shown in SEQ ID NOs: 10-18, respectively. Other human anti-PSMA antibodies include those disclosed in PCT Publication WO03 / 034903 and U.S. Application No. 2004 / 0033229. NW Biotherapeutics: a hybridoma cell line selected from the group consisting of 3F5.4G6, 3D7-1.1 having ATCC accession number HB12060. ATCC Accession Nos. HB12309, 4E10-1.14 ATCC Accession Nos. HB12310, 3E11 (ATCC HB12488), 4D8 (ATCC HB12487), 3E6 (ATCC HB12486), 3C9 (ATCC HB12484), 2C7 (ATCC HB12490), 1 G3 (ATCC HB12489), 3C4 (ATCC HB12494), 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), 1G9 (ATCCHB12495), 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485) - see U.S. Patent No. 5,611,113. U.S. Patent No. 6,150,508. PSMA Development Company / Progenics / Cytogen-Seattle Genetics: mAb 3.9 produced by the hybridoma deposited under ATCC Accession No. PTA-3258, or mAb 10.3 produced by the hybridoma deposited under ATCC Accession No. PTA-3347. U.S. Patent No. 7,850,971. PSMA Development Company - Composition of PSMA Antibodies (US20080286284, Table 1) U.S. Patent No. 10 / 395,894 filed March 21, 2003 (U.S. Patent No. 7,850,971). University Hospital Freiburg, Germany - mAbs 3 / A12, 3 / E7, and 3 / F11 (Wolf P., et al Prostate. ; 70(5):562-9 (2010)).

[0310] (38) SST (somatostatin receptor; note that there are 5 subtypes): (38.1) SSTR2 (Somatostatin Receptor 2): Nucleotide: Genbank Accession No. NM_001050; Genbank Version No. NM_001050.2 GI:44890054. Polypeptide: Genbank Accession No. NP_001041; Genbank Version No. NP_001041.1 GI:4557859. Cross references: Yamada Y., et al Proc. Natl. Acad. Sci. USA 89 (1), 251-255 (1992); Susini C., et al Ann Oncol. 17(12):1733-42(2006) Additional information: Official symbol: SSTR2; Other names: SRIF-1, SS2R, somatostatin receptor type 2. (38.2) SSTR5 (Somatostatin Receptor 5): Nucleotide: Genbank Accession No. D16827; Genbank Version No. D16827.1 GI:487683. Polypeptide: Genbank Accession No. BAA04107; Genbank Version No. BAA04107.1 GI:487684. Cross reference: Isamu Yamada et al. Biochem. Biophys. Res. Commun. 195 (2), 844-852 (1993). Additional information: Official symbol: SSTR5; Other aliases: SS-5-R; Other names: Somatostatin receptor subtype 5; Somatostatin receptor type 5. (38.3) SSTR1; (38.4) SSTR3; (38.5) SSTR4; AvB6 - both subunits (39+40).

[0311] (39) ITGAV (integrin, alpha V: Nucleotide: Genbank Accession No. M14648 J02826 M18365; Genbank Version No. M14648.1 GI:340306. Polypeptide: Genbank Accession No. AAA36808; Genbank Version No. AAA36808.1 GI:340307. Cross reference: Suzuki S., et al. Proc. National Academy of Sciences. Science. USA 83 (22), 8614-8618 (1986). Additional information: Official symbol: ITGAV. Other aliases: CD51, MSK8, VNRA, VTNR Other names: Antigen recognized by monoclonal antibody L230, integrin alpha-V, integrin alphaVbeta3, integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51), vitronectin receptor subunit alpha.

[0312] (40) ITGB6 (integrin, beta 6): Nucleotide: Genbank Accession No. NM_000888; Genbank Version No. NM_000888.3 GI:9966771. Polypeptide: Genbank Accession No. NP_000879; Genbank Version No. NP_000879.2 GI:9625002. Cross-reference: Sheppard DJ, et al Biol. Chem. 265 (20), 11502-11507 (1990) Additional information: Official symbol: ITGB6, Other designations: Integrin beta 6. antibody: Biogen: US Patent US 7,943,742 - Hybridoma clones 6.3G9 and 6.8G6 have been deposited with the ATCC under accession numbers ATCC PTA-3649 and -3645, respectively. Biogen: US Patent US 7,465,449 - In some embodiments, the antibody comprises the same heavy and light chain polypeptide sequences as the antibody produced by hybridoma 6.1A8, 6.3G9, 6.8G6, 6.2B1, 6.2B10, 6.2A1, 6.2E5, 7.1G10, 7.7.G5, or 7.1C5. Centocor (J&J): U.S. Patent Nos. 7,550,142; 7,163,681. For example, in U.S. Patent No. 5,011,112, U.S. Patent No. 7,550,142 - an antibody having a human heavy chain variable region and a human light chain variable region comprising the amino acid sequences shown in SEQ ID NO:7 and SEQ ID NO:8. Seattle Genetics: 15H3 (Ryan M C., et al Cancer Res April 15, 2012; 72(8 Supplement): 4630).

[0313] (41) CEACAM5 (Carcinoembryonic antigen-related cell adhesion molecule 5): Nucleotide: Genbank Accession No. M17303; Genbank Version No. M17303.1 GI:178676. Polypeptide: Genbank Accession No. AAB59513; Genbank Version No. AAB59513.1 G1:178677. Cross reference: Beauchemin N. et al., Mol. Cel. Biol. 7 (9), 3221-3230 (1987). Additional information: Official symbol: CEACAM5; Other aliases: CD66e, CEA. Other names: Meconium antigen 100. antibody: AstraZeneca-MedImmune: US 20100330103; US20080057063; US20020142359. For example, an antibody having complementarity determining regions (CDRs) with the following sequences: heavy chain; CDR1-DNYMH, CDR2-WIDPENGDTE YAPKFRG, CDR3-LIYAGYLAMD Y; and light chain CDR1-SASSSVTYMH, CDR2-STSNLAS, CDR3-QQRSTYPLT. Hybridoma 806.077 has been deposited at the European Collection of Cell Cultures (ECACC) under deposit number 96022936. Research Corporation Technologies, Inc.: U.S. Patent No. 5,047,507. Bayer AG: U.S. Patent No. 6,013,772. BioAlliance: US Patents US Patent Nos. 7,982,017; 7,674,605; US Patent No. 7,674,605 ​​discloses an antibody comprising a heavy chain variable region sequence from the amino acid sequence of SEQ ID NO: 1, and a light chain variable region sequence from the amino acid sequence of SEQ ID NO: 2. An antibody comprising a heavy chain variable region sequence from the amino acid sequence of SEQ ID NO: 5, and a light chain variable region sequence from the amino acid sequence of SEQ ID NO: 6. Celltech Therapeutics Limited: US Patent U.S. Patent No. 5,877,293. The Dow Chemical Company: U.S. Patent No. 5,611,113; U.S. Patent No. 5,472,693; 6,417,337; 6,333,405; U.S. Patent No. 5,472,693 - e.g., ATCC No. CRL-11215; U.S. Patent No. 6,417,337 - e.g., ATCC CRL-12208; U.S. Patent No. 6,333,405, e.g., ATCC CRL-12208. Immunomedics, Inc: US Pat. Nos. 7,534,431; 7,230,084; 7,300,644; 6,730,300; US20110189085; an antibody having a light chain variable region CDR in which CDR1 comprises KASQDVGTSVA (SEQ ID NO: 20), CDR2 comprises WTSTRHT (SEQ ID NO: 21), and CDR3 comprises QQYSLYRS (SEQ ID NO: 22), and the heavy chain variable region CDRs of the anti-CEA antibody include CDR1 comprises TYWMS (SEQ ID NO: 23), CDR2 comprises EIHPDSSTINYAPSLKD (SEQ ID NO: 24), and CDR3 comprises LYFGFPWFAY (SEQ ID NO: 25). US20100221175; US20090092598; US20070202044; US20110064653; US20090185974; US20080069775.

[0314] (42) MET (Met proto-oncogene; hepatocyte growth factor receptor): Nucleotide: Genbank Accession No. M35073; Genbank Version No. M35073.1 GI: 187553. Polypeptide: Genbank Accession No. AAA59589; Genbank Version No. AAA59589.1 GI: 553531. Cross reference: Dean M., et al Nature 318 (6044), 385-388 (1985). Additional information: Official symbol: MET. Other aliases: AUTS9, HGFR, RCCP2, c-Met. Other names: HGF receptor, HGF / SF receptor, SF receptor, hepatocyte growth factor receptor, met proto-oncogene tyrosine kinase, proto-oncogene c-Met, scatter factor receptor, tyrosine-protein kinase Met. antibody: Abgenix / Pfizer: US20100040629, e.g., the antibody produced by hybridoma 13.3.2 having American Type Culture Collection (ATCC) accession number PTA-5026, the antibody produced by hybridoma 9.1.2 having ATCC accession number PTA-5027, the antibody produced by hybridoma 8.70.2 having ATCC accession number PTA-5028, or the antibody produced by hybridoma 6.90.3 having ATCC accession number PTA-5029. Amgen / Pfizer: US20050054019, e.g., an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:2, where X2 is glutamic acid and X4 is serine, and a light chain having the amino acid sequence set forth in SEQ ID NO:4, where X8 is alanine, and having no signal sequence; an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:6 and a light chain having the amino acid sequence set forth in SEQ ID NO:8, and having no signal sequence; an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:10 and a light chain having the amino acid sequence set forth in SEQ ID NO:12, and having no signal sequence; or an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:14 and a light chain having the amino acid sequence set forth in SEQ ID NO:16, and having no signal sequence. Agouron Pharmaceuticals (currently Pfizer): US20060035907. Eli Lilly: US20100129369. Genentech: US Patent No. 5,686,292; US20100028337; US20100016241; US20070129301; US20070098707; US20070092520, US20060270594; US20060134104; US20060035278; US20050233960; US20050037431; US ​​Patent No. 5,686,292 (e.g., ATCC HB-11894 and ATCC HB-11895) US 20100016241 - e.g., ATCC HB-11894 (hybridoma 1A3.3.13) or HB-11895 (Hybridoma 5D5.11.6). National Defense Medical Center, Taiwan: Lu R M., et al Biomaterials. 2011 Apr;32(12):3265-74. Novartis:US20090175860. For example, an antibody comprising the CDR1, CDR2, and CDR3 sequences of heavy chain 4687, which are residues 26-35, 50-65, and 98-102, respectively, of SEQ ID NO:58, and the CDR1, CDR2, and CDR3 sequences of light chain 5097, which are residues 24-39, 55-61, and 94-100, respectively, of SEQ ID NO:37. Pharmacia Corporation: US20040166544. Pierre Fabre: US20110239316, US20110097262, US20100115639. Sumsung: US 20110129481 - For example, a monoclonal antibody produced from a hybridoma cell having accession number KCLRF-BP-00219 or accession number KCLRF-BP-00223. Samsung: US 20110104176 - for example, an antibody produced by hybridoma cells having accession number: KCLRF-BP-00220. Faculty of Medicine, University of Turin: DN-30 Pacchiana G., et al J Biol Chem.; 285(46):36149-57 (2010). Van Andel Institute: Jiao Y., et al Mol Biotechnol.; 31(1):41-54(2005).

[0315] (43) MUC1 (Mucin 1, cell surface associated): Nucleotide: Genbank Accession No. J05581; Genbank Version No. J05581.1 GI:188869. Polypeptide: Genbank Accession No. AAA59876; Genbank Version No. AAA59876.1 G1:188870. Cross reference: Gendler SJ, et al J. Biol. Chem. 265 (25), 15286-15293 (1990) Additional information: Official symbol: MUC1; Other aliases: RP11-263K19.2, CD227, EMA, H23AG, KL-6, MAM6, MUC-1, MUC-1 / SEC, MUC-1 / X, MUC1 / ZD, PEM, PEMT, PUM. Other names: DF3 antigen; H23 antigen; Breast cancer associated antigen DF3; Carcinoma-associated mucin; Episialin; Krebs von den Lungen-6; Mucin 1, transmembrane; Mucin-1; Peanut-reactive urinary mucin; Polymorphous epithelial mucin; Tumor-associated epithelial mucin; Tumor-associated epithelial membrane antigen; Tumor-associated mucin. antibody: AltaRex - Quest Pharma Tech: US Patent US Pat. No. 6,716,966 - for example, the Alt-1 antibody produced by hybridoma ATCC No PTA-975. AltaRex - Quest Pharma Tech: US Patent No. US 7,147,850. CRT: 5E5-Sorensen AL., et al Glycobiology. 16(2 ) 96-107(2006); HMFG2-Burchell J., et al Cancer Res., 47, 5476-5482 (1987); see WO2015 / 159076 Glycotope GT-MAB: GT-MAB 2.5-GEX (Website: http: / / www.glycotope.com / pipeline / pankomab-gex) Immunogens: U.S. Patent No. 7,202,346, e.g., antibody MJ-170: hybridoma cell line MJ-170 ATCC Accession No. PTA-5286, monoclonal antibody MJ-171: hybridoma cell line MJ-171 ATCC Accession No. PTA-5287, monoclonal antibody MJ-172: hybridoma cell line MJ-172 ATCC Accession No. PTA-5288, or monoclonal antibody MJ-173: hybridoma cell line MJ-173 ATCC Accession No. PTA-5302. Immunomedics: U.S. Patent No. 6,653,104. Ramot Tel Aviv Uni: US Patent. No. 7,897,351. Regents Uni. CA: US Pat. No. 7,183,388; US20040005647; US20030077676. Roche GlycArt: U.S. Patent No. 8,021,856. Russian National Cancer Research Center: Imteran-Ivanov P K., et al Biotechnol J.; 2(7):863-70(2007). Braunschweig University of Technology: (IIB6, HT186-B7, HT186-D11, HT186-G2, HT200-3A-C1, HT220-M-D1, HT220-M-G8) - Thie H., et al PLoS One. ; 6(1):e15921(2011).

[0316] (44) CA9 (Carbonic anhydrase IX): Nucleotide: Genbank Accession No. X66839; Genbank Version No. X66839.1 GI:1000701. Polypeptide: Genbank Accession No. CAA47315; Genbank Version No. CAA47315.1 G1:1000702. Cross reference: Pastorek J., et al Oncogene 9 (10), 2877-2888 (1994). Other information: Official symbol: CA9; Other aliases: CAIX, MN; Other designations: CA-IX, P54 / 58N, RCC-associated antigen G250, RCC-associated protein G250, carbonic anhydrase IX, carbonic anhydrase 9, carbonic anhydrase, membrane antigen MN, pMW1, renal cell carcinoma-associated antigen G250. antibody: Abgenix / Amgen: US20040018198. Affibody: Anti-CAIX Affibody molecule (http: / / www.affibody.com / en / Product-Portfolio / Pipeline / ). Bayer: U.S. Patent No. 7,462,696. Bayer / Morphosys: 3ee9 mAb-Petrul H M., et al Mol Cancer Ther. ; 11(2):340-9(2012) Harvard Medical School: Antibodies G10, G36, G37, G39, G45, G57, G106, G119, G6, G27, G40, G125. Xu C., et al PLoS One. ; 5(3): e9625(2010). Institute of Virology of the Slovak Academy of Sciences (Bayer) - US Patent No. 5,500,000 US No. 5,955,075. For example, M75 - ATCC Accession No. HB 11128, or MN12 - ATCC Accession No. HB 11647. Institute of Virology of the Slovak Academy of Sciences: US Patent No. 5,100,000 and US Patent No. 7,816,493. For example, the M75 monoclonal antibody secreted from the hybridoma VU-M75 has been deposited at the American Type Culture Collection under ATCC number HB11128. Or the V / 10 monoclonal antibody secreted from the hybridoma V / 10-VU, which has been deposited at the International Depository of the Belgian Cooperative Collection of Microorganisms (BCCM) at the Institute of Molecular Biology and Plasmidenkollekti (LMBP) of the University of Gent, Belgium, under accession number LMBP 6009CB. Institute of Virology of the Slovak Academy of Sciences US20080177046; US20080176310; US20080176258; US20050031623. Novartis: US20090252738. Wilex: US Pat. No. 7,691,375 - for example, antibodies produced by the hybridoma cell line DSM ASC 2526. Wilex: US20110123537; Rencarex: Kennett R H., et al Curr Opin Mol Ther.; 5(1):70-5(2003). Zencore:US20090162382.

[0317] (45) EGFRvIII (Epidermal Growth Factor Receptor (EGFR), Transcriptional Variant 3): Nucleotide: Genbank Accession No. NM_201283; Genbank Version No. NM_201283.1 G1:41327733. Polypeptide: Genbank Accession No. NP_958440; Genbank Version No. NP_958440.1 G1:41327734. Cross reference: Batra SK., et al Cell Growth Differ .; 6(10):1251-1259(1995). Antibodies: U.S. Patent Nos. 7,628,986 and 7,736,644 (Amgen) For example, a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NO: 142 and variants thereof, and a light chain variable region amino acid sequence selected from the group consisting of SEQ ID NO: 144 and variants thereof. US20100111979 (Amgen); for example, an antibody comprising a heavy chain amino acid sequence comprising a CDR1 consisting of a sequence selected from the group consisting of the amino acid sequences of the CDR1 regions of antibodies 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2), 170 (SEQ ID NO:4), 150 (SEQ ID NO:5), 095 (SEQ ID NO:7), 250 (SEQ ID NO:9), 139 (SEQ ID NO:10), 211 (SEQ ID NO:12), 124 (SEQ ID NO:13), 318 (SEQ ID NO:15), 342 (SEQ ID NO:16), and 333 (SEQ ID NO:17). CDR2 consisting of a sequence selected from the group consisting of amino acid sequences of the CDR2 regions of antibodies 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2), 170 (SEQ ID NO:4), 150 (SEQ ID NO:5), 095 (SEQ ID NO:7), 250 (SEQ ID NO:9), 139 (SEQ ID NO:10), 211 (SEQ ID NO:12), 124 (SEQ ID NO:13), 318 (SEQ ID NO:15), 342 (SEQ ID NO:16), and 333 (SEQ ID NO:17). and a CDR3 consisting of a sequence selected from the group consisting of the amino acid sequences of the CDR3 regions of antibodies 13.1.2 (SEQ ID NO:138), 131 (SEQ ID NO:2), 170 (SEQ ID NO:4), 150 (SEQ ID NO:5), 095 (SEQ ID NO:7), 250 (SEQ ID NO:9), 139 (SEQ ID NO:10), 211 (SEQ ID NO:12), 124 (SEQ ID NO:13), 318 (SEQ ID NO:15), 342 (SEQ ID NO:16), and 333 (SEQ ID NO:17). US20090240038 (Amgen): For example, an antibody having at least one of a heavy chain polypeptide or a light chain polypeptide comprising an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof. US20090175887 (Amgen): For example, an antibody having a heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequences of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17). US20090156790 (Amgen): For example, an antibody having a heavy chain polypeptide and a light chain polypeptide, wherein at least one of the heavy chain polypeptide or the light chain polypeptide comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof. US20090155282, US20050059087 and US20050053608 (Amgen): for example, an antibody heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequences of antibodies 13.1.2 (SEQ ID NO: 138), 131 (SEQ ID NO: 132), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 211 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17). MR1-1 (U.S. Patent No. 7,129,332, Duke): A mutant antibody having the sequence of SEQ ID NO. 18, for example, with an S98P-T99Y substitution in the CDR3 VH and an F92W substitution in the CDR3 VL. L8A4, H10, Y10 (Wikstrand CJ., et al Cancer Res.; 55(14):3140-8(1995); Duke). US20090311803 (Harvard University): For example, SEQ ID NO: 9 for antibody heavy chain variable region, and SEQ ID NO: 3 for light chain variable region amino acid sequence US20070274991 (EMD72000, aka matuzumab, Harvard University) For example, light and heavy chain sequence numbers 3 and 9. U.S. Patent No. 6,129,915 (Schering) e.g., SEQ ID NOs: 1, 2, 3, 4, 5, and 6. mAb CH12-Wang H., et al FASEB J.; 26(1):73-80(2012) (Shanghai Cancer Institute). RAbDMvIII-Gupta P., et al BMC Biotechnol. ; 10:72 (2010)(Stanford University Medical Center). mAb Ua30-Ohman L., et al Tumour Biol.; 23(2):61-9 (2002) (Uppsala University). Han DG., et al. “Nan Fang Yi Ke Da Xue Xue Bao”. ; 30(1):25-9(2010)(Xi'an Jiaotong University).

[0318] (46)Cd33 (Cd33 molecule): Nucleotide: Genbank Accession No. M_23197; Genbank Version No. NM_23197.1 G1:180097. Polypeptide: Genbank Accession No. AAA51948; Genbank Version No. AAA51948.1 G1:188098. Cross reference: Simmons D., et al J. Immunol. 141 (8), 2797-2800 (1988). CD33 is a member of the sialic acid-binding immunoglobulin-like lectin family and is a glycosylated 67 kDa transmembrane protein. CD33 is expressed on most myeloid and monocytic leukemia cells, as well as committed myelomonocytic and erythroid progenitor cells. It is not found on most primitive pluripotent stem cells, mature granulocytic, lymphocytic cells, or nonhematopoietic cells (Sabbath et al., (1985) J. Clin. Invest. 75:756-56; Andrews et al., (1986) Blood 68: 1030-5). CD33 contains two tyrosine residues at its cytoplasmic tail, each followed by a hydrophobic residue that resembles immunoreceptor tyrosine-based inhibitory motifs (ITIMs) found in many inhibitory receptors. Additional information: Official symbol: CD33; Other aliases: SIGLEC-3, SIGLEC3, p67. Other names: CD33 antigen (gp67); gp67; myeloid cell surface antigen CD33; sialic acid-binding Ig-like lectin 3; sialic acid-binding Ig-like lectin. Antibodies: H195 (lintuzumab) - Raza A. et al., Leuk Lymphoma. 50(8):1336-44 (2009); US Patent No. 6,759,045 (Seattle Genetics / Immunomedics). mAb OKT9: Sutherland, DR et al. ProcNatl Acad Sci USA 78(7):4515~4519 (1981), Schneider C. et al. J Biol Chem 257(14), 8516~8522 (1982). mAb E6: Hoogenboom, HR et al., J Immunol 144(8), 3211-3217 (1990). See, e.g., SEQ ID NOs: 1 and 2, and ATCC Accession No. 6,590,088 (Human Genome Sciences). 97521. No. 7,557,189 (Immunogen) For example, an antibody or fragment thereof comprising a heavy chain variable region comprising three CDRs having the amino acid sequences of SEQ ID NOs: 1 to 3, and a light chain variable region comprising three CDRs having the amino acid sequences of SEQ ID NOs: 4 to 6.

[0319] (47)Cd19 (Cd19 molecule): Nucleotide: Genbank accession number NM_001178098; Genbank version number NM_001178098.1 G1:296010920. Polypeptide: Genbank accession number NP_001171569; Genbank version number NP_001171569.1 G1:296010921. Cross reference: Tedder T F., et al J. Immunol. 143 (2): 712-7 (1989) Additional information: Official symbol: CD19. Other aliases: B4, CVID3. Other names: B lymphocyte antigen CD19, B lymphocyte surface antigen B4, T cell surface antigen Leu-12, differentiation antigen CD19. antibody Immunogen: HuB4 - Al-Katib A M., et al Clin Cancer Res.; 15(12):4038-45(2009). 4G7: Kugler M., et al Protein Eng Des Sel.; 22(3):135-47(2009). See, for example, the sequence of Figure 3 in Knappik, A. et al. J Mol Biol. ; 296(1):57-86(2000). AstraZeneca / MedImmune: MEDI-551-Herbst R., et al J Pharmacol Exp Ther. ; 335(1):213-22(2010). Glenmark Pharmaceuticals: GBR-401-Hou S., et al Mol Cancer Ther (conference abstract supplement) C164(2011). No. 7,109,304 (Immunomedics): For example, an antibody comprising the sequence of hA19Vk (SEQ ID NO:7) and the sequence of hA19VH (SEQ ID NO:10). No. 7,902,338 (Immunomedics): For example, an antibody or antigen-binding fragment thereof comprising the light chain complementarity determining region CDR sequence CDR1 (KASQSVDYDGDSYLN) of SEQ ID NO: 16. The parent mouse antibody sequences also include human antibody framework (FR) and constant region sequences having one or more framework region amino acid residues replaced from the corresponding framework region, the replaced FR residue including a phenylalanine to serine substitution at Kabat residue 91 of the heavy chain variable region. Medarex: MDX-1342 - Cardarelli P M. et al. Cancer Immunol Immunother. ; 59(2):257-65(2010). MorphoSys / Xencor: MOR-208 / XmAb-5574-Zalevsky J., et al Blood.; 113(16):3735-43(2009) U.S. Patent No. 7,968,687 (Seattle Genetics) An antibody or antigen-binding fragment comprising a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:24. 4G7 chim-Lang P., et al Blood.; 103(10):3982-5(2004) (University of Tubingen) See e.g., Figure 6 and SEQ ID No: 80 of US20120082664. Zhejiang University School of Medicine: 2E8-Zhang J., et al J Drug Target.; 18(9):675-8(2010).

[0320] (48) IL2RA (Interleukin 2 receptor, alpha); NCBI Reference Sequence: NM_000417.2): Nucleotide: Genbank Accession No. NM_000417; Genbank Version No. NM_000417.2 GI:269973860. Polypeptide: Genbank Accession No. NP_000408; Genbank Version No. NP_000408.1 G1:4557667. Cross reference: Kuziel WA, et al J. Invest. Dermatol. 94 (6 SUPPL), 27S-32S (1990) Additional Information: Official Symbol: IL2RA. Other Synonyms: RP11-536K7.1, CD25, IDDM10, IL2R, TCGFR. Other Designations: FIL-2 receptor subunit alpha, IL-2-RA, IL-2R subunit alpha, IL2-RA, TAC antigen, interleukin-2 receptor subunit alpha, p55. Antibodies: US Patent No. 5,200,101 US Patent No. 6,383,487 (Novartis / UCL: Baxilisimab [Simulect]) For example, an antibody having an antigen-binding site comprises at least one domain including CDR1 having the amino acid sequence of SEQ ID NO:6. ID. NO:7, CDR2 having the amino acid sequence of SEQ ID NO:7. ID. NO:8, and CDR3 having the amino acid sequence of SEQ ID NO:8. ID. NO:9; or, the sequences of said CDR1, CDR2 and CDR3 as a whole comprise an amino acid sequence that is at least 90% identical to SEQ ID NO:1. ID. NO:7, 8, 9 taken in sequence throughout. Daclizumab - Rech A J. et al., Ann NY Acad Sci.; 1174:99-106(2009)(Roche).

[0321] (49)AXL (AXL receptor tyrosine kinase): Nucleotide: Genbank Accession No. M76125; Genbank Version No. M76125.1 G1:292869. Polypeptide: Genbank Accession No. AAA61243; Genbank Version No. AAA61243.1 G1:29870. Cross reference: O'Bryan JP, et al. Mol. Cell. Biol. 11 (10), 5016-5031 (1991); Bergsagel PL et al., J. Immunol. 148 (2), 590-596 (1992). Additional information: Official symbol: AXL; Other aliases: JTK11, UFO. Other names: AXL oncogene; AXL transforming sequence / gene; AXL oncogene; Tyrosine protein kinase receptor UFO. Antibody:YW327.6S2-Ye X., et al Oncogene.; 29(38):5254-64(2010). (Genentech); BergenBio: BGB324 (http: / / www.bergenbio.com / BGB324).

[0322] (50)CD30-TNFRSF8 (Tumor necrosis factor receptor superfamily, member 8): Nucleotide: Genbank Accession No. M83554; Genbank Version No. M83554.1 G1:180095. Polypeptide: Genbank Accession No. AAA51947; Genbank Version No. AAA51947.1 G1:180096. Cross reference: Durkop H., et al Cell 68 (3), 421-427 (1992). Additional information: Official symbol: TNFRSF8; Other aliases: CD30, D1S166E, Ki-1 Other names: CD30L receptor; Ki-1 antigen; Cytokine receptor CD30; Lymphocyte activation antigen CD30; Tumor necrosis factor receptor superfamily member 8.

[0323] (51) BCMA (B-cell maturation antigen) - TNFRSF17 (Tumor necrosis factor receptor superfamily, member 17): Nucleotide: Genbank Accession No. Z29574; Genbank Version No. Z29574.1 GI:471244. Polypeptide: Genbank Accession No. CAA82690; Genbank Version No. CAA82690.1 GI:471245. Cross reference: Laabi Y. et al., Nucleic Acids Res. 22 (7), 1147-1154 (1994). Additional information: Official symbol: TNFRSF17; Other aliases: BCM, BCMA, CD269. Other names: B cell maturation antigen; B cell maturation factor; B cell maturation protein; Tumor necrosis factor receptor superfamily member 17.

[0324] (52) CT Antigen - CTA (Cancer Testis Antigen): Cross-references: Fratta E., et al. Mol. Oncol.; 5(2):164-82(2011); Lim S H., et al Am J Blood Res. 2(1):29-35(2012).

[0325] (53) CD174 (Lewis Y) - FUT3 (Fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group): Nucleotide: Genbank Accession No. NM000149; Genbank Version No. NM000149.3 GI:148277008. Polypeptide: Genbank Accession No. NP_000140; Genbank Version No. NP_000140.1 G1:4503809. Cross-reference: Kukowska-Latallo, JF, et al. Genes Dev. 4 (8), 1288-1303 (1990). Additional information: Official symbol: FUT3; Other aliases: CD174, FT3B, FucT-III, LE, Les Other Designations: Lewis FT; α-(1,3 / 1,4)-fucosyltransferase; Blood group Lewis α-4-fucosyltransferase; Fucosyltransferase III; Galactoside 3(4)-L-fucosyltransferase.

[0326] (54) CLEC14A (C-type lectin domain family 14, member a; Genbank accession number NM175060): Nucleotide: Genbank Accession No. NM175060; Genbank Version No. NM175060.2 G1:371123930. Polypeptide: Genbank Accession No. NP_778230; Genbank Version No. NP_778230.1 G1:28269707. Additional information: Official symbol: CLEC14A; Other aliases: UNQ236 / PRO269, C14orf27, CEG1, EGFR-5. Other names: C-type lectin domain family 14 member A; CIECT and EGF-like domain-containing protein; epidermal growth factor receptor 5.

[0327] (55) GRP78-HSPA5 (heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa): Nucleotide: Genbank Accession No. NM005347; Genbank Version No. NM005347.4 G1:305855105. Polypeptide: Genbank Accession No. NP_005338; Genbank Version No. NP_005338.1 GI:16507237. Cross reference: Ting J. et al., DNA 7 (4), 275-286 (1988). Additional information: Official symbol: HSPA5; Other aliases: BIP, GRP78, MIF2. Other names: 78 kDa glucose-regulated protein. Endoplasmic reticulum luminal Ca(2+)-binding protein grp78. Immunoglobulin heavy chain-binding protein.

[0328] (56) Cd70 (Cd70 molecule) L08096: Nucleotide: Genbank Accession No. L08096; Genbank Version No. L08096.1 GI:307127. Polypeptide: Genbank Accession No. AAA36175; Genbank Version No. AAA36175.1 GI:307128. Cross reference: Goodwin RG, et al Cell 73 (3), 447-456 (1993). Additional information: Official symbol: CD70; Other aliases: CD27L, CD27LG, TNFSF7. Other names: CD27 ligand; CD27-L; CD70 antigen; Ki-24 antigen; surface antigen CD70; tumor necrosis factor (ligand) superfamily, member 7. Tumor necrosis factor ligand superfamily member 7. Antibodies: MDX-1411 (Medarex) h1F6 against CD70 (Oflazoglu, E., et al, Clin Cancer Res.; 14(19):6171-80(2008); (Seattle Genetics) See, e.g., SEQ ID NOs: 1, 2, 11, 12 and FIG. 1 of US20060083736.

[0329] (57) Stem cell specific antigens: e.g., 5T4 (see item (63) below); CD25 (see item (48) above); CD32. Polypeptide: Genbank Accession No. ABK42161; Genbank Version No. ABK42161.1 GI: 117616286; LGR5 / GPR49. Nucleotide: Genbank Accession No. NM_003667; Genbank Version No. NM_003667.2 G1: 24475886. Polypeptide: Genbank Accession No. NP_003658; Genbank Version No. NP_003658.1 G1: 4504379. Prominin / CD133. Nucleotide: Genbank Accession No. NM_006017; Genbank Version No. NM_006017.2 G1: 224994187. Polypeptide: Genbank accession number NP_006008; Genbank version number NP_006008.1 G1:5174387.

[0330] (58)ASG-5: Cross-references: (Smith LM, et. al. AACR 2010 Annual Meeting (abstract #2590); Gudas JM, et. al. AACR 2010 Annual Meeting (abstract #4393). Antibody Anti-AGS-5 antibody: M6.131 (Smith, LM et al., AACR 2010 Annual Meeting (abstract #2590)).

[0331] (59) ENPP3 (ectonucleotide pyrophosphatase / phosphodiesterase 3): Nucleotide: Genbank Accession No. AF005632; Genbank Version No. AF005632.2 G1:4432589. Polypeptide: Genbank Accession No. AAC51813; Genbank Version No. AAC51813.1 G1:2465540. Cross reference: Jin-Hua P., et al Genomics 45 (2), 412-415 (1997). Additional information: Official symbol: ENPP3. Other aliases: RP5-988G15.3, B10, CD203c, NPP3, PD-IBETA, PDNP3. Other Designations: E-NPP 3; dJ1005H11.3 (phosphodiesterase I / nucleotide pyrophosphatase 3); dJ914N13.3 (phosphodiesterase I / nucleotide pyrophosphatase 3); ectonucleotide pyrophosphatase / phosphodiesterase family member 3; gp130RB13-6; phosphodiesterase I beta; phosphodiesterase I / nucleotide pyrophosphatase 3; phosphodiesterase-1 beta.

[0332] (60) PRR4 (Proline Rich 4 (Tear)): Nucleotide: Genbank Accession No. NM_007244; Genbank Version No. NM_007244.2 G1:154448885. Polypeptide: Genbank Accession No. NP_009175; Genbank Version No. NP_009175.2 G1:154448886. Cross-reference: Dickinson DP, et al Invest. Ophthalmol. Vis. Sci. 36 (10), 2020-2031 (1995). Additional information: Official symbol: PRR4. Other aliases: LPRP, PROL4. Other names: Tear proline-rich protein, nasopharyngeal carcinoma-associated proline-rich protein 4, proline-rich polypeptide 4, proline-rich protein 4.

[0333] (61) GCC-GUCY2C (Guanylate cyclase 2C (heat-stable enterotoxin receptor): Nucleotide: Genbank accession number NM_004963; Genbank version number NM_004963.3 G1:222080082. Polypeptide: Genbank accession number NP_004954; Genbank version number NP_004954.2 G1:222080083. Cross-references: De Sauvage FJ, et al J. Biol. Chem. 266 (27), 17912-17918 (1991); Singh S., et al Biochem. Biophys. Res. Commun. 179 (3), 1455-1463 (1991). Additional information: Official symbol: GUCY2C; Other aliases: DIAR6, GUC2C, MUCIL, STAR. Other names: GC-C; STA receptor; guanylyl cyclase C; hSTAR; heat-stable enterotoxin receptor; intestinal guanylate cyclase.

[0334] (62) Liv-1-SLC39A6 (solute carrier family 39 (zinc transporter), member 6): Nucleotide: Genbank Accession No. U41060; Genbank Version No. U41060.2 GI:12711792. Polypeptide: Genbank Accession No. AAA96258; Genbank Version No. AAA96258.2 GI:12711793. Cross reference: Taylor KM., et al Biochim Biophys Acta.; 1611(1-2):16-30(2003). Additional information: Official symbol: SLC39A6. Other aliases: LIV-1. Other names: LIV-1 protein, estrogen regulated; ZIP-6; estrogen regulated protein LIV-1; solute carrier family 39 (metal ion transporter), member 6; solute carrier family 39 member 6...

Claims

1. A method for homogeneous conjugation comprising the steps of: (a) providing an effective amount of a zinc-amino chelate / complex (Zn(NR 1 R 2 R 3 ) m1 2+ 2. Incubating the antibody or antibody-like protein in the presence of 100 mM NaCl and a reducing agent; (b) adding an effective amount of a conjugate or drug / conjugate conjugate having a thiol-reactive group to react with the thiol group generated in step (a); and (c) optionally adding an effective amount of an oxidizing agent to reoxidize unreacted thiol groups or adding a quenching agent to cap unreacted thiol groups; and (d) purifying the resulting conjugate; Including, Optionally, step (c) above can be replaced by adding an effective amount of cysteine, or a related disulfide compound, or an azide compound to quench any unreacted reducing agent, while generating a cysteine ​​or thiol compound from the reduction of the cystine or disulfide compound to quench excess conjugation of conjugates or drug / conjugate conjugates containing thiol reactive groups, or an effective amount of cysteine ​​or a related thiol compound can be added to quench excess conjugate or conjugate / payload conjugate molecules; R 1 , R 2 and R 3 are each independently 1 -C 8 Alkyl, C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 selected from aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; m1 is 1, 2, 3, 4, 5, 6, 7, or 8; or N, R 1 , R 2 and / or R 3 may themselves form a heterocycle, a carbocycle, a heterobicycle, or a carbobicycle; 1 R 2 R 3 ) m1 can form dimers, trimers, tetramers, pentamers, or hexamers, and these polymers are N, R 1 , R 2 and / or R 3 are covalently bonded between The zinc-amino chelate / complex Zn(NR 1 R 2 R 3 ) m1 2+ is at a concentration of 0.01 mM to 1.0 mM, or 0.5-20 equivalents per mole of protein; The reducing agent is an organic phosphine, and the amount used is 1.0 to 20 equivalents per mole of protein; The oxidizing agent in step (c) is DHAA, Fe 3+ , I 2 , Cu 2+ , Mn 3+ , MnO 2 , or Fe 3+ / I - the concentration of the oxidizing agent used in the reaction solution of step (c) is 0.02 mM to 1.0 mM, or 1-100 equivalents per mole of protein; The pH of the conjugation reaction in step (b) is typically about 5.0 to 8.0; The reaction solution of step (a) comprises, as a co-solvent, up to 30% of a water-miscible organic solvent selected from DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropyl alcohol, dioxane, propylene glycol, or ethylene glycol in an aqueous buffer system; The temperature of the coupling reaction in step (b) is from about −5° C. to about 40° C.; the optimal reaction time of the coupling reaction in step (b) is from about 15 minutes to about 48 hours; The conjugate is purified by Sephadex G25 or Sephacryl S300 column gel filtration, adsorption chromatography, ion (cation or anion) exchange chromatography, or dialysis (ultrafiltration or ultrafiltration (UF) and / or diafiltration (DF); The drug / antibody-like protein (antibody) ratio (DAR) of the conjugate is measured by hydrophobic interaction chromatography (HIC-HPLC), capillary electrophoresis (CE), LC-MS, CE-MS, or LC-MS / MS in the UV wavelength range of 240-380 nm.

2. (a) The zinc cation-amino chelate is selected from the group consisting of: Zn(NH 2 CH 3 ) 2 2+ , Zn(NH 2 CH 2 CH 3 ) 2 2+ , Zn(NH 2 CH 2 CH 2 CH 3 ) 2 2+ , Zn(NH 2 CH (CH 3 ) 2 ) 2 2+ , Zn(NH 2 C (CH 3 ) 3 ) 2 2+ , Zn(NH 2 CH 2 C (CH 3 ) 3 ) 2 2+ , Zn(NH(CH 3 ) 2 ) 2 2+ , Zn(NH(CH 2 CH 3 ) 2 ) 2 2+ , Zn(NH(CH(CH 3 ) 2 ) 2 ) 2 2+ Zn(NH(C(CH 3 ) 3 ) 2 ) 2 2+ Zn(NH(CH(CH 2 CH3) 2 ) 2 ) 2 2+ Zn(NH(CH 2 C(CH 3 ) 3 ) 2 ) 2 2+ Zn(NH(CH 2 C(CH 2 CH 3 ) 3 ) 2 ) 2 2+ Zn(NH(CH 2 CH 2 C(CH 3 ) 3 ) 2 ) 2 2+ Zn(NH 2 CH 2 CH 2 OH) 2 2+ Zn(NH(CH 2 CH 2 OH) 2 ) 2 2+ Zn(N(CH 2 CH 2 OH) 3 ) 2 2+ Zn(NH 2 CH 2 COOH) 2 2+ Zn(NH 2 CH 2 P. 2 ) 2 2+ Zn(NH 2 CH 2 COOCH 3 ) 2 2+ Zn(NH 2 CH 2COOCH 2 CH 3 ) 2 2+ Zn(NH 2 CH 2 P.S. 3 ) 3 ) 2 2+ Zn(NH 2 CH 2 P.S. 3 ) 2 ) 2 2+ Zn(NH 2 CH 2 CH 2 COOH) 2 2+ Zn(NH(CH 2 COOH) 2 ) 2 2+ Zn(N(CH 2 CH 2 COOH) 3 ) 2 2+ Zn(NH 2 CH 3 ) 4 2+ Zn(NH 2 CH 2 CH 3 ) 4 2+ Zn(NH 2 CH 2 CH 2 CH 3 ) 4 2+ Zn(NH 2 CH(CH 3 ) 2 ) 4 2+ Zn(NH 2 C(CH 3 ) 3 ) 4 2+ Zn(NH 2 CH 2 C(CH 3 ) 3 ) 4 2+ Zn(NH(CH 3 ) 2) 4 2+ 、Zn(NH(CH 2 CH 3 ) 2 ) 4 2+ 、Zn(NH(CH(CH 3 ) 2 ) 2 ) 4 2+ 、Zn(NH(C(CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH(CH(CH 2 CH 3 ) 2 ) 2 ) 4 2+ 、Zn(NH(CH 2 C(CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH(CH 2 C(CH 2 CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH(CH 2 CH 2 C(CH 3 ) 3 ) 2 ) 4 2+ 、Zn(NH 2 CH 2 CH 2 OH) 4 2+ 、Zn(NH(CH 2 CH 2 OH) 2 ) 4 2+ 、Zn(N(CH 2 CH 2 OH) 3 ) 4 2+ 、Zn(NH 2 CH 2 COOH) 4 2+ 、Zn(NH 2 CH 2 CONH 2 ) 4 2+ , Zn(NH 2 CH 2 COOCH 3 ) 4 2+ , Zn(NH 2 CH 2 COOCH 2 CH 3 ) 4 2+ , Zn(NH 2 CH 2 COOC (CH 3 ) 3 ) 4 2+ , Zn(NH 2 CH 2 COOCH (CH 3 ) 2 ) 4 2+ , Zn(NH 2 CH 2 CH 2 COOH) 4 2+ , Zn(NH(CH 2 COOH) 2 ) 4 2+ , Zn(N(CH 2 CH 2 COOH) 3 ) 4 2+ , [Formula 1] [ka] and any of the above cations and Cl - , B - , I - , S.O. 4 2- , H.S.O. 4 - , NO 3 - , P.O. 4 3- , H.P.O. 4 2- , H 2 P.O. 4 - , CO 3 2- , HCO 3 - , H.C.O. - , C.H. 3 COO - , F 3 Chief Creative Officer - , Cl 3 Chief Creative Officer - , F.C.H. 2 COO - , ClCH 2 COO - , F 2 CHCOO - , Cl 2 CHCOO - , B.F. 4 - , S.O. 3 2- , H.S.O. 3 - , C.H. 3 SO 3 - , C 6 H 5 CH 2 SO 3 - , C 6 H 5 SO 3 - , C 6 H 5 COO - , C 6 H 5 CH 2 COO - , C 6 F 5 O - , C 6 H 4 (OH)COO - , C 6 H 2 F 3 O - , C 6 H 4 (NO 2 ) O - , and C 6 H 2 (NO 2 ) 3 O - and an anion selected from the group consisting of The concentration of the zinc-amino complex in the reaction solution in step (a) is 0.5 to 20 equivalents per mole of protein, and is selected from ethanol, methanol, propanol, propanediol, DMA, DMSO, THF, or CH 3 CN is added to the reaction solution together with a water-miscible organic solvent selected from; (b) The organic phosphine reducing agent is tris(2-carboxyethyl)phosphine (TCEP) (P(CH 2 CH 2 COOH) 3 ) and tris(hydroxypropyl)phosphine (P(CH 2 CH 2 CH 2 O.H. 3 ) and the reducing agent used in the reaction solution of step (A) is used at 2.0-4.0 equivalents per mole of protein; 2. The method of claim 1, wherein (c) the buffer system is selected from PBS, Mes, Bis-Tris, Bis-Tris propane, Pipes, Aces, Mopso, Bes, Mops, Hepes, Tes, Pipps, Dipso, Tapso, Heppso, Tris-up, Tris-HCl, Tricine, Hepps, Gly-Gly, Bicine, Taps, Hepee, acetate, histidine, citrate, MES, borate, or any two, three or four thereof; the pH of the buffer is 4.0-9.0; and the concentration of the buffer in the reaction solution of step (a) is 0.02-1.0 M.

3. The drug / conjugate conjugate has formula (I), (II), (III), or (IV): [Case 2] During the ceremony, Lv 1 and Lv 2 is a reactive group and is independently selected from: [C3] [ka] [ka] [ka] [ka] [ka] [ka] [ka] During the ceremony, X 1 ' and X 2 ' are independently F, Cl, Br, I, OTf, OMs, OC 6 H 4 (NO 2 ), O.C. 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 H.F. 4 , or Lv 3 is; 2 is O, NH, N(R 1 ), or C.H. 2 R 3 and R 5 are independently H, R 1 , aromatic, heteroaromatic, or aromatic group, and one or several H atoms are independently selected from -R 1 , -halogen, -OR 1 , -SR 1 , -NR 1 R 2 , -NO 2 , -S(O)R 1 , -S(O) 2 R 1 , or -COOR 1 is replaced by; 3 and Lv 3' is independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl, N-hydroxysuccinimide (NHS), phenoxyl, benzenethiol, dinitrophenoxyl, pentafluorophenoxyl, tetrafluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, triflate, imidazole, dichlorophenoxyl, tetrachlorophenoxyl, 1-hydroxybenzotriazole, tosylate, mesylate, 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed with themselves or with other anhydrides, acetyl anhydride, formyl anhydride, or an intermediate molecule generated with a condensation reagent for a peptide coupling reaction or a Mitsunobu reaction; E 1 Lv 1 and Lv 2 is a linking group connecting two thiol-reactive groups of E 1 , CH, CH 2 , NH, NHNH, N(R 3 ), N(R 3 ) N (R 3’ ), N=N, N-N, P, P(=O), S, Si, C 2 ~C 8 Alkyl, heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; a peptide comprising 1 to 4 units of an amino acid, preferably aspartic acid, glutamic acid, arginine, histidine, lysine, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, tyrosine, phenylalanine, glycine, proline, tryptophan, alanine; or any of the following structures: [C4] [ka] X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 is O, NH, S, N(R 3 ), C.H. 2 R 3 is C 1 ~C 6 is alkyl; In formula (II), formula (III), and formula (IV), [C5] can be selected from: [C6] [ka] [ka] [ka] [ka] [ka] [ka] [ka] In the formula, Lv 3 , Lv 3 ', X 1 ', and X 2 ' is as above; the bond in the middle of two atoms [C7] means that it can bond to either of the two atoms; L 1 , L 2 , L 1’ , and L 2’ are the same or different, and each independently represents O, NH, S, NHNH, N(R 3 ), N(R 3 ) N (R 3 '), or the formula (OCH 2 CH 2 ) p OR 3 , (OCH 2 CH (CH 3 )) p OR 3 , NH(CH 2 CH 2 O) p OR 3 , NH(CH 2 CH (CH 3 ) O) pR3 p OR 3 , N[(CH 2 CH 2 O) p R 3 ][(CH 2 CH 2 O) p’ R 3’ ], (OCH 2 CH 2 ) p COOR 3 , or C.H. 2 CH 2 (O.C.H. 2 CH 2 ) p COOR 3 where p and p′ are independently an integer selected from 0 to about 1000, or a combination thereof; 1 -C 8 Alkyl; C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; 3 and R 3’ are independently H, C 1 -C 8 Alkyl; C 2 -C 8 heteroalkyl, alkylcycloalkyl, aryl of heterocycloalkyl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or 1 to 8 natural or unnatural amino acids as described in the definitions; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) pwhere p is an integer from 0 to about 1000, or a combination thereof; L 1 , L 2 , L 1’ , and L 2’ may contain self-immolative or non-self-immolative moieties, peptidyl units, hydrazone bonds, disulfide, ester, oxime, amide, or thioether bonds, said self-immolative units including aromatic compounds electronically similar to para-aminobenzylcarbamoyl (PAB) groups, including 2-aminoimidazole-5-methanol derivatives, heterocyclic PAB analogs, β-glucuronides, and ortho- or para-aminobenzyl acetals; Preferably, the self-immolative linker moiety has any of the following structures: [C8] In the formula, ( * Atoms labeled with X are points of attachment to additional spacers, releasable linker units, cytotoxic agents, and / or cell binding molecules (CBAs); 1 , Y 1 , Z 2 , and Z 3 is independently NH, O or S; Z 1 is independently H, NH, O, or S; v is 0 or 1; U 1 are independently H, OH, C 1 -C 6 Alkyl, (OCH 2 CH 2 ) n ,F,Cl,Br,I,OR 5 , S.R. 5 , N.R. 5 R 5’ , N=NR 5 , N=R 5 , N.R. 5 R 5’ , NO 2 , S.O.R. 5 R 5’ , S.O. 2 R 5 , S.O. 3 R 5 , OSO 3 R 5 , P.R. 5 R 5’ , P.O.R. 5 R 5’ , P.O. 2 R 5 R 5’ , OPO (OR 5 ) (OR 5’ ), or OCH 2 PO (OR 5 ) (OR 5’ ) in which R 5 and R 5’ is as defined above; preferably R 5 and R 5’ are independently H, C 1 -C 8 Alkyl; C 2 -C 8 Alkenyl, alkynyl, heteroalkyl; 3 -C 8 aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or a medicinal cationic salt; The non-self-immolative linker moiety has any of the following structures: [C9] [ka] [ka] In the formula, ( * ) are atoms marked with an additional spacer R 1 , a releasable linker unit, a cytotoxic agent, and / or a point of attachment to a binding molecule; X 1 , Y 1 , U 1 , R 1 , R 5 , R 5’ is as defined above; r is 0 to 100; m and n are independently 0 to 6; L 1 , L 1’ , L 2 , or L 2’ may be a releasable linker and include any of the following structures: - (CR 5 R 6 ) m (Aa) r (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-(CR 5 R 6 ) m (CR) 7 R 8 ) n (A) r (OCH) 2 CH 2 ) t -、-(A]) r -(CR) 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-(CR 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) r (A) t -、-(CR 5 R 6 ) m -(CR) 7 =CR 8 )(CR 9 R 10 ) n (A) t (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (A) t (NR) 11 CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (O) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCNR) 7 )(Aa) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (C) (A) t -(CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m -(O・)(Aq) t (CR) 9 R 10 ) n -(OCH 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCNR) 7 )(Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, - (CR 5 R 6 ) m (CO)(Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, - (CR 5 R 6 ) m -phenyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -furyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -oxazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -Thiazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) t -Thienyl-(CO)(CR 7 R 8 ) n -, - (CR 5 R 6 ) t -imidazolyl-(CO)(CR 7 R 8 ) n -, - (CR 5 R 6 ) t -Morpholino-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) t -piperazino-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) t -N-methylpiperazine-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -(Aa) t Phenyl-, -(CR 5 R 6 ) m -(Aa) t Frill-,-(CR 5 R 6 ) m -Oxazolyl (Aa) t -, - (CR 5 R 6 ) m -Thiazolyl (Aa) t -, - (CR 5 R 6 ) m -Thienyl (Aa) t -, - (CR 5 R 6 ) m -Imidazolyl (Aa) t -, - (CR 5 R 6 ) m -Morpholino-(Aa) t -, - (CR 5 R 6 ) m -Piperazino- (Aa) t -, - (CR 5 R 6 ) m -N-methylpiperazino- (Aa) t -, -K(CR 5 R 6 ) m (Aa) r(CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-K(CR 5 R 6 ) m (CR) 7 R 8 ) n (A) r (OCH) 2 CH 2 ) t -、-K(Aa) r (CR) 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-K(CR 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) r (A) t -、-K(CR 5 R 6 ) m (CR) 7 =R 8 )(CR 9 R 10 ) n (A) t (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (A) t (NR) 11CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (O) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCNR) 7 )(Aa) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (C) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (O) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCNR) 7 )(Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, -K(CR 5 R 6 ) m (CO) (Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, -K(CR 5 R 6 ) m -phenyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -furyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -oxazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -Thiazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Thienyl-(CO)(CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -imidazolyl-(CO)(CR 7 R 8 ) n -, -K(CR 5 R 6 ) t-Morpholino-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -piperazino-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -N-methylpiperazine-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -(Aa) t Phenyl-, -K(CR 5 R 6 ) m -(Aa) t Frill-, -K (CR 5 R 6 ) m -Oxazolyl (Aa) t -, -K(CR 5 R 6 ) m -Thiazolyl (Aa) t -, -K(CR 5 R 6 ) m -Thienyl (Aa) t -, -K(CR 5 R 6 ) m -Imidazolyl (Aa) t -, -K(CR 5 R 6 ) m -Morpholino-(Aa) t -, -K(CR 5 R 6 ) m -Piperazino- (Aa) t G-, -K (CR 5 R 6 ) m -N-methylpiperazino- (Aa) t ; In the formula, m, Aa, m, n, R 3 , R 4 , and R 5 are defined above; t and r are independently 0 to 100; R 6 , R 7 , and R 8 are independently H; halide; C 1 ~C 8 selected from alkyl, aryl, alkenyl, alkynyl, ether, ester, amine, or amide; 1 R 2 , C.F. 3 , OR 1 , aryl, heterocycle, S(O)R 1 , S.O. 2 R 1 , -CO 2 H, -SO 3 H, -OR 1 , -CO 2 R 1 , -CONR 1 , -PO 2 R 1 R 12 , -PO 3 H or P(O)R 1 R 2 R 3’ K is optionally substituted with NR 1 , -SS-, -C(=O)-, -C(=O)NH-, -C(=O)O-, -C=NH-O-, -C=N-NH-, -C(=O)NH-NH-, O, S, Se, B, or C 3 ~C 6 It is a heteroaromatic ring. The connector L 1 , L 1’ , L 2 , or L 2’ The structure may include the following structures or combinations thereof: [C10] [ka] [ka] [ka] [ka] [ka] [ka] X 2 , X 3 , X 4 , X 5 , or X 6 are independently NH, NHNH; N(R 12 );N(R 12 ) N (R 12’ );O;S;C 1 ~C 6 Alkyl; C 2 ~C 6 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; CH 2 OR 12 , C.H. 2 S.R. 12 , C.H. 2 NHR 12 or 1 to 8 amino acids; 12 and R 12’ are independently H; C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 100; or a combination thereof; Furthermore, L 1 , L 2 , X 1 , X 2 , X 3 , X 1’ , X 2’ , and X 3’ may each independently be absent; D 1 and D. 2 is a functional molecule for enhancing the binding or stability of a cytotoxic agent, a therapeutic agent, an immunotherapeutic short antibody-like protein, or a cell-binding antibody-like protein agent, a cell surface receptor binding ligand, an antibody fragment, an siRNA, or a DNA molecule, selected from: 1) Chemotherapeutic agents: a) alkylating agents selected from the group consisting of: nitrogen mustards: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, nobembitine, phenesterine, prednimustine, thiotepa, trofosfamide, uracil mustard; CC-1065 and synthetic analogs of adozelesin, carzelesin and bizeresin; duocarmycin and its synthetic analogs KW-2189 and CBI-TMI; benzodiazepine dimers or pyrrolobenzodiazepine (PBD) dimers, tomaymycin dimers, indolinobenzodiazepine dimers. benzodiazepines, imidazobenzothiadiazepine dimers, or oxazolidinobenzodiazepine dimers; nitrosourea compounds including carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine; alkylsulfonates including busulfan, treosulfan, improsulfan, and piposulfan; triazenes or dacarbazines; platinum-containing compounds including carboplatin, cisplatin, and oxaliplatin; aziridines, benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramine, trimethylolomelamine; b) plant alkaloids selected from the group consisting of: vinca alkaloids including vincristine, vinblastine, vindesine, vinorelbine, navelbine; taxoids including paclitaxel and docetaxel and analogs thereof; maytansinoids including DM1, DM2, DM3, DM4, DM5, DM6, DM7, maytansine, ansamitocins and analogs thereof; cryptophycins including the cryptophycin 1 and cryptophycin 8 groups; epothilones, eleutherobin, discodermolide, bryostatins, dolostatins, auristatins, tubulysins, cephalostatins; pancratistatin; sarcodictiin; spongistatin; c) DNA topoisomerase inhibitors selected from: epipodophyllins, including 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acid (retinols), teniposide, topotecan, 9-nitrocamptothecin or RFS2000; and mitomycins and their analogs; d) Antimetabolites: {[Antifolates: (DHFR inhibitors: including methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid), or other folate analogs); IMP dehydrogenase inhibitors (including mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase inhibitors (including hydroxyurea, deferoxamine)]; [Pyrimidine analogs: uracil uridine analogs (including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-fluorouracil, floxuridine, raltitrexed); cytosine analogs: (including cytarabine, cytosine arabinoside, fludarabine); purine analogs: (including azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine); folic acid supplements such as folinic acid}; e) Hormonal Therapy: Receptor Antagonists: [Antiestrogens: (including megestrol, raloxifene, tamoxifen); LHRH Agonists: (including goserelin, leuprolide acetate); Antiandrogens: (including bicalutamide, flutamide, calsterone, dromostanolone propionate, epithiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane, and other similar androgen inhibitors. retinoids / deltoid: [vitamin D3 analogs: (including CB1093, EB1089, KH1060, cholecalciferol, ergocalciferol); photodynamic therapy agents: (including verteporfin, phthalocyanines, photosensitizer Pc4, demethoxyhypocrelin A); cytokines: (including interferon alpha, interferon gamma, tumor necrosis factor (TNF), TNF domain-containing human proteins)]}; f) Kinase inhibitors: selected from the group consisting of BIBW2992 (anti-EGFR / Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab, panitumumab, ispinesib; f) Polyketides (acetogenins), bullatacin and bullatacinone; gemcitabine, epoxomicins and carfilzomib, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, zygeva, probenge, elvoy, isoprenylation inhibitors and lovastatin, dopaminergic neurotoxins and 1-methyl-4-phenyl Pyridine ion, cell cycle inhibitors (including staurosporine), actinomycins (including actinomycin D and dactinomycin), amanitins, bleomycins (including bleomycin A2, bleomycin B2, and peplomycin), anthracyclines (including daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, and zorubicin), mitoxantrone, MDR inhibitors or verapamil, Ca 2+ATP inhibitors or thapsigargin, histone deacetylase inhibitors (including vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat (MGCD0103), belinostat, PCI-24781, entinostat, SB939, resminostat, gibinostat, AR-42, CUDC-101, sulforaphane, trichostatin A); thapsigargin, celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A, anti-adrenal drugs (selected from the group consisting of aminoglutethimide, mitotane, trilostanca); aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; arabinoside, bestravsil; bisanto len; edatrexate; defofamine; demecolcine; diaziquone; elfornitine (DFMO), elfomitine; elliptinium acetate; etocurside, gallium nitrate, gacytosine, hydroxyurea; ibandronate, lentinan; lonidamine; mitoguazone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK (registered trademark); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (including T2 toxin, verrucarin A, roridin A, and anguidine); urethane, siRNA, antisense medicines, nucleases; 2) Anti-autoimmune disease drugs: cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticoids (including amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, triamcinolone acetonide, and beclomethasone dipropionate), DHEA, etanercept, hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenolic acid, prednisone, sirolimus, and tacrolimus; 3) Anti-infectives, including but not limited to: a) Aminoglycosides: amikacin, astromycin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamycin; b) Amphenicols: azidamphenicol, chloramphenicol, florfenicol, thiamphenicol; c) Ansamycins: geldanamycin, herbimycin; d) Carbapenems: biapenem, doripenem, ertapenem, imipenem, cilastatin, meropenem, panipenem; e) Cephalosporins: carbacephems (loracarbef), cephacetrile, cefaclor, cephradine, cefadroxil, cephalonium, cephaloridine, cephalothin or cephalothin, cephalexin, cephaloglycin, cefamandole, cephapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, Fetameth, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftiolene, ceftizoxime, ceftobiprol, ceftriaxone, cefuroxime, cefuzonam, cephamycins (including cefoxitin, cefotetan, cefmetazole), oxacephems (flomoxef, latamoxef); f) Glycopeptides: bleomycin, vancomycin (including oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g) Glycylcyclines: Tigecycline; h) β-lactamase inhibitors: penams (sulbactam, tazobactam), clavams (clavulanic acid); i) Lincosamides: clindamycin, lincomycin; j) Lipopeptides: daptomycin, A54145, calcium-dependent antibiotic (CDA); k) Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolides (telithromycin, cethromycin), midecamycin, miokamicin, oleandomycin, rifamycin (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; l) Monobactams: aztreonam, tigemonam; m) Oxazolidinones: Linezolid; n) Penicillins: amoxicillin, ampicillin, pivampicillin, hetacillin, bacampicillin, methampicillin, talampicillin, azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, methicillin, nafcillin, oxacillin, penamecillin, penicillin, phenethicillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o) Polypeptides: bacitracin, colistin, polymyxin B; p) quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, canotrovafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin; q) Streptogramins: pristinamycin, quinupristin / dalfopristin; r) Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s) Steroidal antibacterial agents: fusidic acid, etc.; t) Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcycline (such as tigecycline); u) Other antibiotics: annonacin, arsphenamine, bactoprenol inhibitors (bacitracin), DADAL / AR inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin / dalfopristin, rifampicin (rifampin), tazobactamcinidazole, uvaricin; 4) Antiviral drugs: a) Entry / fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO140, CD4 (ibalizumab); b) Integrase inhibitors: raltegravir, elvitegravir, globoidnan A; c) Maturation inhibitors: Bevirimat, Vivecon; d) Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e) Nucleosides and Nucleotides: Abacavir, Acyclovir, Adefovir, Amdoxovir, Apricitabine, Brivudine, Cidofovir, Clevudine, Dexerbucitabine, Didanosine (DDI), Elvucitabine, Emtricitabine (FTC), Entecavir, Famciclovir, Fluorouracil (5-FU), 3'-Fluoro substituted 2',3'-deoxynucleoside analogues (e.g., 3'-Fluoro-2',3'-dideoxythymidine (FLT) and 3'-Fluoro-2',3'-deoxythymidine (FLT), dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridine, lamivudine (3TC), L-nucleosides (e.g., including the group consisting of β-L-thymidine and β-L-2'-deoxycytidine), penciclovir, rasvir, ribavirin, stampidine, stavudinecet (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine, valacyclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f) Non-nucleosides: amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphorylformate), imiquimod, interferon alpha, loviride, rhodenosine, methisazone, nevirapine, NOV-205, peginterferon alpha, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g) Protease inhibitors: amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h) Other antivirals: abzyme, arbidol, calanolide A, ceragenin, cyanovirin-N, diarylpyrimidine, epigallocatechin gallate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib; 5) Radioisotopes (radionuclides): 3 H. 11 C. 14 C. 18 F. 32 P. 35 S. 64 Cu, 68 G.A. 86 Y. 99 Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 133 Xe, 177 Lu, 211 At, and 213 Bi; 6) Pharmaceutically acceptable salts, acids, or derivatives of any of the above drugs.

4. 2. The method of claim 1, wherein the reduced thiol group in the antibody or antibody-like protein of step (a) is reacted simultaneously or sequentially with a drug / linker conjugate of formula (I), (II), (III), or (IV), respectively, to produce a conjugate of formula (VI), (VII), (VIII), or (IX), as depicted below: [C11] In the formula, n is 1 to 20; n' is 1 to 10; D 1 , D 2 , L 1 , L 1’ , L 2 , L 2’ , and E 1 is the same as the definition in claim 3; S (sulfur) is generated by reducing a disulfide bond in an antibody or antibody-like protein; mAb is an antibody or antibody-like protein; Lv 1’ and Lv 2’ independently has one of the following structures: [C12] In the formula, Ar, 2’ and R 3 has the same definition as in claim 3; In formulae (VII), (VII) and (IX), [C13] is independently selected from: [C14] [ka] [ka] [ka] [ka] In the formula, R 1 , R 2 , and X 2 has the same definition as above; mAb is an antibody or antibody-like protein.

5. The thiol group of the antibody or antibody-like protein produced in step (a) is reacted with a condensation compound having the following structural formula (X), (XI), (XII), or (XIII) and a drug, D 1 And / or D 2 2. The method of claim 1 , wherein the compound is a cyclic alkyl group, and the compound is a cyclic alkyl group. [C15] In the ceremony, L 1 , L 1’ , L 2 , L 2’ , E 1 , Lv 1 , and Lv 2 is as defined in the claims; Lv 5 and Lv 6 is independently selected from: [C16] [ka] During the ceremony, X 1’ is F, Cl, Br, I, OTs (tosylate), OTf (triflate), OMs (mesylate), OC 6 H 4 (NO 2 ), O.C. 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 H.F. 4 , or Lv 3 is; 2’ is O, NH, N(R 1 ), or C.H. 2 is; R 3 and R 5 are independently H, R 1 , aromatic, heteroaromatic, or one or several H atoms are independently -R 1 , -halogen, -OR 1 , -SR 1 , -NR 1 R 2 , -NO 2 , -S(O)R 1 , -S(O) 2 R 1 , or -COOR 1 Lv is an aromatic group substituted by 3 and Lv 3’are independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl; N-hydroxysuccinimide (NHS); phenoxyl; benzenethiol, dinitrophenoxyl; pentafluorophenoxyl; tetrafluorophenoxyl; difluorophenoxyl; monofluorophenoxyl; pentachlorophenoxyl; triflate; imidazole; dichlorophenoxyl; tetrachlorophenoxyl; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3′-sulfonate, anhydrides formed with themselves or with other anhydrides selected from acetyl anhydride and formyl anhydride, or intermediate molecules generated with condensation reagents for peptide coupling reactions or Mitsunobu reactions; 1 Or Lv 2 and the thiol in the antibody or antibody-like protein, the functional group Lv 5 And / or Lv 6 can also react with thiols in cytotoxic agents.

6. The method of claims 4 and 5, wherein an antibody / conjugate conjugate molecule of formula (XIV), (XV), (XVI), or (XVII) as shown below is generated by reaction of a reduced thiol group in an antibody or antibody-like protein with a conjugate of formula (X), (XI), (XII), or (XIII), which is then reacted independently with a drug to form a conjugate of formula (VI), (VII), (VIII), or (IX): [C17] In the formula, Lv 5 , Lv 6 , L 1 , L 2 , L 1’ , L 2’ , E 1 , Lv 1’ , Lv 2’ , mAb, n, and n′ have the same definitions as in claims 3 and 7.

7. In formula (VI), [C18] In formula (VII), [C19] In formula (VIII), [C20] In formula (IX), [C21] A conjugate of formula (VI), (VII), (VIII), or (IX) according to claim 4, wherein each of [C22] [ka] [ka] [ka] During the ceremony, [C23] is a drug or a linker L 1 Or L 2 "#" is the site of attachment to an antibody S (thiol), O (phenol), NH (amino), CHO (aldehyde), C(=O) (ketone), C(O)(NH) (amide), C(O)(OH) (carboxylate); Aa is an L- or D-natural or unnatural amino acid; R 1 , R 1’ , R 2 , and R 2’ are independently H, C 1 -C 8 Alkyl, OH, CH 2 O.H., C.H. 2 CH 2 O.H., N.H. 2 , S.H., S.C.H. 3 , C.H. 2 COOH, CH 2 CH 2 COOH, CH 2 CH 2 CH 2 CH 2 N.H. 2 , C 6 H 5 , C.H. 2 C 6 H 5 , C.H. 2 C 6 H 4 OH, CH(OH)CH 3 , C.H. 2 C(O)NH 2 , C.H. 2 CH 2 C(O)NH 2 , C.H. 2 CH 2 CH 2 NHC (=NH)NH 2 Selected from: r,r 1 , r 1’ , r 2 , and r 2’ are each independently 0 to 12; when r is not 0, (Aa)r is an amino acid or peptide unit of the same or different sequence; m 1 and m 1’ are independently 1 to 18; 2 and m 2’ are independently 1 to 100; m 3 and m 3’ are independently 1 to 8; 4 and m 4’ are independently 0 to 8; 5 and m 5’ are independently 1-8; Y 7 and Y 7’ NH, OCH 2 NH, NHC(=O), NHNH, C(=O)NH, N(R 1 ), S.O. 2 , P(O)(OH), NHS(O) 2 , N.H.S. (O) 2 NH, NHS (O) 2 NHC (O), NHS (O) 2 NHC(O)O, NHS(O) 2 NHC(O)NH, NHP(O)(OH), NHP(O)(OH)NH, OP(O)(OH)O, NHP(O)(OH)O, OP(O)(OH)NH, S ,O,OP(O)(OH)OP(O)(OH)NH,NHP(O)(OH)OP(O)(OH)NH,NHP(O)(OH)OP(O)(OH)O,OCH 2 CH 2 O, OCH 2 CH 2 NH, N(CH 2 CH 2 ) 2 N, N.H.C. 6 H 4 N.H., C.H. 2 is; Y 8 and Y 8’ are NHC(=O), NHS(O 2 ), NH(SO), NHS(O 2 )NH, NHP(O)(OH)NH, or C(O)NH; Y 9 and Y 9’ is H, (O=)CR 1 , (O=)CNHR 1 , R 1 COOH, R 1 (COCH 2 N H) m 2 H, R 1 (Aa) r or R 1 (COCH 2 NCH 3 ) m2 H, where R 1 is defined above.

8. Drug D 1 , D 2 , D 3 , D 4 are chromophore molecules that have the ability to absorb UV light, fluorescent light, IR light, near-IR light, and visible light; xanthophores, erythrophores, iridophores, leucophores, melanophores, and cereus; a class or subclass of fluorescent molecules, which are fluorescent chemicals that re-emit light with light; a class or subclass of visual light sensitive molecules; a class or subclass of light emitting molecules; a class or subclass of luminescent molecules; and a class or subclass of luciferin compounds; The chromophore molecules include non-proteinaceous organic fluorophores such as: xanthene derivatives (including fluorescein, rhodamine, Oregon Green, eosin, and Texas Red); cyanine derivatives (including cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, and merocyanine); squalene derivatives and ring-substituted squaraines (including Seta, SeTau, and Square dyes); naphthalene derivatives (including dansyl and prodan derivatives); coumarin derivatives; oxadiazole derivatives (including pyridyloxazole, nitrobenzoxadiazole, and benzoxadiazole); anthracene derivatives (including anthraquinones, including DRAQ5, DRAQ7, and CyTRAK Orange); pyrene derivatives (Cascade Blue); oxazine derivatives (including Nile Red, Nile Blue, Cresyl Violet, and Oxazine 170); and acridine derivatives (including proflavine, acridine orange, and acridine yellow). Arylmethine derivatives (including auramine, crystal violet, malachite green), tetrapyrrole derivatives (including porphine, phthalocyanine, bilirubin); The chromophore molecules can be selected from analogs and derivatives of the following fluorophore compounds: CF dyes, DRAQ and CyTRAK probes, BODIPY, Alexa Fluor, DyLight Fluor, Atto and Trancey, FluoProbes, Abberior dyes, DY and MegaStokes dyes, SulfoCy dyes, HiLyte Fluor, Seta, SeTau and Square dyes, Quasar and Cal. Flour dyes, SureLight dyes (APC, RPEPerCP, phycobilisome), APC, APCXL, RPE, BPE, allophycocyanin (APC), aminocoumarin, APC-Cy7 conjugates, BODIPY-FL, Cascade Blue, Cy2, Cy3, Cy3.5, Cy3B, Cy5, Cy5.5, Cy7, fluorescein, FluorX, hydroxycoumarin, Lissamine rhodamine B, Lucifer Yellow, methoxycoumarin, NBD, Pacific Blue, Pacific Orange, PE-Cy5 conjugate, PE-Cy7 conjugate, PerCP, R-Phycoerythrin (PE), Red613, Seta-555-azide, Seta-555-DBCO, Seta-555-NHS, Seta-580-NHS, Seta-680-NHS, Seta-780-NHS, Seta-APC-780, Seta-PerCP-680, Seta-R-PE-670, SeTau380-NHS, SeTau405-maleimide, SeTau405-NHS, SeTau425-NHS, SeTau647-NHS, Texas Red, TRITC, T ruRed, X-rhodamine, 7-AAD (7-aminoactinomycin D, CG selective), acridine orange, chromomycin A3, CyTRAK orange (red excitation dark), DAPI, DRAQ5, DRAQ7, ethidium bromide, Hoechst 33258, Hoechst 33342, LDS751, mithramycin, propidium iodide (PI), SYTOX blue, SYTOX green, SYTOX orange, thiazole orange, TO-PRO: cyanine monomer, TOTO-1, TO-PRO-1, TOTO-3, TO-PRO-3, YOYO-1, YO-1;Fluorescent dyes including the following compounds or their derivatives: DCFH (2′7′-dichlorodihydro-fluorescein, oxidized form), DHR (dihydrorhodamine 123, oxidized form, photocatalytic oxidation), Fluo-3 (AM ester, pH>6), Fluo-4 (AM ester, pH 7.2), Indo-1 (AM ester, low / high calcium (Ca; 2+ )), SNARF (pH 6 / 9), the method of claim 4.

9. Drug D 1 , D 2 , D 3 , D 4 are independently a polyalkylene glycol selected from poly(ethylene glycol) (PEG), poly(propylene glycol), and copolymers of ethylene oxide and propylene oxide; said polyalkylene glycol having a molecular weight of from about 10 Daltons to about 200 kDa.

10. Drug D 1 , D 2 , D 3 , and D 4However, the present invention is not limited to tubulysin and its analogues, maytansine and its analogues, taxanes and its analogues, CC-1065 and its analogues, daunorubicin or doxorubicin and its analogues, amatoxin and its analogues, benzodiazepine dimers (dimers of pyrrolobenzodiazepines (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinobenzodiazepines) and their analogues, calicheamicin and enediyne antibiotic analogues, actinomycin, and its analogs, azaserine and its analogs, bleomycin and its analogs, epirubicin and its analogs, tamoxifen and its analogs, idarubicin and its analogs, dolastatins and its analogs, auristatins (including monomethylauristatin (MMAE), MMAF, auristatin PYE, auristatin TP, auristatin 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)) and their analogs, combretastatins, duocarmycins and their analogs, camptothecins and and analogs thereof, geldanamycin and analogs thereof, methotrexate and analogs thereof, thiotepa and analogs thereof, vindesine and analogs thereof, vincristine and analogs thereof, hemiasterin and analogs thereof, nazmamide and analogs thereof, spliceostatin, pladienolide, microginin and analogs thereof, radiosumin and analogs thereof, alterobactin and analogs thereof, microsclerodermin and analogs thereof, theonellamide and analogs thereof, esperama isin and its analogs, PNU-159682 and its analogs, protein kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, immunotoxins, specific cell receptor agonists, cell stimulatory or intracellular signaling molecules, one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA), as well as stereoisomers, equivalents, analogs, or derivatives of the above-mentioned drugs; (a) Tubulysin and its analogs, or derivatives having one or more isotopes, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures, or optical isomers, racemates, diastereomers, or enantiomers thereof, having the following formula (V): [C24] During the ceremony, [C25] is independent, L 1 And / or L 2 is a binding site that binds to; [C26] Two of them are L 1 and L 2 , R 1 and R 2 , or Z 2 and Z 3 When it binds to both: R 1 , R 2 , R 3 , and R 4 are independently H, C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl or heterocycle; C 3 ~C 8 Ar is aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or R 1 R 2 , R 1 R 3 , R 2 R 3 , R 3 R 4 , R 5 R 6 , R 11 R 12 , or R 13 R 14 form a 3- to 7-membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; L 1 Or L 2When independently or simultaneously bound to R 1 and R 2 may be independently absent; Y 1 is N or CH; R 5 , R 6 , R 8 , R 10 , and R 11 are independently H or C 1 ~C 4 alkyl or heteroalkyl; R 7 are independently H, R 14 , -R 14 C(=O)X 1 R 15 or -R 14 X 1 R 15 is; 1 is O, S, SS, NH, CH 2 , or NR 14 is; R 9 is H, OH, -O-, =O, -OR 14 , -OC(=O)R 14 , -OC(=O)NHR 14 -, -OC(=O)R 14 SSR 15 -, OP (=O) (OR 14 )-, -OC(=O)NR 14 R 15 ,OP(=O)(OR 14 ), or OR 14 OP(=O)(OR 15 ) selected from R 11 are independently H, R 14 , -R 14 C(=O)R 15 , -R 14 C(=O)X 2 R 15 wherein X 2 is -O-, -S-, -NH-, or -N(R 14 )-is; R 12 is R 1 , -OH, -SH, -NH 2 , N.H., N.H. 2 , -NH(R 15 ), -OR 15 , -R 15 C.O.R. 16 , -R 15 COOR 16 , -R 15 C(O)NH 2 , -R 15 C(O)NHR 17 , -SR 16 , R 15 S(=O)R 16 , -R 15 P(=O)(OR 17 ) 2 , -R 15 OP(=O)(OR 17 ) 2 , -CH 2 OP(=O)(OR 17 ) 2 , -R 15 SO 2 R 17 , -R 15 X 2 R 16 , -R 15 C(=O)X 2 wherein X 2 is -O-, OH, SH, -S-, NH 2 , -NH-, -N(R 15 ) -, -O-R 15 -, -S-R 15 -, -S(=O)-R 15 -, CH 2 , or -NHR 15 - is; R 13 and R 14 are independently H, O, S, NH, N(R 15 ), NHNH, -OH, -SH, -NH 2 , N.H., N.H. 2 , -NH(R 15 ), -OR 15 , CO, -COX 2 , -COX 2 R 16 , R 17 ,F,Cl,Br,I,SR 16 , N.R. 16 R 17 , N=NR 16, N=R 16 , NO 2 , S.O.R. 16 R 17 , S.O. 2 R 16 , S.O. 3 R 16 , OSO 3 R 16 , P.R. 16 R 17 , P.O.R. 16 R 17 , P.O. 2 R 16 R 17 , OP(O)(OR 17 ) 2 , O.C.H. 2 OP(O)(OR 17 ) 2 , O.C.(O)R 17 ,OC(O)OP(O)(OR 17 ) 2 , PO(OR 16 ) (OR 17 ), OP(O)(OR 17 ) OP (O) (OR 17 ) 2 , O.C.(O)N.R. 17 -O-(C 4 ~C 12 Glycoside), -N-(C 4 ~C 12 Glycoside); C 1 ~C 8 Alkyl, heteroalkyl; 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; 3 ~C 8 Aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, or an ester, ether, or amide having 2 to 8 carbon atoms; or a peptide containing 1 to 8 amino acids (NH(Aa) 1~8 Or CO(Aa) 1~8 (N-terminus or C-terminus (Aa) r , r=1 to 8 identical or different amino acid sequences), or 2 CH 2 ) p Or (OCH 2CH (CH 3 )) p where p is an integer from 0 to about 1000, or a combination of the above groups; X 2 is O, S, SS, NH, CH 2 , O.H., S.H., and N.H. 2 , CHR 1 , or N.R. 1 It is. R 15 , R 16 , and R 17 are independently H, C 1 ~C 8 Alkyl, heteroalkyl; 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; 3 ~C 8 Aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, alkylcarbonyl, or Na + , K + , Cs + , Li + , Ca 2+ , Mg + , Zn 2+ , N + (R 1 ) (R 2 ) (R 3 ) (R 4 ), or HN + (C 2 H 5 O.H. 3 It is salt; Y 1 and Y 2 is independently N or CH; q is 0 or 1; when q=0, Y 3 does not exist, and Y 4 , Y 5 , Y 6 , and Y 7 are independently CH, N, NH, O, S, or N(R1), so that Y 2 , Y 4 , Y 5 , Y 6 , and Y 7form a heteroaromatic ring of furan, pyrrole, thiophene, thiazole, oxazole, imidazole, pyrazole, triazole, tetrazole, thiadiazole; when q=1, Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 are independently CH or N, so that Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 forms an aromatic ring in benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine, or pentazine; In particular, tubulysin analogs have the structure shown below: [C27] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] During the ceremony, R 20 is H;C 1 ~C 8 A linear or branched alkyl or heteroalkyl group of 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 or a carboxylate, ester, ether, or amide having 1 to 8 carbon atoms; or an amino acid having 1 to 8 carbon atoms; or a group represented by the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 1000; or 20 is absent and the oxygen atom forms a ketone, or a combination of the above; Z 2 and Z 3 are independently H, OH, NH 2 , O, NH, COOH, COO, C(O), C(O), C(O)NH, C(O)NH 2 , R 18 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO (OR 18 ) 2 , NHPO (OR 18 ) 2 , OP(O)(OR 18 ) OP (O) (OR 18 ) 2 , O.C.(O)R 18 , O.C.(O)N.R. 18 , OSO 2 (OR 18 ), O-(C 4 ~C 12 -glycoside), C 1 ~C 8 Linear or branched alkyl or heteroalkyl of C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl, C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 19 is H, OH, NH 2 , OSO 2 (OR 18 ), X.H.H. 2 OP(O)(OR 18 ) 2 , XPO(OR 18 ) 2 ,XC(O)OP(O)(OR 18 ) 2 , XC(O)R 18 , XC(O)NHR 18 , C 1 ~C 8 Alkyl or carboxylate; C 2 ~C 8 Alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 aryl or alkylcarbonyl; or a pharmaceutical salt; X is O, S, NH, NHNH, or CH 2 is; R 7 H, R 14 , -R 14 C(=O)X 1 R 15 or -R 14 X 1 R 15 is; 1 is O, S, SS, NH, CH 2 , or NR 14 R 14 and R 15 is independent, C 1 ~C 8 Alkyl, heteroalkyl; 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; 3 ~C 8 Aryl, Ar-alkyl; Bonding sites in formulae (IV-01) to (IV-94) [C28] is as defined in claim 4; (b) calicheamicin and related enediyne antibiotics having the formula: [C29] (c) maytansinoids or derivatives thereof represented by the following formula: [C30] (d) Camptothecin (CPT) or a derivative thereof represented by the following formula: [C31] During the ceremony, R 1 , R 2 , and R 4 are independently H, F, Cl, Br, CN, NO 2 , C 1 ~C 8 Alkyl; O-C 1 ~C 8 Alkyl; NH-C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; R 3 is H, OH, NH 2 , C 1 ~C 8 Alkyl; O-C 1 ~C 8 Alkyl; NH-C 1 ~C 8 Alkyl; C 2 ~C 8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; or an ester, ether, amide, carbonate, urea, or carbamate having from 2 to 8 carbon atoms; Or, R 1 R 2 , R 2 R 3 , and R 3 R 4 independently form a 5-7 membered carbocyclic, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; [C32] L 1 , L 2 , L 1’ , and L 2’ It is an internal site of the molecule that can bind to (e) a combretastatin which may have the formula: [C33] (f) a taxane having the formula: [C34] During the ceremony, [C35] L 1 , L 1’ , L 2 , or L 2’ Ar and Ar' are independently aryl or heteroaryl. (g) Anthracyclines having the formula: [C36] [ka] (h) the vinca alkaloid is selected from vinblastine, vincristine, vindesine, leurosine, vinorelbine, catharanthine, vindoline, vincaminol, vineridine, minovincine, methoxyminovincine, minovincine, vincadifformine, desoxyvincaminol, vincamazine, vincamine, vinpocetine, and vinbrunin and has the formula: [C37] [ka] (i) dolastatin and peptide analogs and derivatives thereof are selected from dolastatin 10, dolastatin E (AE), dolastatin EB (AEB), dolastatin EFP (AEFP), MMAD (monomethylauristatin D or monomethylauristatin 10), MMAF (monomethylauristatin F or N-methylvaline-valine-dolaisoleucine-dolaproine-phenylalanine), MMAE (monomethylauristatin E or N-methylvaline-valine-dolaisoleucine-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), auristatin F phenylenediamine (AFP), having the formula: or one or more isotopes of chemical elements, or a pharma- ceutically acceptable salt, hydrate or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer; [C38] [ka] [ka] During the ceremony, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C 1 ~C 8 a linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 1 to about 1000; 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 may be taken together to form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; Y 1 and Y 2 is the connection site (L 1 , L 1’ , L 2 , and / or L 2’ (which binds independently to [C39] and independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NHR 1 or a connection site [C40] If not bonded to OH, NH 2 , N.H.N.H. 2 , N.H.R. 5, SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )(C(O)NH(R 2 ), C(O)NHNH C(O)OH, and C(O)NH R 1 ; R 12 is OH, NH 2 , NHR 1 , NHNH 2 , NHNHCOOH, O-R 1 -COOH, NH-R 1 -COOH, NH-(Aa) n COOH, O(CH 2 CH 2 O) p CH 2 CH 2 OH, O(CH 2 CH 2 O) p CH 2 CH 2 NH 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 , NR 1 R 1’ , NHOH, NHOR 1 , O(CH 2 CH 2 O) p CH 2 CH 2 COOH, NH(CH 2 CH 2 O) p CH 2 CH 2 COOH, NH-Ar-COOH, NH-Ar-NH 2 , O(CH 2 CH 2 O) p CH 2 CH 2 NHSO 3 , NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p CH 2 CH 2 P. 3 H 2 NH(CH 2 CH 2 O) p CH 2 CH 2 P. 3 H 2 OR 1 、R 1 -NHPO 3 H 2 、R 1 -OPO 3 H 2 O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 OR 1 -NHPO 3 H 2 NH-R 1 -NHPO 3 H 2 NH(CH 2 CH 2 NH) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 S) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 NH) p CH 2 CH 2 Hmm, Hmm 2 CH 2 S) p CH 2 CH 2 OH, NH-R 1 -NH 2 , or NH(CH 2 CH 2 O) p CH 2 CH 2 N.H.P.O. 3 H 2 where Aa is 1 to 8 identical or different amino acids; p is 1 to 1000; R 1 , R 2 , R 3 , R 4 , R 5 , R 5’ , Z 1 , Z 2 , and n are as defined above. (j) Hemiasterlin and its analogs having the following formula: [C41] During the ceremony, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C 1 ~C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 1 to about 5000; 2 R 3 can form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group. (k) Eribulin, having the formula: [C42] (l) Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors having the following formulas NP01, NP02, NP03, NP04, NP05, NP06, NP07, NP08, and NP09, or one or more isotopes of chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers: [C43] During the ceremony, [C44] is the same as above; X 5 is F, Cl, Br, I, OH, OR 1 , R 1 , O.P.O. 3 H 2 , OSO 3 H, N.H.R. 1 , O.C.O.R. 1 , NHCOR 1 It is. (m) Benzodiazepine dimers and analogs thereof having the formula PB01, PB02, PB03, PB04, PB05, PB06, PB07, PB08, PB09, PB10, PB11, PB12, PB13, PB14, PB15, PB16, PB17, PB18, PB19, PB20, PB21, PB22, PB23, PB24, PB25, PB26, PB27, and PB28, or isotopes of one or more chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers: [C45] [ka] [ka] [ka] [ka] During the ceremony, X 1 , X 2 , Y 1 , Y 2 , Z 1, Z 2 and n are as defined above; preferably, X 1 , X 2 , Y 1 , and Y 2 are independently O, N, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), CH, C(O)NHNHC(O), and C(O)NR 1 is; R 1 , R 2 , R 3 , R 1’ , R 2’ , and R 3’ are independently H; F; Cl; =O; =S; OH; SH; C 1 -C 8 Linear or branched alkyl, aryl, alkenyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester (COOR 5 or -OC(O)R 5 ), ester (OR 5 ), amide (CONR 5 ), carbamates (OCONR 5 ), amine (NHR 5 , N.R. 5 R 5’ ), heterocycloalkyl, or acyloxylamine (-C(O)NHOH, -ONHC(O)R 5 ); or a peptide comprising 1 to 20 natural or unnatural amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 1 to about 5000; 1 R 2 , R 2 R 3 , R 1 R 3 , R 1’ R 2’ , R 2’ R 3’ , or R 1’ R 3’ can independently form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 and Y 3 are independently N, NH, CH 2 , or C.R. 5 or X 3 and Y 3 Any one of may be absent; R 1 and R 2 is C 1 -C 8 Linear or branched alkyl, heteroalkyl; 3 -C 8 Aryl, heteroaryl, alkylcycloalkyl, acyloxyl, alkylaryl, alkylaryloxyl, alkylarylamino, alkylarylthiol; or 1-6 identical or different amino acids / peptides (Ar)r (r=1-6); R 4 , R 5 , R 5’ , R 6 , R 12 , and R 12’ are independently H, OH, NH 2 , NH(CH 3 ), N.H.N.H. 2 , COOH, SH, OZ 3 , S.Z. 3 , F, Cl, or C 1 -C 8 Linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine; Z 3 is H, OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1, or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N.R. 1 R 2 R 3 is; X 6 are CH, C(O), N, P(O)NH, P(O)NR 1 , CHC(O)NH,C 1 ~C 8 a straight or branched alkyl or heteroalkyl of 3 ~C 8 Aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, or Aa (amino acid, preferably selected from Lys, Phe, Asp, Glu, Ser, Thr, His, Cys, Tyr, Trp, Gln, Asn, Arg); [C46] is either a single bond or a double bond; [C47] is the same as defined above; (n) CC-1065 analogs and doucarmycin analogs having structures of formulas CC01, CC02, CC03, CC04, CC05, CC06, and CC07: [C48] [ka] X 1 , X 2 , Y 1 , and Y 2 is the connection site [C49] and independently O, NH, NHNH, NR 5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 or a connection site [50] If not bonded to OH, NH 2 , N.H.N.H. 2 , N.H.R. 1 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 is; Z 3 , H, PO (OM 1 ) (O.M. 2 ), S.O. 3 M 1 , C.H. 2 PO (OM 1 ) (O.M. 2 ), C.H. 3 N (CH 2 CH 2 ) 2 NC(O)-, O(CH 2 CH 2 ) 2 N-C(O)-, R 1 or a glycoside; R 1 , R 2 , R 3 , M. 1 , M. 2 , and n are as defined above. (o) Amatoxin and its analogs, or isotopic substitutions of one or more chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polycrystalline structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers, having the following formulae Am01, Am02, Am03, and Am04: [C51] During the ceremony, X 1 and Y 1 are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , CHNH, CH 2 O, C(O)NHNHC(O), and C(O)NR 1 is; R 7 , R 8 , and R 9 are independently H, OH, OR 1 , N.H. 2 , N.H.R. 1 , C 1 ~C 6 Alkyl, or lacking; Y 2 , O, O 2 , N.R. 1 , NH, or absent; R 10 is CH 2 , O., N.H., N.R. 1 , NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR 1 ), (NR 1 ) C(O)(NR 1 ), C(O)R 1 , or lacking; R 11 OH, NH 2 , N.H.R. 1 , N.H.N.H. 2 ,NHNHCOOH,OR 1-COOH、NH-R 1 -COOH、NH-(Aa) r COOH, O(CH 2 CH 2 O) p CH 2 CH 2 Hmm, Hmm 2 CH 2 O) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 NR 1 R 2 O(CH 2 CH 2 O) p CH 2 CH 2 -COOH, A. 2 CH 2 O) p CH 2 CH 2 COOH、NH-Ar-COOH、NH-Ar-NH 2 O(CH 2 CH 2 O) p CH 2 CH 2 -NHSO 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p -CH 2 CH 2 P. 3 H 2 NH(CH 2 CH 2 O) p CH 2 CH 2N.H.P.O. 3 H 2 , OR 1 , R 1 -NHPO 3 H 2 , R 1 -OPO 3 H 2 , O(CH 2 CH 2 O) p CH 2 CH 2 O.P.O. 3 H 2 , OR 1 -NHPO 3 H 2 , N.H.-R. 1 -NHPO 3 H 2 , or NH(CH 2 CH 2 O) p CH 2 -CH 2 N.H.P.O. 3 H 2 where: (Aa) r is 1 to 8 amino acids; n and m 1 is independently 1 to 20; p is 1 to 5000; R 1 , R 2 and Ar are defined as throughout this application; [C52] is the same as the definition above. (p) The spliceostatins and pladienolides are spliceostatin A, FR901464, and (2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-hydrazinyl-2-oxoethyl)-4-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl-1}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate, pladienolide B, pladienolide D, and E7107, which have the core structure of Sp-01: [C53] (q) Protein kinase inhibitors include PK01 to PK40 having the following structures: adavosertib, afatinib, axitinib, bafitinib, bosutinib, cometinib, crizotinib, cabozantinib, dasatinib, entrex erlotinib, erdafitinib, erlotinib, fostatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, and nilotinib. The present invention is selected from the group consisting of ribociclib, pazopanib, ponatinib, ponatinib, revastinib, regorafenib, ruxolitinib, sorafenib, sunitinib, SU6656, tofacitinib, vandervemurafenib, entrectinib, palbociclib, ribociclib, aveciclib, dacomitinib, neratinib, rociletinib (CO-1686), osimertinib, AZD3759, and nazatinib (EGF816): [C54] [ka] [ka] [ka] [ka] [ka] During the ceremony, Z 5 and Z 5’ are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 R is selected from 1 and R 2 , and Ar are defined as above. (r) MEK inhibitors selected from PD0325901, selumetinib (AZD6244), cobimetinib (XL518), lefatinib, trametinib (GSK1120212), pimasertib, binimetinib (MEK162), AZD8330, RO4987655, RO5126766, WX-554, E6201, GDC-0623, PD-325901, and TAK-733, having the following structure: [C55] During the ceremony, Z 5 is O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2) , C(O)NHNHC(O), and C(O)NR 1 R is selected from 1 and R 2 is the same as the definition above. (s) the protease inhibitor is selected from carfilzomib, clindamycin, retapamulin, and indibulin, which have the following structures: [C56] (t) geldanamycin or a derivative thereof having the formula: [C57] (u) an immunotoxin selected from diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA), erythrogenic toxin, diphtheria toxin, AB toxin, type III exotoxin, prohemolysin, and apihemolysin; (v) The cell receptor agonist or cell stimulating molecule is selected from the following: folic acid derivatives; glutamic acid urea derivatives; somatostatin and its analogs (selected from the group consisting of octreotide (sandostatin) and lanreotide (somatilin)); aromatic sulfonamides; pituitary adenylate cyclase activating peptide (PACAP) (PAC1); vasoactive intestinal peptide (VIP / PACAP) (VPAC1, VPAC2); melanocyte stimulating hormone (α-MSH); cholecystokinin (CCK) / gastrin receptor agonist, bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 Neurotensin receptor ligands (NTR1, NTR2, NTR3), substance P (NK1 receptor) ligands; neuropeptide Y (Y1-Y6); homing peptides including RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), dimeric and multimeric cyclic RGD peptides (cRGDfV), TAASGVRSMH, and LTLRWVGLMS (chondroitin sulfate proteoglycan NG2 receptor ligand), and F3 peptide; cell membrane permeable peptides Peptides (CPPs); peptide hormones, luteinizing hormone releasing hormone (LHRH) agonists and antagonists, and gonadotropin releasing hormone (GnRH) agonists that act by targeting follicle stimulating hormone (FSH) and luteinizing hormone (LH) as well as testosterone production, such as buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ), goserelin (Pyr-His-Trp-Ser-)Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH 2), histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH 2 ), Triptorelin (Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 ), nafarelin, deslorelin, abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH 2 ), Cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH 2 ), degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carbamoyl)-Leu-isopropylLys-Pro-D-Ala-NH 2 ), and ganirelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-(N9,N10-diethyl)-homoArg-Leu-(N9,N10-diethyl)-homoArg-Pro-D-Ala-NH 2 ); pattern recognition receptors (PRRs) selected from Toll-like receptor (TLR) ligands, C-type lectins, and Nodlike receptor (NLR) ligands; calcitonin receptor agonists; integrin receptors and their receptor subtypes (α V β 1 , α V β 3 , α V β 5 , α V β 6 , α 6 β 4 , α 7 β 1 , α L β 2 , α IIb β 3 agonists (selected from the group consisting of GRGDSPK, cyclo(RGDfV)(L1) and its derivatives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo(RG-N(Me)D-fV), cyclo(RGD-N(Me)f-V), cyclo(RGDf-N(Me)V-)(cilengitide)]; anticalins (derivatives of lipocalin); adnectins (tenth FN3 (fibronectin)); designed ankyrin repeat proteins (DARPins); avimers; EGF receptor or VEGF receptor agonists; Specific small molecules of cell receptor agonists are selected from the following: LB01 (folic acid), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (somatostatin), LB06 (somatostatin), LB07 (octreotide, somatostatin analog), LB08 (ramareotide, somatostatin analog), LB09 (vapreotide (sambar), somatostatin analog), LB10 (CAI), LB11 (CAI), LB12 (CAI), LB13 (CAI), LB14 (CAI), LB15 (CAI), LB16 (CAI), LB17 (CAI), LB18 (CAI), LB19 (CAI), LB20 (CAI), LB21 (CAI), LB22 (CAI), LB23 (CAI), LB24 (CAI), LB25 (CAI), LB26 (CAI), LB27 (CAI), LB28 (CAI), LB29 (CAI), LB30 (CAI), LB31 (CAI), LB32 (CAI), LB33 (CAI), LB34 (CAI), LB35 (CAI), LB36 (CAI), LB37 (CAI), LB38 (CAI), LB39 (CAI), LB40 (CAI), LB41 (CAI), LB42 (CAI), LB43 (CAI), LB44 (CAI), LB45 (CAI), LB46 (CAI), LB47 (CAI), LB48 (CAI), LB49 (CAI), LB50 (CAI), LB51 (CAI), LB52 (CAI), LB53 (CAI), LB54 (CAI), LB55 (CAI), LB56 (CAI), LB57 (CAI), LB5 X ligand), LB11 (CAIX ligand), LB12 (gastrin releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone releasing hormone (LH-RH) ligand and GnRH), LB14 (luteinizing hormone releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (α v β 3 for integrin receptors), LB19 (heterobivalent peptide ligand for VEGF receptors), LB20 (neuromedin B), LB21 (bombesin for G protein-coupled receptors), LB22 (TLR for Toll-like receptors), 2 ), LB23 (for androgen receptor), LB24 (α vCilengitide / cyclo(-RGDfV-) for integrin receptors), LB23 (fludrocortisone), LB25 (rifabutin analog), LB26 (rifabutin analog), LB27 (rifabutin analog), LB28 (fludrocortisone), LB29 (dexamethasone), LB30 (fluticasone propionate), LB31 (beclomethasone dipropionate), LB32 (triamcinolone acetonide), LB33 (prednisone), LB34 (prednisolone), LB35 (methylprednisolone), LB36 (betamethasone), LB37 (irinotecan analog), LB3 8 (crizotinib analog), LB39 (bortezomib analog), LB40 (carfilzomib analog), LB41 (carfilzomib analog), LB42 (leuprolide analog), LB43 (triptorelin analog), LB44 (clindamycin), LB45 (liraglutide analog), LB46 (semaglutide analog), LB47 (retapamulin analog), LB48 (indibulin analog), LB49 (vinblastine analog), LB50 (lixisenatide analog), LB51 (osimertinib analog), LB52 (nucleoside analog), LB53 (erlotinib analog), or LB54 (lapatinib analog); [C58] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] In the formula, X 4 and Y 1 are independently O, NH, NHNH, NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 R 1 and R 2 has the same definition as above; (w) one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA): [C59] [60] is the site of attachment of the side chain linker; [61] is a single or double strand of DNA, RNA, mRNA, siRNA, miRNA, or piRNA; X 1 and Y is independently O, NH, NHNH, NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 R 1 and R 2 has the same definition as above.

11. 5. The method of claim 1, 3, or 4, wherein the antibody or antibody-like protein is selected from: (A) the group consisting of probodies, nanobodies, peptides, polymeric micelles, liposomes, lipoprotein-based drug carriers, nanoparticle drug carriers, dendrimers, and the above molecules or particles conjugated to or coated with cell-binding ligands, or combinations thereof; (B) full length antibodies (polyclonal antibodies, monoclonal antibodies, dimers, multimers), multispecific antibodies (selected from bispecific antibodies, trispecific antibodies, or tetraspecific antibodies); single chain antibodies, antibody fragments that bind to target cells, monoclonal antibodies, single chain monoclonal antibodies, monoclonal antibody fragments that bind to target cells, chimeric antibodies, chimeric antibody fragments that bind to target cells, domain antibodies, domain antibody fragments that bind to target cells, resurfaced antibodies, single chain resurfaced antibodies, resurfaced antibody fragments that bind to target cells, human the group consisting of: humanized or resurfaced humanized antibodies, single chain humanized antibodies or humanized antibody fragments binding to target cells, anti-idiotypic (anti-Id) antibodies, CDRs, dimers, trimers, tetramers, miniantibodies, probodies, probody fragments, small immune proteins (SIPs), lymphokines, hormones, vitamins, growth factors, colony stimulating factors, nutrient transport molecules, large molecular weight proteins, fusion proteins, kinase inhibitors, gene targeting drugs, and nanoparticles or polymers modified with antibodies or large molecular weight proteins; (C) the group consisting of IgG antibodies capable of binding to tumor cells, virus-infected cells, microbial-infected cells, parasite-infected cells, autoimmune disease cells, activated tumor cells, bone marrow cells, activated T cells, affected B cells, or melanocytes, or to non-normal cells expressing one or more of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD12w , CD14, CD15, CD16, CD16a, CD16b, CDw17, CD18, CD19, CD20, CD21, CD22, CD2 3, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD32a, CD32b, CD3 3, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD42a, CD42b, CD4 2c, CD42d, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD49c, CD49d, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, C D60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD65, CD65s, C D66, CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD67, CD68, CD69, CD70, CD 71, CD72, CD73, CD74, CD74, CD75, CD75s, CD76, CD77, CD78, CD79, CD79a, CD7 9b, CD80, CD81, CD82, CD83, CD84, CD85, CD85a, CD85b, CD85c, CD85d, CD85e , CD85f, CD85g, CD85g, CD85i, CD85j, CD85k, CD85m, CD86, CD87, CD88, CD89 , CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101 , CD102, CD103, CD104, CD105, CD106, CD107, CD107a, CD107b, CD108, CD109,CD110、CD111、CD112、CD113、CD114、CD115、CD116、CD117、CD118、CD119、CD120a、CD120b、CD121、CD121a、CD121b、CD122、CD123、CD123a、CD124、CD125、CD126、CD127、CD128、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、CD139、CD140、CD140a、CD140b、CD141、CD142、CD143、CD144、CD145、CDw145、CD146、CD147、CD148、CD149、CD150、CD151、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、CD156d、CD157、CD158、CD158a、CD158b1、CD158b2、CD158c、CD158d、CD158e1、CD158e2、CD158f2、CD158g、CD158h、CD158i、CD158j、CD158k、CD159、CD159a、CD159b、CD159c、CD160、CD161、CD162、CD163、CD164、CD165、CD166、CD167、CD167a、CD167b、CD168、CD169、CD170、CD171、CD172、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177、CD178、CD179、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186、CDw186、CD187、CD188、CD189、CD190、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CD198、CDw198、CDw199、CD200、CD201、CD202(a,b)、CD203、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210、CDw210a、CDw210b、CD211、CD212、CD213、CD213a1、CD213a2、CD214、CD215、CD216、CD217、CD218、CDw218a、CD218、CD21b9、CD220、CD221、CD222、<h2 style=";text-align:left;direction:ltr">CD223、CD224、CD225、CD226、CD227、C D228、CD229、CD230、CD231、CD232、CD 2333、CD234、CD235a、CD235b、CD236、CD236R、CD238、CD239、CD240、CD240ce 、CD240d、CD241、CD242、CD243、CD244 、CD245、CD246、CD247、CD248、CD249、 CD250、CD251、CD252、CD253、CD254、C D255、CD256、CD257、CD258、CD259、CD2 50、CD261、CD262、CD263、CD264、CD265、CD266、CD267、CD268、CD269、CD270 、CD271、CD272、CD273、CD274、CD275、 CD276、CD277、CD278、CD279、CD281、CD 282、CD283、CD284、CD285、CD286、CD2 87、CD288、CD289、CD290、CD291、CD29 2、CD293、CD294、CD295、CD296、CD297、CD298、CD299、CD300、CD300a、CD300b 、CD300c、CD301、CD302、CD303、CD304 、CD305、CD306、CD307、CD307a、CD307 b、CD307c、CD307d、CD307e、CD307f、C D308、CD309、CD310、CD311、CD312、CD3 13、CD314、CD315、CD316、CD317、CD318、CD319、CD320、CD321、CD322、CD323 、CD324、CD325、CD326、CD327、CD328、 CD329、CD330、CD331、CD332、CD333、CD 3344、CD335、CD336、CD337、CD338、CD339、CD340、CD341、CD342、CD343、CD34 4、CD345、CD346、CD347、CD348、CD349 、CD350、CD351、CD352、CD353、CD354、C D355、CD356、CD357、CD358、CD359、CD 360、CD361、CD362、CD363、CD364、CD3 55、CD366、CD367、CD368、CD369、CD370、CD371、CD372、CD373、CD374、CD375、CD376, CD377, CD378, CD379, CD381, CD382, CD383, CD384, CD385, CD386, CD387, CD388, CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB, APO2, ASLG659, BMPR1B, 4-1BB, 5AC, 5T4 (trophoblast glycoprotein, TPBG, 5T4, Wnt activation inhibitor 1 or WAIF1), adenocarcinoma antigen, AGS-5, AG S-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, α integrin, αvβ6, aminopeptidase N, amyloid β, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3 (VAP-1), B7-H3, anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cells, bcr-abl, bombesin, BORIS, C5, C242 antigen, CA125 (anthrax) Hydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, canine IL31, carbonic anhydrase IX, cardiac myosin, CCL11 (C-C motif chemokine 11), CCR4 (CC chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (factor D), Ch4D5, cholecystokinin 2 (CCK2R), CLDN18 (claudin-18) , CLDN18.1 (claudin-18.1), CLDN18.2 (claudin-18.2), clumping factor A, cMet, CRIPTO, FCSF1R (colony-stimulating factor 1 receptor, CD115), CSF2 (colony-stimulating factor 2, granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, CXC chemokine receptor type 4, cADP ribose hydrolase, Cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL3 (delta-like ligand 3), DLL4 (delta-like ligand 4), DPP4 (dipeptidyl peptidase 4),DR5 (death receptor 5), E. coli Shiga toxin type 1, E. coli Shiga toxin type 2, ED-B, EGFL7 (EGF-like domain containing protein 7), EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, episialin, ERBB2 (epidermal growth factor receptor 2), ERBB3, ERG (TMPRSS2ETS fusion gene), E. coli , ETV6-AML, FAP (fibroblast activation protein α), fibroblast surface antigen, FCGR1, α-fetoprotein, fibrin II, β chain, fibronectin ectodomain B, FOLR (folate receptor), folate receptor α, folate hydrolase, respiratory syncytial virus Fos-related antigen 1F protein, Frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28 (cell surface glycolipid antigen), GD3 idiotype Type, GloboH, Glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α chain, growth differentiation factor, GP100, GPNMB (transmembrane protein NMB), GUCY2C (guanylate cyclase 2C, guanylate cyclase C (GC-C), intestinal guanylate cyclase, guanylate cyclase-C receptor, heat-stable enterotoxin receptor (hSTAR)), heat shock protein, hemagglutinin, B Hepatitis surface antigen, Hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2 / neu, HER3 (ERBB-3), IgG4, HGF / SF (stem cell growth factor / scatter factor), HHGFR, HIV-1, histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human scatter factor receptor kinase, HPV E6 / E7, Hsp90, hTERT, ICAM-1 (intercellular adhesion molecule 1), idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGHE, interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19, IL-20, IL-21, IL-22,IL-23, IL-27, or IL-28), IL-31RA, ILGF2 (insulin-like growth factor 2), integrin (α4, α, IIIb β 3 , αvβ3, α 4 β 7 , α5β1, α6β4, α7β7, αIIβ3, α5β5, αvβ5), interferon gamma-inducing protein, ITAGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1 (lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGEA1, MAGEA3, MAGE4, ​​MART1, MCP-1, MIF (macrophage migration inhibitory factor or glycosylation inhibitory factor (GIF)), MS4A1 (transmembrane 4 domain subfamily A member 1), MSLN (mesothelin), MUC1 (mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM)), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemotactic protein 1), MelanA / MART1, ML-IAP, MPG, MS4A1 (transmembrane 4 domain subfamily A), MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, neuronal apoptosis-regulating proteinase 1, NOGO-A, Notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (oxidized low density lipoprotein), OY-TES1, P21, non-mutant p53, P9 7, Page 4, PAP, anti-(N-glycolylneuraminic acid) paratope, PAX3, PAX5, PCSK9, PDCD1 (PD-1, programmed cell death protein 1), PDGF-Rα, (platelet-derived growth factor receptor α), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor β, sodium phosphate cotransporter, PMEL17, polysialic acid, proteinase 3 (PR1), prostate cancer, PS (phosphatidylserine), prostate cancer cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), Rhesus factor, RANKL, PhoC,Ras mutants, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma metastasis breakpoint, SART3, sclerostin, SLAMF7 (SLAM family member 7), selectin P, SDC1 (syndecan 1), sLe(a), somatomedin C, SIP (sphingosine-1-phosphate), somatostatin, sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial of the prostate 1) antigen), STEAP2, STn, TAG-72 (tumor-associated glycoprotein 72), survivin, T cell receptor, T cell transmembrane protein, TEM1 (tumor epithelial marker 1), TENB2, tenascin-C (TN-C), TGF-α, TGF-β (transforming growth factor beta), TGF-β1, TGF-β2 (transforming growth factor beta 2), Tie (CD202b), Tie2, TIM-1 (CDX-014), TN, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis-inducing ligand receptor 1), TRAILR2 (death receptor 5 (DR5)), tumor-associated calcium signaling Transducer 2, tumor-specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-1 (Trop1), TRP-2 (Trop2), tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or vimentin, WT1, XAGE1, or any insulin growth factor receptor, or any epidermal growth factor receptor.

12. In the conjugate, the drug is conjugated mainly to the disulfide bond site between the heavy and light chains (Fab) of the antibody, and is selected from the group consisting of C-25, C-30, C-36, C-45, C-51, C-58a, C-68a, C-68b, C-68c, C-72a, C-72b, C-73, C-83, C-88, C-91, C-96, C-102, C-115, C-120, C-121, C-126, C-130, C-137, C-140, C-152, C-157, C-168, C-178, C-181a, C-181b, C-181c, C-181d, C-190, and C-192. , C-195, C-202, C-209, C-215, C-221, C-221b, C-227, C-233, C-241, C-255, C-258, C-267, C-277, C-283, C-284, C-290, C-295, C-300, C-306, C-309, C- 310, C-312, C319, C-322, C-326, C-328, C-330, C-334, C-335, C-336, C-337 , C-338, C-361, C-362, C-372, C-373, C-374, C-375, C-384, C-385, C-390, C- 396, C-399, C-400, C-402, C-406, C-409, C-416, C-417, C-427, C-432, C-43 7, C-441, C-450, C-455, C-462, C-464, C-470, C-478, C-481, C-484, C-487, C-488, C-494, C-498, C-499, C-500, C-501, C-504, C-508, C-511, C-514, C- 518, C-519, C-521, C-527, C-531, C-532, C-537, C-542, C-543, C-544, C-546 , C-550, C-553, C-560, C-561, C-562, C-565, C-570, C-573, C-577, C-581, C -582, C-587, C-591, C-595, C-599, C-602a, C-602b, C-602c, C-602d, C-603 a, C-603b, C-604, C-606, C-608, C-609a, C-609b, C-609c, C-610a, C-610b, C-610c, C-610d, C-610e, C-610f, C-610g, C-611a, C-611b, C-611c, C-611d,C-612, C-613, C-614, C-615, C-616, C-617, C-618, C-619, C-620, C-621, C-622, C-623, C-624, C-625, C-6 26, C-627, C-628, C-629, C-630, C-631, C-632, C-633, C-634, C-635, C-636, C-637, C-639, C-640, C-641, C-642, C-643, C-644, C-645, C-646, C-647, C-648, C-649, C-650, C-651, C-652, C-653, C-654, C-655, C-6 56, C-657, C-658, C-659, C-660, C-661, C-662, C-663, C-664, C-665, C-666, C-667, C-668, C-669, C-670, C -671, C-672, C-673, C-674, C-675, C-676, C-677, C-678, C-679, C-680, C-681, C-682, C-683, C-684, C-68 5, C-686, C-687, C-688, C-689, C-690, C-691, C-692, C-693, C-694, C-695, C-696, C-697, C-698, C-699, C- 700, C-701, C-702, C-703, C-704, C-705, C-706, C-707, C-708, C-709, C-710; or a derivative having one or more isotopes; a pharma- ceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure thereof; or an optical isomer, racemate, diastereomer, or enantiomer thereof; [62] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] where n is 1-10; mAb is an antibody or antibody-like protein.

13. 4. The method of claim 3, wherein the drug / conjugate conjugate has any of the following structures: or a derivative having one or more isotopes; a pharma- ceutically acceptable salt, hydrate, or hydrated salt thereof; or a polymorphic crystal structure thereof; or an optical isomer, racemate, diastereomer, or enantiomer thereof: [63] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] In the formula, n is 1 to 10.

14. The method of claim 11, wherein the tumor cells are selected from the group consisting of lymphoma cells, myeloma cells, renal cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colon cancer cells, gastric cancer cells, squamous cell carcinoma cells, small cell lung cancer cells, non-small cell lung cancer cells, testicular cancer cells, malignant cells, or any cells that grow and divide unregulated and promote the pace that causes cancer.

15. 27. A pharmaceutical composition comprising a therapeutically effective amount of a conjugate according to any one of claims 4, 12 or 20 and a pharma- ceutically acceptable salt, carrier, diluent, or excipient, or a combination of said conjugates, or a combination of two or more of said conjugates, for the treatment or prevention of cancer, an autoimmune disease, or an infectious disease.

16. 17. The pharmaceutical composition of claim 16, which is a liquid formulation or a lyophilized solid / powder formulation, comprising, by weight 0.01% to 99% of one or more conjugates according to any one of claims 4, 12 or 20; Polyol 0.0% to 20.0%; 0.0% to 2.0% of one or more surfactants; 0.0% to 5.0% of one or more preservatives; 0.0% to 30% of one or more amino acids; 0.0% to 5.0% of one or more antioxidants; 0.0% to 0.3% of one or more metal chelating agents; 0.0% to 30.0% of one or more buffer salts to adjust the pH of the formulation to 4.5 to 7.5; and one or more tonicity agents, 0.0% to 30.0%, to adjust the osmolality to between about 250 and 350 mOsm after reconstitution for administration to a patient; The polyol is selected from fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, glucose, sucrose, trehalose, sorbose, melezitose, raffinose, mannitol, xylitol, erythritol, maltitol, lactitol, erythritol, sorbitol, glycerol, or L-gluconate and its metal salts; The surfactant may be polysorbate 20, polysorbate 40, polysorbate 65, polysorbate 80, polysorbate 81, or polysorbate 85, poloxamer, poly(ethylene oxide)-poly(propylene oxide), polyethylene-polypropylene, Triton; sodium dodecyl sulfate (SDS), sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamide propyl- myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; dodecyl betaine, dodecyl dimethylamine oxide, cocamidopropyl betaine, and cocoamphoglycinate; or isostearyl ethylimidonium ethosulfate; polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol; The preservative is selected from benzyl alcohol, octadecyl dimethyl benzyl ammonium chloride, hexatonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol; The amino acids are selected from arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycine, glutamic acid, or aspartic acid; The antioxidant is selected from ascorbic acid, glutathione, cystine, or methionine; The chelating agent is selected from EDTA or EGTA; The buffer salt is selected from sodium, potassium, ammonium, or trihydroxyethylamino salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetate, or phthalic acid; tris or tromethamine hydrochloride, phosphate, or sulfate; anionic acetate, chloride, phosphate, sulfate, or succinate of arginine, glycine, glycylglycine, or histidine; 16. The pharmaceutical composition of claim 15, wherein the isotonicity agent is selected from mannitol, sorbitol, sodium acetate, potassium chloride, sodium phosphate, potassium phosphate, trisodium citrate, or sodium chloride.

17. 16. The pharmaceutical composition of claim 15, which is filled into a vial, bottle, prefilled syringe, or prefilled autoinjector syringe in liquid or lyophilized solid form.

18. 19. The method of claim 18, comprising administering the pharmaceutical composition of claim 15 simultaneously with a chemotherapeutic agent, a radiotherapeutic agent, an immunotherapeutic agent, an autoimmune disease agent, an anti-infective agent, or a synergist of other conjugates.

19. 19. The method of claim 18, wherein the synergist is one or more selected from the following drugs: abatacept, abiraterone acetate, abraxane, acetaminophen / hydrocodone, acalabrutinib, aducanumab, adalimumab, ADXS31-142, ADXS-HER2, afatinib dimaleate, aldesleukin, alectinib, alemtuzumab, alitretinoin, adotrastuzumab emtansine, amphetamine / dextroamphetamine, anastrozole, aripiprazole, anthracycline, aripiprazole, atazanavir, atezolizumab, atorvastatin, avelumab, axicabtagene Ciloreucel, axitinib, belinostat, live BCG, zumab, bexarotene, blinatumomab, bortezomib, bosutinib, brentuximab vedotin, brigatinib, budesonide, budesonide / formoterol, buprenorphine, cabazitaxel, cabozantinib, capmatinib, capecitabine, carfilzomib, chimeric antigen receptor modified T (CAR-T) cells, celecoxib, ceritinib, cetuximab, chidamide, cyclosporine, cinacalcet, crizotinib, cobimetinib, cosentyx, crizotinib, CTL01 9. Dabigatran, dabrafenib, dacarbazine, daclizumab, dacomitinib, daptomycin, daratumumab, darbepoetin alfa, darunavir, dasatinib, denileukin diftitox, denosumab, depakote, dexlansoprazole, methylphenidate, dexamethasone, dinutuximab, doxycycline, duloxetine, duvelisib, durval Umab, elotuzumab, emtricitabine / rilpivirine / tenofovir, disoproxil fumarate, emtricitabine / tenofovir / efavirenz, enoxaparin, ensartinib, enzalutamide, epoetin alfa, erlotinib, esomeprazole, eszopiclone, everolimus, exemestane, everolimus, exenatide ER, ezetimibe, ezetimibe / simvastatin, fenofibrate, filgrastim, fingolimod, fluticasone propionate, fluticasone / salmeterol, fulvestrant, gaziva, gefitinib, glatiramer, goserelin acetate, icotinib, imatinib, ibritumomabTiuxetan, ibrutinib, idelarib, ifosfamide, infliximab, imiquimod, immucyst, immune BCG, iniparib, insulin aspart, insulin detemir, insulin glargine, insulin lispro, interferon alpha, interferon alpha 1b, interferon alpha 2a, interferon alpha 2b, interferon beta, interferon beta 1a, interferon beta 1b, interferon gamma 1a, iapatinib, ipilimumab, ipratropium bromide / salbutamo oxal, ixazomib, Kanuma, lanreotide acetate, lenalidomide, lenalidomide, lenvatinib mesylate, letrozole, levothyroxine, lidocaine, linezolid, liraglutide, examfetamine, LN-144, lorlatinib, memantine, methylphenidate, metoprolol, mekinist, melicitabine / rilpivirine / tenofovir, modafinil, mometasone, misidac-C, necitumumab, neratinib, nilotinib, niraparib, nivolumab, ofatumumab, obinutuzumab, ora Paribu, olmesartan, olmesartan / hydrochlorothiazide, omalizumab, omega-3 fatty acid ethyl ester, oncoline, oseltamivir, osimertinib, oxycodone, palbociclib, palivizumab, panitumumab, panobinostat, pazopanib, pembrolizumab, PD-1 antibody, PD-L1 antibody, pemetrexed, pertuzumab, pneumococcal conjugate vaccine, pomalidomide, poziotinib, pregabalin, proskavax, propranolol, quetiapine, rabeprazole, radium chloride M223, raloxifene, raltegravir, ramucirumab, ranibizumab, regorafenib, rituximab, rivaroxaban, romidepsin, rosuvastatin, ruxolitinib phosphate, salbutamol, savolitinib, semaglutide, sildenafil, siltuximab, sipulcel-T, sitagliptin, sitagliptin / metformin, solifenacin, solanezumab, sonidegib, sorafenib, sunitinib, tacrolimus, taclimus, tadalafil, tamoxifen, tafinlar, talimogene laherparepvec, talazoparib, telaporebrib, IR / emtricitabine, tenofovirDisoproxil fumarate, testosterone gel, thalidomide, TICE BCG, tiotropium bromide, tisagencleucel, toremifene, trametinib, trastuzumab, trastuzumab deruxtecan, trabectedin (ecteinascidin 743), trametinib, tremelimumab, trifluridine / tipiracil, tretinoin, ustekinumab, valsartan, veliparib, vandetanib, vemurafenib, venetoclax, vorinostat, dibuaflibercept, zostavax, and analogs, derivatives, pharma- ceutically acceptable salts, carriers, diluents or excipients thereof, or combinations thereof.

20. 13. The conjugate of claim 4 or 12, having in vitro, in vivo, or ex vivo cell killing activity.

Citation Information

Patent Citations

  • Preparation process of compounds useful as SGLT2 inhibitors

    JP2014510776A

  • Conjugates of tubulysin analogues with branched linkers

    JP2021507928A

  • Symmetrical hyperbranched silicone-modified polymerizable compound and preparation method modularizing same

    WO2014141578A1

  • Process for preparing antibody-drug conjugates with improved homogeneity

    WO2020164561A1

  • Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system

    US20100184135A1